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Experiment is the interpreter of nature. Experiments never deceive. It is our judgment 
which sometimes deceives itself because it expects results which experiment refuses. 
 





La lumière joue dans notre vie un rôle essentiel: elle intervient dans la plupart de nos 
activités. Les Grecs de l'Antiquité le savaient déjà, eux qui pour dire «mourir» 
disaient «perdre la lumière». 
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Abstract 
Background: Molecular imaging (MI) is fundamental in clinical settings for 
diagnosis, treatment selection, intraoperative guidance and treatment efficacy 
evaluation. This field has progressed rapidly in recent years, driven by the need for 
diagnostic tools and as a tool to monitor the efficacy of new cancer treatments, 
including gene-based therapies. MI in combination with reporter genes allows in vivo 
monitoring of enzyme expression and follow-up of the success of gene-directed 
enzyme prodrug therapies (GDEPT), where the suicide gene also acts as reporter 
gene. In this thesis, nitroreductase NfsB (NTR) from E. coli has been concurrently 
employed as a reporter gene (Papers I and III) and suicide gene (Paper III). The 
work of this thesis has also focused on the contrast agents of two main MI 
methodologies, namely optical imaging (mainly fluorescence imaging (FLI) for 
longitudinal imaging (Papers I – III) and fluorescence image-guided surgery (FIGS) 
(Paper II)) and nuclear-based PET/CT imaging (Paper III). 
Aims: To highlight and resolve the discrepancies present in the literature in regard to 
the near-infrared (NIR) dye CytoCy5S. For this purpose, four NIR dyes were 
synthesised and analysed. Based on their physicochemical and optical properties and 
their in vivo behaviour, we aimed to define the best candidate for preclinical optical 
imaging of NTR (Paper I). To compare how common NIR dyes affect the in vivo 
behaviour of conjugates and to identify the optimal dye that could be used to improve 
the further development of fluorescent conjugates for FIGS (Paper II). To repurpose 
the hypoxia radiopharmaceutical 18F-FMISO for PET/CT imaging of NTR expression 
in an in vivo GDEPT setting (Paper III). 
Materials and methods: We synthesised, purified and characterised four NTR 
substrates (1 – 4), including alternately described structures currently referred by the 
name CytoCy5S. A comparative NTR enzymatic assay was performed to assess the 
spectroscopic characteristics of the different reductively activated dyes. The NTR 
expressing triple-negative breast carcinoma cell line, MDA-MB-231 NTR+, was 
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employed to compare, both in vitro and in vivo, the suitability of these fluorophores 
as reporters of NTR activity. Comparison of the reporting properties was achieved by 
flow cytometry, fluorescence microscopy and optical imaging, both in vivo and ex 
vivo (Paper I). The NHS esters of ZW800-1, ZW800-1 Forte, IRDye® 800CW, ICG, 
and Cy7 derivative were conjugated to folate through an ethylenediamine linker to 
give conjugates 1 – 5, respectively. The optical properties of conjugates 1 – 5 were 
determined by spectroscopy, their specificity assessed in vitro by flow cytometry and 
FLI, and their biodistribution studied in vivo and ex vivo using FLI in a subcutaneous 
Skov-3 ovarian cancer model (Paper II). The efficacy of 18F-FMISO to report NfsB 
NTR activity in vivo was investigated using the MDA-MB-231 model. For validation, 
subcutaneous xenografts of cells constitutively expressing NTR were imaged using 
18F-FMISO PET/CT and FLI with CytoCy5S. Further, examination of the non-
invasive functionality of 18F-FMISO PET/CT in reporting NfsB NTR activity in vivo 
was assessed in metastatic orthotopic NfsB NTR expressing xenografts and 
metastasis confirmed by bioluminescence imaging. 18F-FMISO biodistribution was 
acquired ex vivo by an automatic gamma counter measuring radiotracer retention to 
confirm in vivo results. To assess the functional imaging of NTR-based GDEPT with 
18F-FMISO, PET/CT was performed to assess both gene transduction and 
cytotoxicity effects of prodrug therapy (CB1954) in subcutaneous models (Paper 
III). 
Results: The introduction of the methoxy group in 3 and the sulfonate and cyanine 
scaffold in 4 resulted in a modest bathochromic shift compared to 1 and 2. All 
compounds were confirmed as NTR substrates with delayed kinetics observed for 2 
and low emission intensities for 3 and 4. In vitro, 3 was found to display the highest 
NTR+/NTR- ratio, followed by 1. 4 performed poorly in vitro and in vivo. 1 and 2 
provided similar suitability for NTR interrogation, being 1 slightly more sensitive at 
smaller tumour volumes and presenting faster kinetics and a functional group for 
conjugation to biomolecules. We determined that substrate 1 is the ideal candidate for 
further studies (Paper I). We demonstrated time- and receptor-dependent binding of 
folate conjugates in vitro and in vivo. Healthy tissue clearance characteristics and 
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tumour-specific signal varied between conjugates 1 - 5. 2 revealed the highest 
contrast in folate receptor alpha (FRα) positive xenografts and was the only conjugate 
that reported significant differences between Skov-3 and A549 (p < 0.05). Whilst 
conjugates 1, 2 and 3 are renally cleared, hepatobiliary excretion and no or very low 
accumulation in tumours was observed for 4 and 5 (Paper II). 18F-FMISO retention 
was detected in NTR+ subcutaneous xenografts, displaying significantly higher PET 
contrast than NTR- xenografts (p < 0.0001). Substantial 18F-FMISO retention was 
evident in metastases of orthotopic xenografts (p < 0.05). Accordingly, higher 18F-
FMISO biodistribution was prevalent ex vivo in NTR+ xenografts. 18F-FMISO NfsB 
NTR PET/CT imaging proved useful for monitoring in vivo NTR transduction and 
the cytotoxic effect of prodrug therapy (Paper III). 
Conclusions: We have fully characterised the chemical and biological properties of 
four NIR dyes and clearly defined which is the best for imaging of NTR (Paper I). 
Our work highlights the high impact the physicochemical properties of the dye have 
on the tumour accumulation and biodistribution of the conjugate and demonstrates 
the potential of alternative fluorophores to IRDye® 800CW for targeted approaches in 
FIGS (Paper II). We have demonstrated that 18F-FMISO is a readily implementable 
PET probe to be employed as companion diagnostic test for NTR-based GDEPT 
systems (Paper III). 
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Cancer is characterised by the rapid increase of abnormal cells that grow 
uncontrolled, followed by invasion of adjacent tissues, entry into the blood stream 
migrating to other organs, and infiltration in a process known as metastasis [1]. It 
defines a range of diseases with high heterogeneity and challenging prognosis based 
on its molecular phenotype, location or stage 
of disease. Cancer requires accumulation of 
several mutations in different genes to pass 
from a normal cell to a malignant one and this 
occurs in a multistep process (tumour 
progression) (Figure 1) [2]. Mutations in two 
main types of genes are believed responsible 
in the early stages of cancer initiation in 
healthy cells, i.e. activation of oncogenes or 
loss of tumour suppressor genes. 
The different biological capabilities acquired by the cells during clonal evolution 
allow them to become malignant and conform the hallmarks of cancer [3] (Figure 2). 
They include biological capabilities such as sustained proliferative signalling, 
replicative immortality or induced angiogenesis; and enabling characteristics such as 
genomic instability or inflammation. The exploitation of these cellular traits can be 
applied to select appropriate treatment strategies (examples included in Figure 2), as 
well as to develop novel molecular probes for imaging modalities suitable for disease 
monitoring [4, 5]. 
Figure 1: Schematic representation 
of tumour progression and clonal 
evolution of tumours. [2] 
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According to the WHO, more than 70% of the deaths caused by cancer are reported 
in low- to middle-income countries, where the resources in place for prevention, 
diagnosis or treatment are limited [6]. Early detection, either by early diagnosis of 
symptomatic patients at early stages of the disease or by mass screening of an 
asymptomatic population (for breast, cervical and colorectal cancers), plays a key 
role in disease control [7]. One of the most successful examples of screening 
methods, and one of the few imaging-based, has 
been the use of mammography for breast cancer 
[8]. This X-ray picture of the breast permits the 
detection of cancerous lesions in asymptomatic 
women prior to the development of metastatic 
disease. Accordingly, breast cancer is more 
often successfully treated in early stages 
resulting in a pronounced decrease in mortality 
in the last decades (Figure 3) [9]. 
In general, conventional imaging, including mammography screening [10], has 
limitations, such as false-positive or false-negative results due to insufficient 
Figure 3: Breast cancer mortality 
statistics over 20 years from 
Norway, Spain and USA. [9] 
Figure 2: Therapeutic targeting of the hallmarks of cancer. 
Reproduced from [3] with permission from Elsevier. 
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specificity and sensitivity, respectively, which molecular imaging (MI) aims to 
overcome [11]. A recently published multicenter study investigated the use of a novel 
imaging strategy. This method combined prostate specific membrane antigen 
(PSMA) and positron emission tomography/computed tomography (PET/CT) and has 
been shown to be superior to CT and bone scanning, supporting the claim of being “a 
suitable replacement for conventional imaging” [12]. This supports a paradigm shift 
from conventional imaging (structure) towards MI (function). 
 
1.2 Molecular imaging of cancer 
Cancer therapies have progressed rapidly in recent decades [13], moving from 
chemotherapies to personalised therapies using cancer-specific targeted approaches 
[14] (e.g. with prognosis (HER-2) and prediction (KRAS) biomarkers). In addition, 
immune cell therapies are used to boost the patient's tumour-supressing immune 
responses [15] (e.g. with CAR T-cells or immune checkpoint inhibitors). These 
personalised strategies targeting specific molecular traits have led to reduced toxicity 
and increased efficacy, and their development requires the employment of MI to 
clinically monitor efficacy. Moreover, the emergence of drug resistance requires 
continuous therapeutic development in relevant preclinical models, where MI is a 
prerequisite. This remains key to advancing the most promising therapies into clinical 
trials, while reducing the bench-to-bed time required [16, 17]. 
MI allows the study of gene and protein function, as well as molecular processes 
preclinically in small animals or clinically in humans [18]. Therefore, MI in cancer 
has gained traction in the last 25 years, with more than 6000 works published on the 
subject in the last five years [19]. This highly multidisciplinary strategy begins with 
the identification of a molecular target. Once the relevant target has been validated, 
the proof-of-principle testing phase follows, which includes synthetic chemistry, cell 
biology and imaging technology. If the preclinical results obtained are favourable, 
further translational phases with clear endpoints will be implemented to ultimately 
develop the imaging strategy for clinical use (Figure 4). This lengthy research process 
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is a challenge that must be addressed by an interdisciplinary team of chemists, 
biologists, physicists, physicians, pharmacists and imaging specialists [20]. 
 
 
Figure 4: Schematic overview of the main steps of a molecular imaging study. 
From conceptualisation identifying a molecular target to the clinical evaluation of 
the imaging methodology. Adapted from [18, 21]  
MI can be divided in two main groups: nuclear imaging (pink in Table 1) and non-
radionuclide-based imaging (blue in Table 1). Nuclear imaging requires the use of 
radionuclides that decay via the emission of two collinear gamma rays (positron 
emission tomography, PET) or of a single gamma ray (single-photon emission 
computed tomography, SPECT). These rays are captured by detector rings (PET) or 
by a gamma camera that rotates around the imaged subject (SPECT) creating a 
tomographic reconstruction. Optical imaging comprises a variety of techniques 
including fluorescence imaging (FLI) and bioluminescence imaging (BLI). They 
allow non-invasive monitoring of biological processes by detection of light and will 
be described in detail below. Magnetic resonance imaging (MRI) is an 
anatomical/morphological methodology that employs an external magnetic field to 
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obtain images based on the different relaxation times of magnetic particles from 
certain atomic nuclei like 1H in different tissues. Computed tomography (CT) is a 
tomographic technique that relies on the attenuation of X-rays when travelling 
through tissues providing 3D anatomic images. CT is often combined with functional 
techniques such as PET or SPECT. Ultrasound (US) relies on the propagation of 
sound waves from a transducer through tissue. Interaction of these waves with the 
tissues, that present different elastic properties, reflect the waves (echo) non-
uniformly and energy is detected by the transmitting transducer, reporting structural 
or functional information. 
All the aforementioned imaging modalities differ in key features such as depth 
penetration, spatial and time resolution and type of probes employed. Other factors 
such as the target organ or cells, its use in either human or animal models, together 
with the availability of the necessary probes, determine which technique is best for a 
specific purpose [22]. Each of these techniques shows weaknesses, such as use of 
radiation or low penetration, and strengths such as being non-invasive or high spatial 
resolution. The synergistic integration of several techniques is a favourable strategy 
to overcome drawbacks of the individual techniques [23]. The different 
characteristics of the methodologies comprised within each group are briefly 
described in Table 1 [18, 21, 22]. In clinical practice, molecular imaging techniques 
that provide information about function are combined with anatomical modalities that 
provide structure information. Some common examples are PET/CT and PET/MRI, 
which improve the image visualisation and thereby aid surgeons in locating diseased 





1.2.1 Optical imaging 
The use of light to visualise cells and tissues is a simple method that has been widely 
employed in preclinical and clinical settings since the invention of the microscope in 
1674 [21]. The introduction of live cell fluorescence microscopy has permitted the 
evaluation of molecular events in real time using fluorophores. Further development 
of macroscopic imaging techniques allowed whole-body interrogation of molecular 
events in living small animals and patients. A number of different macroscopic 
optical imaging techniques [24] are available, including endoscopy [25, 26], optical 
coherence tomography (OCT) [27, 28], super-resolution intravital microscopy [28, 
29], photoacoustic imaging [30, 31] or Raman spectroscopy [32, 33]. All these 
techniques present distinct advantages and are at different stages of technology 
readiness and clinical acceptance and they are further discussed elsewhere [21]. The 
main focus of this thesis is in reflectance FLI and to a minor extent BLI, techniques 
that are described in detail below.  
FLI requires an external energy source, i.e. light, to obtain information from cells and 
tissues. Light with an appropriate wavelength excites either an endogenous or an 
exogenous fluorophore that upon relaxation will emit light with lower energy than 
that absorbed. In the case of bioluminescence imaging, an enzymatic reaction causes 
the spontaneous emission of photons and therefore the presence of an external 
excitation source is not needed.  
FLI systems, including fluorescence image-guided surgery (FIGS) systems, are 
composed of an excitation light source, a detection system, excitation and emission 
filters and imaging software. Based on the position of the light source and the 
detector, epi-illumination or trans-illumination techniques are distinguished. In epi-
illumination, the light source and the detector are placed on the same side and the 
light is reflected (Figure 5). For trans-illumination, the light source and detector are 
on opposite sides and the light is transmitted through the imaged subject (Figure 5A). 
This distinct configuration of the FLI system confers different advantages, such as 
rapid imaging times in the case of epi-illumination or increased sensitivity due to the 
attenuation of tissue autofluorescence in the case of trans-illumination [34]. For BLI, 
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the same instruments are employed, but only the detection system and the imaging 
software come into play (Figure 5B).  
 
Figure 5: Schematic overview of the instrumentation employed in fluorescence 
imaging (FLI), depicting the differences between A) epi-illumination and trans-
illumination, and B) in bioluminescence imaging (BLI). C) Fluorescence planar 
image of a subcutaneous xenograft obtained with epi-illumination and 
bioluminescence planar image of an orthotopic xenograft (Image courtesy of Katrin 
Kleinmanns).  
The excitation source can be a laser at a given wavelength or a white-light source 
with low-pass filters. Excitation and emission filters maximise the detected signal by 
blocking the photons at undesired wavelengths. This maximised signal is detected by 
a photomultiplier tube detector (PMT) or by a charged-coupled device (CCD) 
camera. CCD cameras, particularly cooled back-tinned and back-illuminated CCD, 
are preferred over PMTs since they are more sensitive and provide better resolution. 
For BLI, the use of emission filters is not required and all the photons emitted by the 
sample under study are collected. The acquired photons are then converted into 
electric charges proportional to the light intensity that are further amplified and 
digitised by means of the imaging software. This results in a planar (Figure 5C) 
image that allows localisation of the fluorophore under study and hence evaluation of 
the physiological process of interest [35-37]. This final image shows the number of 
photons per region in the animal under study and this fluorescent/bioluminescent 
signal is often reported as average radiance (p/s/cm2/sr). 
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1.2.2 Positron Emission Tomography (PET) 
PET is a functional imaging modality that allows preclinical and clinical evaluation 
of metabolic or biologic function by radiotracer uptake. It is commonly combined 
with X-ray CT for structural localisation. Clinically, it is a very relevant modality that 
allows investigation of cancer during the different stages of the disease from 
diagnosis to treatment efficacy assessment [38].  
Radiotracers are composed of a radionuclide, an organic targeting ligand and, in 
many cases, a linker between these. Radionuclides are the unstable isotopes of a 
given atom and they emit radiation while decaying towards more stable nuclear 
configurations. One of the most widely employed radionuclides is 18F, which is 
present in the glucose analogue 18F-fluorodeoxyglucose (18F-FDG). Different 
synthetic methods are known to obtain 18F [39], but the most commonly employed 
method is the proton bombardment of 18O-enriched water in a cyclotron, 18O(p,n)18F 
[40]. 18F exhibits an excess of protons, and neutron deficiency, and its decay results in 
positron (β+) emission accompanied by a neutrino (Figure 6) [41]. One of the 
advantages of 18F over other positron emitters, such as 15O, 13N or 11C, is its low 
positron energy (0.635 MeV), which translates into shorter diffusion ranges within 
tissues and hence higher resolution [42].  
 
Figure 6: The principles of PET. The positron (β+) is emitted and it travels a short 
distance before interacting with an electron (β-) and undergoing annihilation. The 
two gamma photons (511 keV and 180°) are simultaneously detected by detector 
rings (coincidence). Reconstruction of registered events gives a PET/CT 3D image 
that can be overlaid with a CT image (image from a subcutaneous xenograft).  
As illustrated in Figure 6, the emitted positron travels briefly through tissue until it 
loses its kinetic energy. It then reacts with an electron (β-) in an annihilation process 
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that produces two 511 keV gamma photons with opposed directions of around 180°. 
These photon pairs, when detected simultaneously in a coincidence event by the 
detector rings that are formed of scintillation crystals coupled to PMTs, provide the 
localisation of the annihilation process. The many annihilation processes registered 
by the detectors are reconstructed to give accurate 3D images of the radiotracer 
biodistribution in the tissue under study [41, 42]. The radiotracer activity 
(disintegrations per second) is most commonly reported as Standard Uptake Value 
per body weight (SUVbw) and it comprises the activity concentration of the 
radionuclide (kBq/mL), the total dosage of injected radiotracer (MBq) and the body 
weight of the study subject [43]. 
 
1.3 Reporter genes 
MI techniques based on indirect imaging strategies require the genetic insertion of a 
reporter gene that encodes for a certain protein that can be visualised employing MI. 
This genetic insertion, or cell transduction, is commonly performed, both in vitro and 
in vivo, using viral vectors. Non-replicating adenoviruses are widely employed, but 
dilution of the expressed gene through division and proliferation limits their potential. 
Retroviruses target only actively dividing cells and DNA methylation leads to 
undesired gene silencing. Thus, lentiviruses, a class of retroviruses, which target 
replicating cells and cells in the stationary phase, integrating the exogenous gene in 
the host cells with low cytotoxicity and exhibiting no gene silencing are preferred 
[44].  
When the reporter gene is a fluorescent protein, FLI can be employed for 
visualisation. In other instances, exogenous reporter probes (e.g fluorophore or 
radiotracer) are necessary to image the reporter gene [45, 46]. In these cases, reporter 
genes allow retention and accumulation of the reporter probe thereby permitting 
detection of the signal by different imaging techniques (e.g. FLI or PET) [45]. The 
reporter genes used in imaging express a wide variety of proteins, such as membrane 
 27 
transporters (e.g. sodium iodide symporter, NIS [47]), intra- and extra-cellular 
receptors (e.g. human estrogen receptor ligand, hERL [48] and dopamine 2 receptor, 
D2R [49]) or enzymes (e.g. thymidine kinase, HSV1-TK [50] and β-lactamase [51]). 
Some of the most commonly used reporter genes are luciferase and green fluorescent 
protein (GFP), which have been used together with the nitroreductase (NTR) in this 
project, and are further described (see section 1.7).  
1.3.1 Luciferase and bioluminescence imaging (BLI) 
Luciferase proteins have been isolated from different terrestrial organisms, such as 
the firefly Photinus pyralis (FLuc) and from marine species, such as the sea pansy 
Renilla reniformis (hRLuc). These enzymes can be divided into two main groups 
based on the substrate preference, benzothiazoyl-thiazole luciferin (FLuc) or 
benzylimidazo-pyrazinone coelenterazine (hRLuc) (Figure 7) [52]. 
 
Figure 7: Substrates of luciferase and organisms from which the enzymes were 
isolated. D-Luciferin is the substrate of Fluc from Photinus pyralis (left) and 
Coelenterazine is the substrate of hRLuc from Renilla reniformis (right).  
BLI of molecular and cellular processes is routinely employed in different biomedical 
fields [53] and is a reporter-based technique that requires the combination of an 
enzyme, luciferase, and its corresponding substrate, luciferin. FLuc catalyzes the 
oxidation of D-luciferin to oxyluciferin in the presence of O2, Mg2+ and ATP (Figure 
8). Unlike FLuc, coelenterazine-oxidasing enzymes (hRLuc) do not require ATP to 
convert coelenterazine into its corresponding coelenteramide, CO2 and light. 
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Figure 8: The enzymatic oxidation of luciferin to produce light in the presence of 
different cofactors. 
This biochemical reaction produces spontaneous emission of visible light when the 
electrons of the oxidised molecule, which are in an electronically excited state, return 
to the ground state (S1 Æ S0). The emitted photons are captured by the CCD camera 
and converted into electronic signals that are processed to provide planar real-time 
images within short data acquisition times [18, 52].  
BLI does not require an excitation source, thus avoiding photon attenuation, scatter 
and diffusion of light when passing through the different tissues. It is a very sensitive 
technique due to the lack of enzyme expression in animal tissues, and hence signal, 
from healthy surrounding tissues, providing high signal to background ratios (SBR). 
One of the major limitations is the requirement of cell engineering by means of viral 
transduction to achieve luciferase expression. This has hampered its clinical 
translation but it remains a key tool in preclinical oncological models for visualisation 
of cancer cells. 
1.3.2 Green fluorescence protein (GFP)  
GFP, a visible light-emitting fluorophore isolated from the bioluminescent jellyfish 
Aequorea victoria (Figure 9), is one of the most widely employed reporter genes. Its 
discovery and development awarded three scientists with the Nobel Prize in 
Chemistry in 2008.  
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Figure 9: Aequorea victoria and schematic representation of the β-barrel structure 
of EGFP and its covalently bound chromophore. Representation of the alternative 
colours obtained by modification of the chromophore. [54-57] 
The chromophore of this protein is located inside a β-barrel structure in the protein 
and it is formed by three amino acid residues (Ser 65, Tyr 66 and Gly 67) that 
spontaneously cyclise to form a highly conjugated imidazolidinone ring (Figure 9) 
[54, 55]. Genetic modifications of this chromophore, e.g. substitution of Ser 65 by 
Thr 65, have provided fluorescent proteins with higher photostability, longer 
emission and absorption wavelengths, generating a whole palette of alternative 
colours, e.g. enhanced green fluorescent protein (EGFP; λexc = 490 nm λem = 510 nm), 
blue-shifted (EBFP; λexc = 382 nm λem = 448 nm), cyan-shifted (ECFP; λexc = 439 nm 
λem = 476 nm) or yellow-shifted variants (EYFP; λexc = 514 nm λem = 527 nm) [54-
57]. Moreover, problems such as low fluorescence or slow maturation (fluorophore 
formation) have been overcome [18]. These fluorescent proteins have allowed 
monitoring of gene expression or tumour growth in vivo [58, 59].  
1.3.3 Nitroreductase (NTR)  
The nitroreductase superfamily, with its diverse enzymatic functionalities that 
contains over 20,000 different sequences [60], receives its name from the discovery 
of the killing potency of some nitroaromatic compounds towards bacteria. This 
observation, which led to the development of nitrofurazone [61], was followed by the 
discovery of nitrofurazone sensitivity genes (NfsA and NfsB) in Escherichia coli [62].  
The NfsB gene encodes for the NTR enzyme that is formed by two identical subunits 
(homodimeric, 48 kDa) that catalyses the reduction of nitro-containing compounds in 
the presence of bound flavin mononucleotide (FMN) cofactor and NADH or NADPH 
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as electron donors [63-65]. This catalytic reaction, in which a nitro group (R-NO2) is 
reduced to the hydroxylamine group (R-NHOH) via the nitroso form (R-NO), 
requires two electron (e-) transfers (Figure 10) [66].  
 
Figure 10: The catalytic mechanisms of type I and II nitroreductases under 
different oxygenation conditions. 
The reduction of the substrate follows a ping-pong Bi-Bi mechanism and in this type 
of non-sequential mechanism, the enzyme, like a ping-pong ball, bounces from the 
initial state to an intermediate state and back to the initial state. In the intermediate 
state, reduction by NADPH of FMN in a two e- transfer to FMNH2 leads to a small 
conformational change in the pyrazine ring. The oxidised species, NADP+, leaves the 
binding pocket and the second substrate, in this case a nitro-containing compound, 
binds close to FMNH2. The R-NO2 group is reduced to R-NHOH thereby oxidising 
reduced FMNH2 to its initial state (FMN) in a two e- transfer [63].  
NTR belongs to the Type I or oxygen-insensitive nitroreductases (Figure 10) that are 
able to reduce their substrates in both the presence and absence of oxygen due to the 
simultaneous transfer of the two electrons. Type II or oxygen-sensitive 
nitroreductases, on the other hand, are only able to reduce their substrates in the 
absence of oxygen. The reduction occurs by two consecutive transfers of one e-, 
producing an unstable radical intermediate that oxidises in the presence of oxygen 
(Figure 10) [66, 67]. This type of nitroreductases are found in hypoxia, and are the 
basis of PET/CT or FLI imaging of this condition both pre- and clinically [68, 69]. 
NfsB NTR has been widely used as suicide gene for gene enzyme prodrug therapy 
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(GDEPT) by exploiting the capacity of this enzyme to reductively activate nitro-
containing prodrugs to their cytotoxic metabolites in the presence of oxygen [70, 71]. 
Some examples of commonly employed prodrugs in the setting of NTR-based 
GDEPT are the azidirinyldinitrobenzamide CB1954 and the dinitrobenzamide 
mustard SN23862, whose hydroxylamine products get acetylated causing DNA cross-
linking and hence cell death [72, 73]. In addition, the imaging possibilities offered by 
NTR as reporter gene have been explored in a wide variety of studies. Our group 
demonstrated the promising potential of CytoCy5S, a near-infrared quenched 
fluorophore substrate of NTR, for non-invasive in vivo near-infrared (NIR) reporter 
gene imaging in preclinical metastatic cancers [71]. 
1.3.4 Fluorescence imaging (FLI) of GFP or NTR substrates 
The first written evidence of the phenomenon of fluorescence corresponds to a 
Spanish physician in 1565. Nicolás Monardes reported (in Joyful News out of the New 
Found World) the peculiar blue colour of an infusion of a wood called Lignum 
nephriticum used by the Aztecs to treat kidney and urine diseases [74]. The molecule 
responsible for this case of luminescence, the product of a chain of spontaneous 
oxidations of a flavonoid, was recently identified [75] (Figure 11). 
 
Figure 11: Schematic of the sequential reaction from Coatline B to Matlaline, the 
fluorophore responsible for the blue tinge of Lignum nephriticum [75] 
FLI of biological molecular processes is also broadly employed in different 
biomedical fields, both preclinically and clinically [76]. It requires a fluorophore (e.g. 
a fluorescent protein or an exogenous fluorescent contrast agent) and an external 
excitation source. The fluorophore absorbs photons that bring the molecule to a 
higher singlet electronic state (S1). There it resides for a certain time (ps – ns) before 
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it returns to the fundamental electronic state (S0) with the release of photons and the 
retention of the state multiplicity (Figure 12). This spontaneous emission of radiation 
(fluorescence) occurs at lower energies and higher wavelengths than the absorption, 
and the difference in wavelength between absorption and emission is known as the 
Stokes shift of the probe (Figure 12). The energy loss is caused by vibrational 
relaxation during the residency of the molecule in the excited state. High Stokes shifts 
are desirable to avoid excitation photons contributing to the fluorescent image. Non-
radiative decays from excited electronic states such as S2 Æ S1 or S1 Æ S0 with the 
same spin multiplicity are also possible and are known as internal conversion (IC). 
Additionally, forbidden transitions to the T1 triplet state by inter-system crossing 
(ISC), followed by relaxation to the electronic ground state, result in emission of 
photons in a process known as phosphorescence. Compared to fluorescence, 
phosphorescence is a very slow process due to the fact that the transition T1 Æ S0 is 
forbidden [74].  
 
Figure 12: Perrin-Jablonski diagram depicting absorption, fluorescence and 
phosphorescence processes and their corresponding characteristic times. Straight 
arrows represent radiative processes while wavy arrows correspond to non-
radiative processes, such as internal conversion (IC) or intersystem crossing (ISC). 
Graphical illustration of the Stokes shift, gap between the maximum of the first 
absorption band and the maximum of the fluorescence spectrum expressed in 
wavenumbers. [74] 
FLI is an inexpensive imaging modality that allows non-invasive and repetitive 
imaging of different pathologies in small animals. Due to its low cost it is a key tool 
in the preclinical development of new drugs, since it allows full evaluation of drug 
efficacy in biological systems before moving them into lengthy and more expensive 
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clinical phases. Another advantage is that FLI allows multiplexed imaging [71, 77, 
78]. However, the limited depth of penetration of light (< 1 cm) has hampered its use 
in humans. In addition, autofluorescence, scattering and tissue absorption of light 
diminish the sensitivity of this technique. By taking advantage of fluorophores with 
spectral properties in the NIR region, some of these issues can be circumvented.  
 
1.4 Organic fluorophores for Fluorescence imaging 
To date, the different fluorophores available for in vivo imaging can be divided into 
two groups based on their chemical nature: organic compounds or inorganic 
nanomaterials. The first group (see Figure 13) includes heterocyclic compounds like 
coumarins (D), xanthene dyes (E&F), pyrromethene derivatives (G), cyanines (H&I), 
quinone-imine dyes (J) and fluorescent proteins. The second group is formed by 
nanoparticles (NPs) including semiconductor nanocrystals like quantum dots (QDs) 
[79, 80] or lanthanide-based NPs [81, 82] and by carbon nanostructures like single-
walled carbon nanotubes (SWNTs) [83, 84]. This last group exhibits desirable 
properties such as strong absorption, stability and tunable optical properties, but due 
to their inherent inorganic properties and their safety profile, fluorescent proteins and 
organic dyes are preferred for biomedical imaging applications.  
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Figure 13: General structures of common fluorophores and fluorescent scaffolds 
with emission in the UV, visible and NIR regions. A: N-Carbazole; B: 
Naphthalimide; C: Styryl; D: Coumarin; E: FITC; F: Fluorescein; G: BODIPY; H: 
ICG; I: Cy5; J: MB. [74, 85] 
The chemical structure and the nature of the different organic fluorophores dictate the 
fluorescence properties of these compounds. In figure 13, the chemical structures of 
some representative organic fluorophores and fluorescent scaffolds are shown. As 
observed for the cyanine derivatives (H and I), an increase in the length of the π-
system (conjugation) is translated into a red-shifted emission wavelength, 
bathochromic shift [86]. In addition, introduction of substituents onto the core 
scaffolds of fluorescent probes, such as coumarin or BODIPY (D and G, 
respectively), with either electron-donating or electron-withdrawing groups, will have 
an effect on their physicochemical and optical properties. These derivatisations can 
also be exploited to enhance the affinity of the fluorophores towards a given 
molecular target [87]. 
The ideal fluorophore for biomedical imaging must meet certain minimum 
requirements, such as high brightness, photochemical stability, long Stokes shift, 
aqueous solubility and low toxicity [87, 88]. The brightness of the fluorophore is 
determined by the molar absorption coefficient (ε, or extinction coefficient) and by 
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the quantum yield (ϕF) of the compound [74]. The ε indicates the ability of a 
molecule to absorb light of a given wavelength (λE), with high values indicating 
probable electronic transitions. The ϕF expresses the ratio between the number of 
emitted photons during relaxation and the number of absorbed photons, and the larger 
the value the easier it is to observe the fluorophore. Hence, the product of these two 
terms, ε(λE) x ϕF, determines the brightness of a given fluorophore. Excitation and 
emission spectra are also characteristic properties of each fluorophore. The excitation 
spectrum represents the fluorescence intensity at different wavelengths and the 
emission spectrum represents the distribution of the probability of S1 Æ S0 electronic 
transitions during relaxation [74]. Fluorophores with spectral properties (λex and λem) 
in the NIR region (650 – 900 nm) are of great interest due to their promising 
properties for biomedical imaging [89, 90] (see section 1.4.1). 
1.4.1 Near-infrared Fluorescent (NIRF) probes 
Electromagnetic radiation ranging from the ultraviolet (UV) to the near-infrared 
region (NIR) is widely exploited for imaging in the biomedical field, as illustrated in 
Figure 13. The UV region comprises wavelengths below 400 nm while the visible 
window ranges from 400 to 650 nm. The NIR region is divided further into NIR I 
(650 to 900 nm) and NIR II (1000 to 1700 nm). Between 900 and 1000 nm there is an 
increase in the absorption by water and lipids, limiting the applicability of this small 
region [91]. Compared to UV or visible light, NIR light exhibits favourable properties 
for bioimaging applications, such as reduced scattering and attenuation by tissues, as 
well as reduced absorption by cytochromes, haemoglobin or melanin in living 
organisms (Figure 14) [52, 92]. Thus, the use of fluorescent probes emitting in this 
privileged region of the electromagnetic spectrum allows for deeper tissue penetration 
and increased sensitivity due to reduced tissue autofluorescence [21].  
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Figure 14: Schematic overview of the behaviour of light in the different regions of 
the electromagnetic spectrum. UV suffers from complete absorption by tissue, the 
visible suffers absorption and scattering of light, and NIR allows deep tissue 
imaging [90]. 
Ever since the 1980s, extensive research has been undertaken in order to exploit the 
NIR region of the spectrum for biological imaging applications, with particular 
interest in fluorescence image-guided surgery (FIGS). Two representative examples 
are indocyanine green (ICG; λex = 807 nm and λem= 822 nm) and methylene blue 
(MB; λex = 665 nm and λem = 688 nm), the only two NIR fluorophores clinically 
approved as contrast agents (structures H and J in Figure 13, respectively). They have 
been used to identify sentinel lymph nodes (SLN) [93, 94] and certain tumours [95-
98]. However, the poor optical properties and the high chemical instability of MB 
have hampered its use [88]. ICG exhibits better optical properties than MB, and its 
tumour accumulation by the enhanced permeability and retention (EPR) effect has 
been exploited in intraoperative settings. Despite good malignancy detection rates, it 
was not able to specifically distinguish between healthy and diseased tissue, resulting 
in high background signals and thus high false-positive rates [95]. In addition, its 
poor aqueous stability, poor photostability, tendency to form aggregates and lack of 
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functional groups for conjugation to targeting moieties have limited its adoption as 
the standard contrast agent [4, 88, 99]. Formulations based on the encapsulation of 
ICG have overcome some of these limitations [100-102], however, much effort is 
being dedicated to the development of improved cyanine-derived probes with clinical 
translational potential for disease investigation [103, 104].  
1.4.2 Cyanine derived probes 
Cyanine (derived from the Greek κυανος [kyanos] = dark blue) dyes are a class of 
polymethine functional dyes with applications that range from electrophotography to 
photovoltaics. Cyanines are cationic compounds with two N-heteroaromatic electron-
donating groups connected through a polymethine bridge of varying length with an 
odd number of carbon atoms. Two examples of natural occurring cyanine dyes, 
betanin and musca aurin (Figure 15), were accidentally discovered and their 
structures elucidated in the 1960s by Dreiding and in the 1970s by Musso, 
respectively [105]. Both dyes, responsible for the colour of beetroot and Amanita 
muscaria respectively, were found to share a common pentamethinium scaffold and 
an L-amino acid-derived chiral group.  
 
Figure 15: Structures of betanin (K) and musca aurin (L) with their corresponding 
absorption wavelengths and their distinct colouration. 
Based on the number of methine groups present in the bridge they are classified as 
monomethine (n = 0; Cy1), trimethine (n = 1, Cy3), pentamethine (n = 2, Cy5) or 
heptamethine (n = 3, Cy7) cyanines (Figure 16) [86]. While Cy1 and Cy3 exhibit 
spectral properties in the visible region of the spectrum (400 - 650 nm), Cy5 and Cy7 
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show absorption and emission in the NIR-I region (650 – 900 nm). The increase in 
the number of methine groups and increased conjugation entails an advantageous 
bathochromic shift of around 100 nm for each extra methine group, albeit with 
reduced fluorescence quantum yield [86, 106]. It has also been observed that 
elongation of the polymethine chain alters the pharmacokinetic properties of 
conjugates composed of the same αvβ3–recognising peptide bound to either Cy3, Cy5 
or Cy7 derived fluorophores [107]. Introduction of a squaryl moiety (M, Figure 16) 
or a cyclohexenyl (N, Figure 16) groups in the conjugating system increases the 
planarity and rigidity of the structure and has given compounds with improved 
photochemical stability compared to the corresponding cyanines [89, 106, 108].  
 
Figure 16: Schematic overview of the general structure of cyanines. M and N 
represent two common modifications of the polymethine chain to improve the 
stability of Cy5 and Cy7 derivatives. Some common examples of Cy5 and Cy7 
compounds employed in preclinical and clinical settings for fluorescence imaging 
are shown.  
In addition to modifications of the polymethine chain, variations in the nitrogen 
substituents R1 and R2 and/or in the heterocycles can tune the physicochemical and 
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optical properties of these compounds. Cyanines are quite lipophilic and this limits 
their applicability for in vivo FLI. Introduction of charged groups such as sulfonates 
on the heterocycles or aliphatic chains with terminal sulfonate groups as nitrogen 
substituents has rendered these compounds more hydrophilic [109]. In addition, a 
balanced surface net charge of zero (zwitterionic) is desirable to avoid off-target 
accumulation, thus reducing background signal [110]. ZW800-1 is an example of a 
zwitterionic fluorophore with reduced binding to proteins compared to ICG, however 
the labile ether linkage on the meso carbon renders this compound unstable, which 
results in decreasing fluorescence signal over time [88]. To overcome this, a stable 
derivative with a carbon-carbon bond in the meso position, ZW800-1 Forte, was 
synthesised [111]. This derivative exhibits long-term stability, but it displays H-
aggregation due to the distinct polarity and the rigidity of the meso carbon substituent 
[111]. IRDye® 800CW is the most widely employed cyanine derivative and it has 
been conjugated to a variety of targeting ligands in preclinical FLI and clinical FIGS 
[112-115]. The highly hydrophobic core is decorated with four negatively charged 
groups that confer a highly anionic surface charge [116]. Therefore, excretion is 
expected to occur via the renal route, but when targeting ligands are conjugated to 
this fluorophore, increased liver uptake and off-target accumulation has been 
observed, likely due to the interaction of this fluorophore with serum proteins [116]. 
It is evident that the physicochemical properties of the fluorophores play a key role in 
their in vivo behaviour, even when conjugated to large molecules such as antibodies, 
and should be balanced to obtain optimal results [87].  
These are just a few examples of cyanine dyes under development for optical 
imaging, but the list of potential candidates is long (AF680 [117], BM104 [118, 119], 
AF750 [120, 121], S0456 [122, 123] or LS288 [124, 125]). Hence, part of the work 
of this thesis has focused on derivatives of the polymethines Cy5 and Cy7 and their 
potential as conjugatable fluorophores for targeted approaches.  
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1.5 Targeted fluorescent imaging approaches 
The dyes described in the previous section have proven useful for imaging a wide 
variety of biological processes. However, their utility is often restricted by their lack 
of specificity, rendering them inefficient for FLI [95]. In this context, many different 
targeted approaches have been implemented to reduce undesired background signal 
and thus obtain better contrast [126-128]. 
Targeted approaches employ fluorophores, often referred to as “always-on” probes, 
covalently bound through a linker to a targeting ligand against a specific 
overexpressed target in the tumoral tissue or the tumour microenvironment (TME) 
[129]. The number of molecular targets (biomarkers) that can be exploited for disease 
interrogation has increased in the last decades [114, 130, 131]. And with this, the 
number of different targeting ligands has also risen including small molecules, 
peptides, antibodies (intact or fragments), functionalised nanoparticles, etc. [114, 122, 
132, 133]. Fluorophores for stable labelling and long-term monitoring of these 
molecular ligands are also well developed, as explained earlier [76, 134]. The ideal 
conjugate needs to exhibit low toxicity, high photochemical stability and fast 
clearance. Hence, the design of targeted molecular contrast agents requires special 
attention not only with regard to the choice of targeting ligand, but also to the linker 
and to the fluorescent contrast agent selection. Several cases have been previously 
reported in which the choice of linker or fluorescent contrast agent affected the 
affinity of the targeting ligand for the molecular target of interest [123, 135]. 
Folate receptor alpha (FRα) is an example of a widely studied molecular target with 
both diagnostic [136] and therapeutic applications [137, 138]. FRα is overexpressed 
in several different types of tumours, including ovarian and lung adenocarcinomas, 
but has limited expression in healthy epithelial tissues [139, 140]. Folate is a vital 
vitamin for DNA synthesis and repair, thus playing an important role in rapid cell 
division and growth. The internalisation of folate after binding to the membrane-
bound FRα has been exploited for drug delivery [141-143], as well as for contrast 
agents with imaging purposes [122, 144, 145]. 
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However, most of these targeted approaches employ “always-on” contrast agents that 
contribute to background signal by off-target accumulation of unbound fluorescent 
contrast agent, which degrades the quality of the images and requires longer washout 
periods. To further increase the specificity of the signal, targeted strategies employing 
activatable fluorescent probes [146] could be implemented to provide increased 
tumour-to-background ratios (TBR) by reducing off-target fluorescence signals. The 
fluorescence of such probes is quenched until activation by tumour-specific enzymes 
[147] or by chemical reactions that occur once specifically internalised in the cells 
[148, 149]. CytoCy5S is an example of a quenched fluorescent contrast agent 
activated by NTR enzymatic reduction. NTR reduces the nitro groups of this cyanine 
derivative to hydroxylamine groups, thereby restoring its fluorescence and allowing 
sensitive investigation of NTR expression by fluorescence imaging [150]. 
These activatable probes represent a good choice for applications where high contrast 
is imperative, such as FIGS. Additionally, they offer potential applicability in 
intraoperative settings where washing procedures are not possible, i.e. probes 
topically applied for residual disease identification after tumour debulking or probes 
employed during endoscopic examinations [88, 151, 152]. 
1.6 Applications and clinical translatability of reporter genes 
and/or fluorescence imaging 
1.6.1 Gene-directed enzyme prodrug therapy 
GDEPT is a promising anti-tumour strategy that aims to reduce off-target toxicity and 
limit severe side effects by the combination of a prodrug and its activating enzyme 
[153]. In a first step, tumours are transduced to express a gene encoding the prodrug-
activating enzyme. In a second step, a non-toxic prodrug, delivered systemically, is 
converted in situ into a cytotoxic metabolite by the expressed enzyme [154] (Figure 
17). In some cases, the activated metabolites are able to diffuse to neighbouring cells 
(bystander effect) exerting their cytotoxic effect and thus increasing the killing 
potential of this approach [155, 156]. In this way, GDEPT achieves high 
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concentration of cytotoxic compounds locally, minimising systemic side effects 
associated with conventional cancer chemotherapy [157]. 
 
Figure 17: Schematic overview of the key steps in GDEPT. From left to right: 
Transduction of cells to express protein of interest, in this case NTR. Bioreductive 
activation of prodrug CB1954 by NTR. Reduction of contrast agents, radiotracers 
or fluorescent contrast agents, by NTR allows PET or FLI imaging. 
The most extensively studied prodrug/enzyme pairs for GDEPT are ganciclovir 
(GCV)/herpes simplex virus-thymidine kinase (HSV-TK) [158] and 5-(aziridin-1-yl)-
2,4-dinitrobenzamide (CB1954)/E. coli nitroreductase NfsB (NTR) [159]. HSV-TK 
phosphorylates GCV, allowing its incorporation into DNA and resulting in toxicity 
due to interference with the DNA synthesis. NTR reduces the nitroaromatic groups 
(R-NO2), present in CB1954, into hydroxylamines (R-NHOH), converting it into an 
alkylating agent with cytotoxic activity [160, 161]. In addition, the activity of these 
enzymes can also be exploited with imaging purposes, i.e. to identify promising 
responder candidates before therapy and to monitor the drug efficacy post-treatment. 
Radiolabeled probes, such as 18F-FIAU (1-(2- deoxy-2-[18F]-fluoro-1-D-
arabinofuranoside)-5-iodouracil), 18F-FHBG  (9-[4-[18F]-fluoro-3-
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(hydroxymethyl)butyl]guanine) and GCV analogues are available for the assessment 
of HSV-TK activity. Thus, PET/CT imaging has been successfully applied 
preclinically to monitor transduction efficiency, tissue specificity and therapeutic 
effect [162, 163] and it was subsequently incorporated into phase I clinical trials to 
monitor transduction efficiency in healthy individuals and in cancer patients [164, 
165].  
NTR exhibits promising therapeutic potential by generating alkylating agents that 
target both dividing and quiescent cells indistinctly, a clear advantage compared to 
HSV-TK, which is only able to kill rapidly dividing cells. NTR activity has been 
successfully evaluated in preclinical settings using a NIR fluorescent dye, CytoCy5S 
[150] and a caged bioluminescent substrate, “NTR caged luciferin” (NCL) [166]. 
However, the lack of probes for NTR activity investigation by employing well-
established clinical imaging modalities, such as PET/CT, has hampered the further 
progress of NTR-based GDEPT clinical trials [159]. But the last word is not yet 
spoken as Mowday and co-workers have recently demonstrated effective NTR PET 
imaging employing NfsA from E. coli in combination with the PET tracer 18F-HX4 
[167]. 
1.6.2 Fluorescence image-guided surgery (FIGS) 
FLI has proven useful in a variety of preclinical studies, but translation to the clinic is 
hampered outside the intraoperative settings. This is due to different factors, mainly 
to the low depth of penetration of the light but also to the lack of FDA-approved NIR 
probes hindered by the lack of standardisation protocols, or the lack of adequate 
instrumentation [24]. However, promising examples on the clinical use of 
fluorescence imaging to aid surgeons delineate the surgical area of interest in real-
time are available [114, 168-170].  
FIGS aims for complete diseased tissue resection, while avoiding morbidity by 
preserving vital structures like nerves or blood vessels [90]. It relies on the 
fluorescence emitted by an exogenous fluorescent probe, either untargeted or 
targeted, after excitation by an appropriate light source [171]. This fluorescence-
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based imaging technique provides real-time illumination of tumour burden allowing 
surgeons to resect margins [172] and small metastases that are difficult to identify 
with the naked eye. Other advantages are its safety, because light is non-destructive 
and non-ionising probes are employed to provide contrast, and its low cost compared 
to other techniques employed in the operating room (OR) such as CT or MRI. 
Moreover, this technique can easily be implemented in the OR, without 
compromising sterility or workflow, and allowing increased sensitivity compared to 
preoperative imaging modalities [21].  
One critical aspect for the success of this technique is a high SBR. Targeting highly 
expressed molecular biomarkers with despisable expression in surrounding tissues 
can help to attain the desired high contrast. The use of targeted-activatable 
fluorophores is another promising approach that is being actively researched [88]. In 
addition, the last years have witnessed an increased interest in exploiting the NIR II 
window, were the spectral characteristics of tissues play no role in scattering, 
allowing even better contrast and deeper tissue penetration. Some promising 
examples include the localisation of minute tumour metastases in a murine model of 
ovarian cancer employing SWNT in the NIR II window [84] or the first-in-human 
multispectral approach exploiting simultaneously the NIR I and II windows with 
ICG, suggesting the potential of the latter to improve FIGS outcomes [173]. 
Despite the promising results obtained using FIGS in different clinical trials, unmet 
needs have hampered its extensive use in the clinic and most surgeries are still 
performed without real-time image-based assistance [174]. Vast efforts in chemistry 
and in preclinical imaging research are ongoing [121] to resolve these issues and to 
develop improved targeted contrast agents, with particular emphasis in NIR II agents, 
for optimal performance during intraoperative procedures [149]. Development of 
improved contrast agents and multispectral surgical image-based systems exploiting 
simultaneously the NIR I and II windows will facilitate progress of molecular 
characterisation of disease by means of imaging [175].  
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2. Aims of the study 
2.1 Background and general aims 
Nitroreductases are enzymes of bacterial origin capable of reducing nitro groups. This 
nitroreduction potential has been widely exploited in different biotechnology 
applications. Nitroreductase NfsB (NTR) from E. coli is an example of an oxygen-
insensitive nitroreductase that has been relevant in biomedical research. The presence 
of nitro groups on some aromatic compounds, such as CytoCy5S, quenches the 
fluorescence of these compounds. NTR-catalysed reduction of the nitro groups to 
hydroxylamines or amines restores the fluorescence of these compounds allowing 
detection of the signal in optical imaging settings. In addition, non-toxic nitro-
containing compounds (prodrugs), such as CB1954, can be converted to highly toxic 
compounds by NTR reduction, that restores the reactivity capacity of these 
compounds.  
In this thesis, we aimed to develop fluorescent NTR substrates with improved 
physicochemical and optical properties for NTR fluorescence imaging in oncology 
settings. Furthermore, to improve the tumour contrast provided by ”always-on” 
fluorophores, we employed a targeted approach against an overexpressed biomarker 
such as folate receptor alpha (FRα) and studied and compared the impact of the 
physicochemical properties of five fluorophores on the in vivo behaviour of the same 
ligand. In addition, we assessed whether NTR nitroreduction of a hypoxia 
radionuclide (18F-FMISO) could be exploited in more clinically amenable settings 
employing PET/CT imaging of NTR expression. The suitability of 18F-FMISO for 
imaging transgene expression and prodrug treatment efficacy in an in vivo GDEPT 
setting was evaluated.  
2.2 Specific aims 
1. To define the physicochemical and optical properties of CytoCy5S (Paper I) 
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2. To identify the substrate with the best in vitro and in vivo characteristics for 
NTR interrogation in preclinical oncology animal models (Paper I) 
3. To compare the imaging performance of five different fluorophores conjugated 
to a ligand targeting folate receptor alpha in an ovarian cancer model (Paper 
II) 
4. To repurpose 18F-FMISO for PET/CT imaging of NTR expression (Paper III) 
5. To use the validated NTR PET/CT tracer to monitor the two main steps of an 
NTR gene-directed enzyme prodrug therapy (GDEPT) (Paper III) 
6. To analyse the potential of CytoCy5S in a “two-hit strategy” exploiting NTR 




3. Methodological considerations 
3.1 General synthetic overview 
3.1.1 Synthesis of Fischer bases 
The different Fischer bases employed in the synthesis of the four NTR substrates (1 – 
4 in paper I) and the NIR dyes 3, 5 and 6 in appendix I were obtained through N-
alkylation of 2,3,3-trimethyl-3H-indole, its 5-methoxy analogue or 1,1,2-trimethyl-
1H-benzo[e]indole (Scheme 1). 
Scheme 1: Synthesis of Fischer bases 8 - 13 that have been employed in 
the synthesis of NTR substrates 1 – 4 and NIR dyes 3, 5 and 6. 
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Their reaction with the different halogenated starting materials (3,5-dinitrobenzyl 
iodide, 6-bromohexanoic acid or iodomethane) under the conditions described in 
Scheme 1 yielded the intermediates 8 – 13 (paper I) in yields that ranged from 14% 
to 94% 
3.1.2 Condensation final compounds 
Substrates 1 (4 in appendix I), 3 and 4 in paper I and NIR dyes 16 in paper II and 3 
in appendix I were successfully synthesised through a one-pot condensation of the 
various Fischer bases with either squaric acid, malonaldehyde bis(phenylimine) or the 
Vilsmeier-Haack reagent shown in Scheme 2.  
Scheme 2: Synthesis of A) NTR substrates 1 – 4 (paper I) and NIR dyes 
B) 16 (paper II) and C) 3 (appendix I). 
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Substrate 2 was obtained in a stepwise manner through synthesis of the mono-
substituted methyl squaraine intermediate. Deprotection of the methyl ester under 
acidic conditions to give 14 and subsequent condensation of 14 and 8 gave 2. 
3.1.3 Condensation with squaric acid esters of Substrate 1 (Stepwise 
strategy) 
Substrate 1 in paper I (4 in appendix I) was also synthesised employing an 
alternative strategy that required the stepwise introduction of methylene bases (as 
previously described for substrate 2). Methyl and ethyl squarate were employed as 
starting materials and they were reacted with the Fischer bases 8 and 9 under the 
different conditions depicted in Scheme 3.  
Scheme 3: Stepwise introduction of methylene bases [176-178] 
3.1.4 Solid support synthetic approach for Substrate 1 
A third synthetic approach was attempted to improve the yield of substrate 1 in paper 
I (4 in appendix I). Fischer base 9 was immobilised on a 2-chlorotrytil chloride resin 
and reaction with 18 (Scheme 3) in the presence of carbodiimide (DIC) gave 
substrate 1 (Scheme 4).  
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Scheme 4: Synthesis of substrate 1 using a solid supported approach. 
3.1.5 Synthesis of targeting ligand 
To obtain γ-ethylenediamine folate (EDAF, 7), folic acid was converted to pteroic 
acid (12) in two steps. Ethylenediamine was protected with di-tert-butyl dicarbonate 
(Boc) to give tert-butyl (2-aminoethyl)carbamate (6) that was further reacted with 
Fmoc-Glu-OtBu followed by basic deprotection to yield 11. 12 and 11 were reacted 
to give γ-ethylenediamine folate (7) after acidic deprotection and RP-HPLC 
purification. 
 
Scheme 5: Synthetic route through pteroic acid (12) and tert-butyl N5-(2-
((tert-butoxycarbonyl)amino)ethyl)-L-glutaminate (11) employed to obtain 
γ-ethylenediamine folate (EDAF, 7). (Numbering from paper II) 
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3.1.6 Conjugation to targeting ligands 
Conjugates 1 – 5 in paper II and 1 and 2 in appendix I were synthesised by common 
amide bond formation (Schemes 6 and 7, respectively). The NHS esters of the 
different fluorophores were reacted with the targeting ligand EDAF in dry DMSO at 
rt for 24 h (1 – 5) or for 6 h (1 and 2). All conjugates except 3 were formed in the 
presence of DIPEA as base. The synthesis of conjugate 3 required less sterically 
hindered bases and TEA was employed.  
 
Scheme 6: Synthesis of EDAF-Cy7 conjugates 1 – 5 in paper II  
 
Scheme 7: Synthesis of EDAF-Cy5 conjugates 1 - 2 in appendix I  
 52 
3.2 Purification methods 
Most of the compounds synthesised required purification approaches prior to further 
reaction. Flash column chromatography with narrow particle range silica as stationary 
phase was employed for most of the intermediates. Mobile phase solvent composition 
and isocratic or gradient elutions were chosen based on the polarity properties of the 
different compounds.  
Automated flash chromatography was employed for highly polar intermediates 
(sulfonate containing intermediates, paper I) whose elution required reversed-phase 
methods. 40 g octadecyl silane (C18) columns were employed in combination with 
water-based mobile phases in the presence of ion-pairing substances such as 
ammonium acetate (CH3CO2NH4). This technique, which permits higher loading 
capacities than HPLC, was performed on a Puriflash XS 420 system (Interchim, 
Montlucon Cedex, France).  
Final compounds aimed for biological testing were purified by high-performance 
liquid chromatography (HPLC) using C18 reversed-phase columns. The elution 
methods used mixtures of acetonitrile and water both containing 0.1% of either 
trifluoroacetic acid (TFA), formic acid (CH3CO2H) or 10 mM of ammonium acetate. 
The linear gradients employed are described in detail in the electronic supplementary 
materials for each compound (Papers I and II). 
 
3.3 Characterisation techniques 
Nuclear magnetic resonance (NMR) was employed to confirm the structure of the 
different compounds throughout the synthetic steps. 2D experiments including 
COSY, ROESY and NOESY were employed to unequivocally assign the protons in 
the final structures. This technique proved indispensable to discern the correct isomer 
of the sulfonate substrate (paper I) after purification based in the coupling constants 
J given in Hertz (Hz). Multiplicity of the signals reported as singlet (s), broad singlet 
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(bs), doublet (d), double doublet (dd), triplet (t) or multiplet (m). High-resolution 
mass spectra were recorded with an AccuTOFTM mass spectrometer operated with an 
orthogonal electrospray ionization source (ESI), an orthogonal accelerated time of 
flight (TOF), single stage reflectron mass analyser and a dual micro channel plate 
(MCP) detector (papers I, II and III). 
 
3.4 In vitro experiments 
3.4.1 Enzymatic assay 
The use of the nitroreductase NfsB (NTR) from Escherichia coli in the presence of β-
NADH and β-NADPH allowed us to evaluate the suitability of four different 
compounds as substrates of this oxydoreductase (paper I). Once we proved that 1 - 4 
were substrates of NTR, their kinetic profiles were studied by evaluation of the 
fluorescence emission intensity over time. Fluorescence intensity of the different 
substrates was analysed using a Tecan Spark® multimode microplate reader and it 
was plotted as the average of the triplicates ± standard deviation. 
3.4.2 Cell culture 
The human embryonic kidney HEK-293T cell line is one of the most commonly used 
cell lines for lentiviral vector production. This cell line stably expresses the large T-
antigen (TAg) of simian virus 40 (SV40) that promotes plasmid-mediated gene 
expression during transient transfections [179]. These cells were used for lentiviral 
production for NTR-based gene therapy in papers I and III.  
The human mammary carcinoma MDA-MB-231 cell line was employed for in vitro 
and in vivo studies in papers I and III. Two different variants, MDA-MB-231Luc+ 
referred to as NTR- and MDA-MB-231Luc+/GFP+NTR+ stably expressing NTR (NTR+) 
were used.  
Many non-small cell lung carcinoma (NSCLC) cell lines, including NCI-H460, 
present increased DT-diaphorase (oxidoreductase) activity, which is involved in the 
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bioreduction of nitro-containing compounds [180, 181] and it is known to present 
higher levels of hypoxia. The two variants of this cell line, NCI-H460 Luc+ (NTR-) and 
NCI-H460 Luc+/GFP+NTR+ (NTR+), were employed in vitro and in vivo in paper III to 
study the effect of higher levels of hypoxia in the retention of 18F-FMISO. 
The human ovarian adenocarcinoma Skov-3 cell line is commonly used in ovarian 
cancer models. Skov-3 was employed in paper II for comparative studies of five 
different folate conjugates due to its known folate receptor alpha (FRα) expression 
[182, 183]. Another human NSCLC cell line, A549, was employed as the negative 
control for FRα [184] and the human cervical carcinoma HeLa cell line was used as 
the positive control for FRα in the same study. OV-90, stably expressing GFP, was 
employed in appendix I to study the in vivo fate over time of 1 using confocal 
fluorescence microscopy.  
Cell lines were maintained in DMEM (HEK293T, MDA-MB-231, Skov-3, A549 and 
HeLa) or in RPMI-1640 (NCI-H460, OV-90) media supplemented with 10% fetal 
bovine serum (FBS) and 1% L-glutamine. Cells were incubated in a humidified 
atmosphere at 37 °C and 5% CO2. Media were supplemented with 1% 
penicillin/streptomycin after cells were sorted or virally transduced.  
3.4.3 Viral transduction and gene expression assessment  
For in vitro NTR transduction, retroviruses and lentiviruses have been used. 
Retroviral transductions of the cell lines employed in paper III have been described 
elsewhere [150].  
For in vivo NTR transduction of subcutaneous tumours (paper III), lentiviruses were 
employed. Compared to retroviruses, lentiviruses are able to transduce cells in any 
step of their cycle offering higher transduction efficiencies. A more detailed 
description of the process can be found in the methods section of the corresponding 
paper III.  
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3.4.4 Flow cytometry 
Flow cytometry allows simultaneous characterisation of cell size, granularity (optical 
properties) and protein expression (fluorescence emission) in a single cell basis [185]. 
In addition, the use of several fluorophores with distinct spectral properties can be 
exploited for simultaneous interrogation of different proteins of interest. 
This technique was employed to assess the suitability of four in-house synthesised 
fluorophores to interrogate the levels of NTR expression in MDA-MB-
231Luc+/GFP+NTR+ cells (Paper I) and compared to MDA-MB-231Luc+.  
CytoCy5S was employed as the standard fluorophore for cytometric analysis of NTR 
expression in different cell lines after viral NTR transduction (Papers I, II and III). 
Enrichment of NTR expressing cells before tumour implantation was performed 
based on the 5% brightest population by incubation with CytoCy5S (Paper I).  
In paper II we investigated the expression of FRα in the ovarian carcinoma Skov-3. 
Pre-labelled antibodies and self-conjugated EDAF to commercial fluorophores were 
employed. HeLa was used as positive control showing the highest expression and 
A549 was employed as negative control to set the threshold of no expression. The 
FRα expression level of the different cell lines was quantified using calibration beads 
to measure the antibody-binding capacity (ABC) of each cell line. 
3.4.5 Fluorescence confocal microscopy 
Fluorescence microscopy allows the visualisation of general cell physiology traits and 
biological processes in living cells with the use of fluorophores. Better image 
resolution is achieved with confocal microscopy by acquiring only the light that 
comes from an equivalent point in the cell (confocal) [186]. 
Fluorescence confocal microscopy of live cells allowed us to study the uptake, 
fluorescence release and the intracellular fate of the four different substrates studied 
in paper I as well as the conjugates 1 and 2 from appendix I. Cells were kept at  
37 °C and 5% CO2 while images were acquired using a confocal Andor Dragonfly 
microscope (Oxford instruments).  
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3.5 In vivo experiments  
3.5.1 Ethical approval 
All applicable institutional and/or national guidelines for the care and use of animals 
were followed. Animal experiments were conducted according to The European 
Convention for the Protection of Vertebrates Used for Scientific Purposes and were 
approved by the Norwegian Food Safety Authority (FOTS ID no: 9059 and 14128). 
3.5.2 Optical imaging 
Bioluminescence  
BLI was performed (paper III) to monitor metastatic progression in mice 
orthotopically xenografted with the mammary carcinoma cell line MDA-MB-
231Luc+/GFP+NTR+. Animals were intraperitoneally injected with D-Luciferin (Biosynth, 
Switzerland) at a dose of 150 mg/kg 10 minutes before imaging. BLI images were 
acquired weekly using an In-Vivo FX Pro molecular imaging system (Carestream 
Health Inc., NY, USA). During acquisition, mice were anesthetised with 1.5% 
isoflurane. Regions of interest (ROI) were manually drawn in the primary tumour 
location and in the axillary region were metastasis was observed and BLI signal was 
measured.  
Fluorescence imaging 
FLI is the main in vivo technique used in this thesis. It has been used in all three 
papers with distinct purposes. In paper I, FLI allowed us to evaluate the biological 
behaviour of four different NTR substrates in a subcutaneous MDA-MB-231 model, 
while in paper II, FLI was employed to compare the biological behaviour of five 
different NIR fluorescent probes (Cy7 range) conjugated through the same linker to a 
FRα targeting ligand. In both papers, the fluorophores or fluorescent conjugates in 
solution were intravenously injected and biodistribution studies at different time 
points and longitudinal FLI of xenografted tumours were performed. In paper III, 
CytoCy5S-FLI was used for monitoring disease progression, transgene expression 
and therapeutic response.  
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When working with the Cy5 fluorophores, animals were fed with low-
autofluorescence rodent imaging food (Rodent imaging diet D1001; Research diets 
Inc., Brunswick, USA) from, at least, two weeks prior to experiments in an attempt to 
reduce fluorescence signal from the gastrointestinal tract. The fur was shaved to 
avoid autofluorescence. Animals anaesthetised and maintained with 1.5% isoflurane 
were imaged using an IVIS Spectrum imaging system (PerkinElmer Inc.) with the 
appropriate filter pairs (λex/λem) for each investigated fluorophore. Analysis of the 
collected data was performed with the Living Imaging® software v4.5 (PerkinElmer 
Inc.).  
Ex vivo FLI imaging was performed to further assess biodistribution of the different 
fluorophores and fluorescent conjugates with special attention to tumours and main 
organs involved in excretion. 
In addition, in paper II FLI was exploited using an intraoperative image-guided 
system (FLARETM) to visualise the resected tumours and organs after intravenous 
injection of the five different studied conjugates. A comparative analysis of the 
fluorescent signals in the tumours and the main excretion organs was performed by 
manually drawn ROIs. The purpose was to identify the best conjugate candidates and 
the best imaging conditions to proceed further with more relevant orthotopic models.  
3.5.3 Nuclear imaging 
In paper III nuclear-based imaging was employed to monitor tumour progression, 
metastatic spreading, transgene expression and prodrug therapy response.     
18F-FMISO, a widely used hypoxia radiotracer, was repurposed for interrogation of E. 
coli nitroreductase (NfsB) expression. Mice were intravenously injected with   
18F-FMISO with activities ranging from 8 to 12 MBq. After 90 minutes of washout, 
mice were scanned using a dual mouse bed with integrated heating (37 °C) and 
anaesthesia (3 – 4% sevoflurane) over 30 minutes. PET scans were performed in an 
integrated nanoScan PC PET/CT (Mediso Ltd, Hungary) with whole-body CT scan 
prior to PET acquisition for anatomical information. Spatial resolution of 800 μm and 
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300 μm of the PET and CT detector systems, respectively. Further PET/CT imaging 
and reconstruction details can be found in the methodology section of Paper III. 
 
3.6 Ex vivo analysis 
Histopathology allows microscopic assessment of changes in tissue associated with 
pathologies like cancer, with e.g. haematoxylin and eosin (H&E) staining. In 
addition, immunohistochemistry allows the identification of different proteins 
(antibody-antigen interaction) expressed in the tissues that can be associated with 
distinct molecular processes in tumours.  
For papers II and III tumours and organs of interest were cryopreserved (OCT at -80 
°C) or/and fixed in a 4% paraformaldehyde solution at rt for 24 h. The tissues were 
later kept in PBS and protected from the light at 4 °C before paraffin embedding. 
Formalin fixed paraffin embedded (FFPE) tissue blocks were sectioned (5 μm) and 
stained with H&E for verification of malignancy (Paper III). To evaluate the 
expression of FRα (Paper II) and Hypoxia-inducible factor-1 (HIF-1; Paper III) 
sections were prepared for immunohistochemical staining of rabbit anti-human 
antibodies. Sections were incubated overnight with FRα (Cat# PA5-24186, clone 
SA170417DD, 1:2000, Invitrogen) and HIF-1 (Cat# ab51608, 1:300, Abcam) 
antibodies. Histopathology examinations and scoring of the samples was performed 
by experienced pathologists from the Department of Pathology, Haukeland University 
Hospital (Bergen) and the Department of Pathology, The Norwegian Radium 
Hospital, Oslo University Hospital. 
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4. Summary of results 
4.1 Paper I 
In this study, we set out to clarify an ongoing discrepancy regarding the structure and 
physicochemical properties of CytoCy5S, a NIR fluorescent NTR substrate, in order 
to establish which of the structures denoted as CytoCy5S in the literature is best 
suited for preclinical studies in oncology models. Four substrates (1 – 4) containing a 
3,5-dinitrobenzyl moiety, which renders them non-fluorescent, were synthesised and 
analysed in vitro and in vivo. The introduction of the methoxy group in 3 and the 
sulfonate and cyanine scaffold in 4 resulted in a modest bathochromic shift in the 
spectral properties of these substrates compared to 1 and 2. The kinetic assessment of 
NTR bioreduction of the four different substrates, revealed the delayed kinetics of 
substrate 2 and the low emission efficiency of substrates 3 and 4. The suitability of 
the four substrates for intracellular interrogation of NTR expression was assessed by 
incubation of NTR- and NTR+ MDA-MB-231 cells under different conditions. The 
results evidenced the high contrast between cell lines obtained when using substrate 3 
as well as the high dependence of this substrate on the concentration. Substrates 1 and 
2 exhibited comparable performances and substrate 4 performed poorly. The 
biological behaviour of these substrates was further investigated in murine 
subcutaneous xenograft models. Despite the promising in vitro performance of 
substrate 3, it did not prove as useful for discerning between NTR- and NTR+ tumours 
as substrates 1 or 2 did. Substrate 1 was found to be best suited for imaging of NTR, 
both in vitro and in vivo, with superior kinetics and lower background fluorescence 
from immediate surrounding tissues allowing a better delineation of tumours. In 
addition, this substrate presents a carboxylic functionality that can be further 
derivatised for biomarker interrogation. 
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4.2 Paper II  
In this study, we aimed to compare the impact of five different NIR fluorophores on 
the biodistribution, specificity and contrast of conjugates targeting folate receptor 
alpha (FRα) using an ovarian cancer model. Skov-3 and A549 cell lines with 
intermediate and low FRα expression, respectively, were employed. Four 
commercially available and one in-house synthesised fluorophores, namely ZW800-
1, ZW800-1 Forte, IRDye® 800CW, ICG and Cy7 derivative were conjugated to the 
folate ligand through an ethylenediamine linker to give conjugates 1 - 5, respectively. 
The biodistribution of conjugates 1 – 5 was assessed in vivo by FLI, indicating 
preferential renal clearance for 1, 2 and 3 and hepatobiliary clearance for 4 and 5. 
Tumour accumulation was observed for all conjugates except 4. However, the high 
off-target fluorescence obtained for 3 and the low fluorescence intensity of 5, 
together with its probable albumin-mediated accumulation in tumours by the EPR 
effect, limited their applicability. Conjugate 2 showed an intense fluorescence signal 
in tumours and it was the only conjugate that reported significant fluorescence 
differences between Skov-3 and A549 (p < 0.05). Our results confirmed the high 
impact of the fluorophore on the biodistribution of the conjugates to excretory organs 
and tumours and the potential of 2 as fluorophore for targeted strategies providing 
specific fluorescence signal.  
 
4.3 Paper III 
In this study, we have investigated the repurposing of 18F-FMISO as a companion 
diagnostic tool for NTR-based gene-directed enzyme prodrug therapy (GDEPT). To 
validate the suitability of 18F-FMISO PET/CT to image NTR expression, a 
subcutaneous mammary carcinoma (MDA-MB-231) xenograft model constitutively 
expressing NTR was studied. We demonstrated that 18F-FMISO PET/CT imaging is 
sensitive for detection of NTR with significantly higher contrast between NTR+ and 
NTR- xenografts from week four after implantation (p < 0.0001). We next evaluated 
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the sensitivity of this technique to detect NTR+ small metastatic lesions in an 
orthotopic model. We proved that 18F-FMISO PET/CT imaging allows visualisation 
of nodal metastatic tumours, with significantly higher contrast between healthy tissue 
and metastatic nodes from week ten after implantation (p < 0.05). Additional 
metastatic lesions in distal organs such as liver and lungs were observed in the 
PET/CT images and confirmed ex vivo by histological examination. Lastly, the 
suitability of 18F-FMISO PET/CT imaging was challenged in a GDEPT setting. 
Subcutaneous xenografts of MDA-MB-231 NTR- were transduced by intratumoral 
injection of NTR lentiviral particles. We demonstrated that 18F-FMISO PET/CT 
imaging allowed for detection of NTR expression with significantly higher contrast 
between in vivo NTR transduced xenografts and NTR- xenografts from week four 
after in vivo NTR transduction (p < 0.05). NTR transduced xenografts, NTR+ and 
NTR- xenografts were treated with the prodrug CB1954 and response to treatment 
was monitored by 18F-FMISO PET/CT imaging. We demonstrated that 18F-FMISO 
PET/CT imaging allowed the monitoring of treatment efficacy even when the 
response was limited, as is the case in the in vivo NTR transduced xenografts. Post-
treatment 18F-FMISO PET/CT imaging of in vivo transduced xenografts demonstrated 
a significant decrease in contrast compared to pre-treatment (p < 0.05). This decrease 
in contrast was also confirmed for the NTR+ xenografts with higher significance both 
at day 3 (p < 0.001) and 17 (p < 0.0001) after treatment. This was accompanied by a 
significant tumour volume decrease of NTR+ compared to NTR- xenografts (p < 
0.0001). These preclinical studies confirm 18F-FMISO NTR PET/CT as a readily 
available methodology for clinical application in NTR-based GEDPT. 
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5. General discussion 
Molecular imaging (MI) is fundamental in clinical settings for diagnosis, treatment 
selection, intraoperative guidance and treatment efficacy evaluation. This field has 
progressed rapidly in recent years, driven by the need for sensitive diagnostic tools 
and as a tool to monitor the efficacy of new cancer treatments, including gene-based 
therapies [20]. MI provides fundamental information on the in vivo behaviour of new 
drugs and contrast agents, simultaneously allowing assessment and visualisation of 
target expression and plays a key role in the early stages of drug discovery and 
development [16, 17]. The work of this thesis has focused on the contrast agents of 
two main MI methodologies, namely optical imaging (mainly fluorescence imaging 
(FLI) for longitudinal imaging (Papers I – III) and fluorescence image-guided 
surgery (FIGS) (Paper II)) and nuclear-based PET/CT imaging (Paper III). 
MI in combination with reporter genes allows in vivo monitoring of enzyme 
expression and follow-up of the success of gene-based therapies, where the suicide 
gene also acts as reporter gene (theranostic). In this thesis, nitroreductase NfsB 
(NTR) from E. coli has been concurrently employed as a reporter gene (Papers I and 
III) and suicide gene (Paper III). NTR is an oxygen-insensitive enzyme capable of 
reducing nitro groups to their corresponding hydroxylamines or amines, permitting 
the conversion of prodrugs into highly toxic metabolites (CB1954 in paper III) and 
the activation or retention of contrast agents (CytoCy5S and 18F-FMISO, 
respectively, in papers I and III). Our group has previously demonstrated the 
applicability of NTR in combination with CytoCy5S, a quenched NIR dye substrate 
of NTR, for imaging of cancer cells dissemination in an orthotopic murine model 
[150]. In addition, exploiting the NTR/CytoCy5S imaging platform has allowed the 
non-invasive monitoring of the therapeutic efficacy of prodrugs such as 
metronidazole and CB1954 in gene enzyme directed prodrug therapy (GDEPT) 
settings [150, 187].  
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In the context of this thesis work, the use of MI and different contrast agents for 
tumour detection and evaluation of therapeutic efficacy will be discussed in detail and 
compared with relevant literature. 
5.1 Fluorescent probes and their physicochemical properties, a 
double edged sword 
It is well accepted that exploiting the NIR region of the spectrum (650 – 1700 nm), 
where light scattering and background fluorescence are reduced and the penetration 
depth of light increases, is advantageous for acquiring fluorescent images with higher 
contrast [90]. To achieve the most out of this privileged region of the electromagnetic 
spectrum, novel fluorophores with appropriate spectral properties, high molecular 
brightness (ε x ϕ), large Stokes shifts, hydrophilicity, photochemical stability which 
are also safe to use are required [89, 188, 189]. Although the desired properties are 
clear, achieving all of them in a single molecule is a challenge that has not yet been 
solved.  
Cyanine-based fluorophores, with high molar absorption coefficients (ε) in the NIR, 
are the most widely employed dyes for NIR-I bioimaging in the medical field [88] 
and their use for imaging in the NIR-II region (1000 - 1700 nm) is being actively 
investigated [190]. Cyanine-based dyes have been the main focus of this thesis 
(Papers I – III) and will be used to illustrate the importance of finding common 
ground in terms of their physicochemical properties.  
Fluorophores with large Stokes shifts and emission at longer wavelengths provide 
better resolution and brighter images. However, the shift from Cy5 to Cy7 will have a 
detrimental effect on quantum yields (ϕ) caused by the loss of energy through non-
radiative relaxation processes, which are enhanced at lower energies (longer 
wavelengths) [191, 192]. To mitigate this trade-off, structural elements that impart 
rigidity to the heptamethine scaffold, such as the meso cyclohexyl (conjugates 1, 2, 3 
and 5 in paper II, dashed bonds in figure 18A), have been incorporated, thereby 
improving photostability and quantum yield [193]. Alternative strategies include the 
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substitution of indoline by indolizine groups in Cy5 scaffolds (Figure 18B & C). 
Despite being based on pentamethine chains, these compounds exhibit bathochromic 
shifts with respect to Cy7 dyes such as ICG and enhanced molecular brightness 
compared to their indole counterparts [194]. However, these cyanine derivatives (C5 
and PhIn2SQ) were poorly soluble in water, a major limitation for their use in 
biological systems. To circumvent this, two sulfonate groups were appended to these 
dyes in positions where the substituents did not have a strong impact on conjugation 
and, therefore, on the optical properties, achieving dyes (SO3C5 and SO3SQ) with 
enhanced hydrophilicity and stability in water with comparable spectral properties to 
their lipophilic counterparts [195]. 
Figure 18: Overview of different cyanine/squaraine-based 
fluorophores with indoline and indolizine functionalities highlighted 
in blue. A) General structure of heptamethine dye with cyclohexyl 
functionality in dashed bonds (O) and ICG structure, λem = 835 nm; 
B) Cyanine-based dyes including indoline (P) and indolizine 
derivatives (C5, λem = 852 nm and SO3C5); C) Squaraine-based dyes 
including indoline (Q) and indolizine derivatives (PhIn2SQ and 
SO3SQ). Emission wavelengths reported in DMSO [194,195]  
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The use of sulfonate groups is a common approach to compensate for the high 
hydrophobicity of the cyanine scaffold [188]. However, the introduction of several 
negative charges has proved to be counterproductive, as was found to be the case 
with IRDye® 800CW (conjugate 3 in paper II), which displayed off-target 
fluorescence signals that reduced the contrast of the image in addition to suboptimal 
biodistribution [196]. Furthermore, the presence of a single sulfonate on substrate 4 
(paper I) did not substantially improve water solubility but rather hampered cell 
penetration, limiting its usefulness.  
To increase hydrophilicity while avoiding some of these constraints, different 
strategies have been evaluated including PEGylation of fluorophores and their 
corresponding conjugates [197-199] or encapsulation formulations using 
nanoparticles [200] or micelles [201]. These strategies have the trade-off of creating 
larger molecules with slower excretion rates, requiring delayed imaging time points. 
However, this feature is advantageous to obtain longer blood circulation times and 
enhanced tumour uptake by the EPR effect [202]. Another approach has been the 
synthesis of hydrophilic zwitterionic dyes (conjugates 1 and 2 in paper II). These 
compounds contain two sulfonates but are designed to have a balanced net charge of 
zero through the introduction of trimethylammonium substituents. Such zwitterionic 
dyes exhibit remarkable water solubility and reduced non-specific binding to 
proteins, resulting exclusively in renal clearance [110]. However, ZW800-1 
(conjugate 1) contains a labile ether linkage on the meso position (functionality also 
present in conjugate 3) that renders this compound unstable towards nucleophilic 
attack with a decreasing fluorescence signal over time [203]. To overcome this, 
ZW800-1 Forte (conjugate 2) was designed with a C-C bond substituting the ether 
group and long-term stability was achieved [111]. However, due to the increased 
rigidity of this substituent, self-aggregation (H-aggregates) was observed [111], a 
common problem for such structures [204, 205]. An alternative zwitterionic cyanine-
based dye with improved stability and pharmacokinetic properties was later 
developed through shielding of the linear hydrophobic Cy7 scaffold by the 
introduction of two triethylenglycol chains [196]. These substituents increased the 
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photostability of the dye and prevented aggregation without limiting derivatisation 
with targeting ligands.  
5.2 NTR-activatable cyanine-based fluorophores 
Despite being at the limit of NIR spectral properties, Cy5-based dyes have found 
application in imaging of biological systems, including imaging of nitroreductases 
[206, 207]. In addition to the applications described above for the NTR/CytoCy5S 
imaging platform, it has also been employed in development studies to analyse 
differentiation and interaction of different cell types [208]. Moreover, it has proven 
useful for in vivo imaging of different bacterial strains and bacterial colonisation of 
tumours. The latter feature, has been suggested as a potential gene delivery method 
for gene therapy in cancer [209]. However, the structure or analytical characterisation 
of CytoCy5S is not included in any of the published papers and discrepancies were 
found regarding both the physicochemical and optical characteristics of this Cy5-
based dye. 
In an attempt to clarify these discrepancies and highlight the worryingly high number 
of biology papers reporting results of uncharacterised material, the unsymmetrical 
substrates 1 – 4 (paper I and depicted in Figure 19A) were synthesised, purified and 
chemically characterised, a key step for robust and reproducible inter- and intra-
laboratory results. In general, indoline-containing Fischer bases were easily obtained 
in modest to good yields. However, the sulfonate group required for substrate 4 posed 
a challenge, as several isomers were formed in the sulfonation step and separation of 
these was unsuccessful using conventional purification methods. 
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The final substrates 1 - 4 (Figure 19A) were prepared by condensation reactions via 
one-pot or stepwise approaches with yields that ranged from 1 - 16% due to the 
formation of symmetric by-products (Figure 19B). A stepwise strategy was required 
for substrate 2, since the one-pot approach only produced the N-methylated by-
product, probably due to the higher reactivity of this Fischer base. In addition, the 
synthetic reproducibility of substrate 4 proved to be limited. For the sake of proper 
comparison, substrate 4 from the same batch was used throughout the different 
experiments to avoid dye-based variability. 
Substrates 1, 2 and 3 are based on a squaraine scaffold, which in general imparts 
rigidity, increases polarity and photostability and reduces quantum yields [210, 211]. 
Substrate 4 is a cyanine-based dye and therefore longer absorption and emission 
wavelengths and better quantum yields are expected. However, it was not possible to 
directly compare the quantum yields of the different substrates, hereby limiting the 
Figure 19: A) Chemical structures of substrates 1 to 4 employed in 
paper I with the 3,5-dinitrobenzyl moiety that quenches their 
fluorescence highlighted in red; B) One-pot synthetic route to obtain 
substrates 1, 3 and 4 and stepwise route to 2 where R1 corresponds to 
the N-methyl substitued Fischer base. 
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comparison of the brightness of the dyes. Despite this limitation, the data obtained 
from the emission spectra in comparison to the absorbance and excitation spectra 
suggest that substrates 3 and 4 exhibit limited brightness, possibly due to non-
radiative decay. Most examples of NTR-activatable substrates in the literature [206, 
212, 213] (only those with NIR spectral characteristics have been considered) 
correspond to fluorophores substituted with a p-nitrobenzyl moiety as a caging group 
(depicted in purple in figure 20), rendering the caged fluorophore silent. Upon NTR-
mediated reduction, which results in a rearrangement-elimination reaction, the parent 





In our case, the quite unique 3,5-dinitrobenzyl moiety (depicted in red in Figure 19A) 
for NTR-mediated activation renders the substrates non-fluorescent due to a 
photoinduced electron transfer (PeT) process. Reduction of the nitro groups into 
hydroxylamines by NTR results in an increase in the energy of the lowest unoccupied 
molecular orbital (LUMO) of the acceptor, which hampers the quenching mechanism 
and results in fluorescent properties [214, 215].  
Our results demonstrate the large impact that small modifications in dye structure 
have on the physicochemical and optical properties of the dyes and will help 
scientists to make an informed decision on the optimal fluorophore for their work. 
They also highlight the necessity for stricter reporting requirements of the chemical 
characterisation of compounds used in biomedical research, both for research groups 
and commercial suppliers.   
Figure 20: Example of the NTR-mediated uncaging mechanism of 
p-nitrobenzyl (depicted in purple) and release of the parent 
fluorophore, methylene blue (MB), with restoration of the 
fluorescence [212]. 
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5.3 Stability, sensitivity and specificity: considerations in the 
design of fluorescent conjugates towards the clinic  
To avoid off-target fluorescence, which has a detrimental impact on contrast, in 
addition to activatable fluorophores, the use of fluorophores in targeted approaches is 
preferred. The properties of the fluorophores used should be optimised as described 
in section 5.1 for increased sensitivity [216]. To obtain highly specific signals, the 
conjugates should exhibit high receptor binding affinity leading to increased retention 
in the tumour and rapid clearance from off-target tissues [129]. Currently, a myriad of 
tumour-specific antibodies are approved for clinical use and their labelling with NIR 
cyanine-based fluorophores is a widely exploited approach for FIGS [88, 217]. 
However, the lack of control and consensus over labelling ratios makes it difficult to 
reproduce the results due to the different conjugates’ composition after each 
conjugation [218, 219]. Therefore, small molecules with a single reactive site are 
preferred, as they also overcome the slow in vivo kinetics of antibodies, allowing 
faster imaging time points after conjugate administration. However, as for antibodies, 
the in vivo behaviour and physicochemical properties of these small molecules will be 
greatly influenced by the choice of fluorophore [107]. In paper II we aimed to 
compare how the physicochemical properties of five commonly used NIR 
fluorophores affected the in vivo performance of a folate receptor alpha (FRα) 
targeting ligand. 
FRα is a well-known molecular target that has shown promising results when 
employed for MI as well as when used as a therapeutic target [136-138]. In fact, a 
phase III clinical trial of a folate-targeting small molecule labelled with a NIR 
fluorophore (OTL38, Figure 21A) for intra-operative imaging in ovarian cancer has 
recently been completed and results are awaited (NCT03180307). Hence, the folate 
ligand was conjugated though an ethylenediamine linker (Figure 21C) (same as for 
EC17, Figure 21B [220]) to five different NIR fluorophores and their in vitro and in 
vivo behaviour was compared (conjugates 1 – 5, paper II).  
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Figure 21: A) OTL38 is a folate analogue ligand conjugated to a heptamethine dye 
(S0456); B) EC17 is a γ-folate-fluorescein isothiocyanate (FITC) conjugate; C) 
Chemical structure of the folate ligand composed of pteroic acid (blue) and L-
glutamic acid (purple) with the linker ethylenediamine (green) in the γ-carboxylic 
acid employed in paper II. 
During the literature research for paper II, several references were found claiming 
attachment to folic acid via so-called γ-isomers (Figure 21A), while the chemistry 
described to obtain the conjugate proved to be inefficient for the synthesis of the 
desired regioisomer, resulting in mixtures of γ- and α- isomers [221-223]. This issue 
was also addressed by Figliola et al. [224]. The use of isomeric mixtures could pose a 
major problem for in vivo use, as the binding affinity to the target could be 
compromised, altering the reproducibility of the results, especially when the ratio of 
isomers is unknown. Although Bettio et al. reported that these isomers exhibited 
FRα-binding affinities in the same range [225], another study with a mixture of γ- and 
α- isomers of different conjugates showed differences in their biodistribution [226]. 
Therefore, to avoid variabilities caused by uncontrolled regioisomer ratios, the ideal 
approach is to synthesise isomerically pure compounds. To this end, different 
synthetic routes to obtain the pure γ-isomer were approached for paper II and the 
reaction of pteroic acid (blue in Figure 21C) with the protected glutamic acid (purple 
in Figure 21C) was found to be the most effective, as also described by Figliola et al. 
[224]. 
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In the stepwise strategy, the carboxylic acid side chain of glutamic acid provides a 
convenient handle for conjugation of the probe via various linkers. In addition, it has 
been demonstrated that the glutamic part of the folate conjugate does not play a 
critical role in the FRα-binding affinity [227], as also demonstrated by the OTL38 
structure (Figure 21A). This compound contains a tyrosine residue instead of the 
glutamic acid, in order to avoid by-product formation by R-NH2 nucleophilic attack 
when the ligand is reacted with fluorophores containing an ether linkage in the meso 
position [228]. However, small variations in the structure of the folate conjugates 
have been shown to have a major impact on the optical properties and biological 
behaviour [123]. In our case, the use of the lipophilic fluorophores for conjugates 4 
and 5 (Figure 22) compromised the targeting affinity of the conjugates, resulting in 
no tumour accumulation for 4 and the EPR effect-mediated accumulation for 5 after, 
most probably, fluorophore-mediated binding to albumin [229].   
 
 
Figure 22: Chemical structures of conjugates 1 – 5 with the folate ligand and the 
linker part showed in Figure 21A abbreviated as EDAF. Conjugates 1 – 5 are based 
on ZW800-1, ZW800-1 Forte, IRDye® 800CW, ICG and an in house synthesised 
Cy7 derivative, respectively. 
Due to the misplacement of one analytical HPLC trace, conjugates 1 – 5 were re-
analysed six months after finalising the project. To our surprise, we found that 
conjugates formed by hydrophilic fluorophores (1, 2 and 3) did not exhibit the same 
high purity as when they were analysed prior to use. An additional peak 
corresponding to a polar compound eluting at early retention times which absorbs 
both at 220 and at around 750 nm was observed for conjugates 1 - 3. This finding led 
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us to initiate a study on the stability of the conjugates over time and this work is 
currently in progress. In addition, it was observed that one of the combined fractions 
for conjugate 1 exhibits a small shoulder in the HPLC trace, indicating the presence 
of free dye, as confirmed by the MS spectrum. Our study highlights the need for 
quality control and stability studies prior, during and after the imaging experiment to 
guarantee reproducible results from fluorophores and fluorescent conjugates.  
5.4 NTR beyond preclinical research 
Gene-based therapies, including in vivo delivery of viral vectors or genetically 
engineered T-cells and haemotopoietic stem cells, are applied to treat a myriad of 
inherited and acquired conditions and have become a promising therapeutic strategy 
[230]. In turn, the development of genome editing technologies, such as CRISPR-
Cas9 [231], which awarded Charpentier and Doudna, two female biochemists the 
Nobel Prize in Chemistry in 2020, allows for precise genome modifications through 
the addition, ablation or correction of genes ex vivo or in vivo, and has revolutionised 
the field of gene therapy [232].  
Suicide gene therapies, which aim to reduce the toxicity of cancer treatment by 
specifically activating prodrugs in cancer cells, have been investigated for several 
decades and there is resurgent interest in their use [167, 233-235]. Despite their 
promising potential and success in preclinical studies [155], their clinical application 
in cancer patients has not been fully realised [236]. There are several reasons for this, 
such as the choice of vector, suicide gene, prodrug or their combination thereof [237]. 
Despite this, I believe that the lack of appropriate molecular imaging methodologies 
to monitor transgene expression, particularly in the case of NTR, is a major limitation 
[238].  
As stated earlier, our group has previously demonstrated the feasibility of using 
CytoCy5S as a fluorescent NTR reporter in a preclinical model of GDEPT [150]. 
Despite the promising results exhibited, its translatability to clinical gene therapies is 
hampered due to the main drawback of FLI, namely low tissue penetrance of light, 
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and clinically relevant methodologies such as PET/CT are preferred. Since there are 
no clinical radiopharmaceuticals currently available to image NTR, our aim in paper 
III was to demonstrate that, due to the similar mechanistic reduction characteristics 
between oxygen-sensitive (hypoxia) and oxygen-insensitive nitroreductases (NTR), 
the hypoxia radiopharmaceutical 18F-FMISO could be repurposed to monitor the two 
steps of an NTR-based GDEPT.  
To do so, we employed NfsB from E. coli (NTR) in combination with CB1954 as this 
is the most extensively investigated enzyme/prodrug combination in NTR-based 
GDEPT strategies. Despite some limitations, we have demonstrated in paper III that 
the hypoxia tracer 18F-FMISO is useful to monitor NTR transgene expression after in 
vivo transduction and to evaluate prodrug treatment efficacy in an in vivo GDEPT 
setting. In parallel, Mowday et al. demonstrated the potential use of 18F-HX4 to 
detect NfsA NTR expression in two cell models engineered for NfsA overexpression. 
However, I believe that the use of 18F-FMISO, extensively used in clinical hypoxia 
imaging, compared to 18F-HX4, which is in the early stages of clinical development 
[239], would accelerate the approval for repurposed applications, making it a 
valuable companion diagnostic for clinical NTR-based GDEPT. 
In addition to NTR, other suicide genes have been investigated for their utility to treat 
different tumour types including HSV/TK [164], cytosine deaminase (CD) [240], 
purine nucleoside phosphorylase (PNP) [241] or carboxylesterases (CE) [242]. 
However, HSV/TK is the only one with a demonstrated clinically compatible imaging 
modality using either 18F-FHBG or 124I-FIAU. Furthermore, this imaging strategy has 
also been employed clinically for cell-based therapy imaging in glioma patients [243] 
emphasising the need for further development of MI to aid the improvement and 
rapid clinical translatability of these immunotherapies [244].  
Cell therapies, in particular immune cell therapies, have flourished in recent decades 
and their clinical benefit has already been demonstrated in various diseases [15]. 
However, despite promising results, for example in the treatment of B-cell 
haematological diseases [245], side effects, such as cytokine release syndrome in 
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chimeric antigen receptor (CAR) T-cell therapies, and the lack of appropriate non-
invasive clinical imaging techniques to follow the distribution of the engineered cells 
have hindered their wider application [246-248]. To avoid or modulate the side 
effects, safety strategies involving suicide genes have been envisaged. In a similar 
fashion to what has been proposed with the suicide genes HSV-TK [249] or caspase 9 
[250], NTR could be inserted as a suicide gene switch in CAR T-cells. When 
required, dosing of the prodrug CB1954 would eliminate these NTR-expressing cells 
with remission of side effects. However, this approach is not a one-size-fits-all 
remedy and in a recent study, elevated cytotoxicity and gene expression silencing was 
reported when human induced pluripotent stem cells (iPSCs) expressing HSV/TK 
were employed as a safety switch [251]. This highlights the necessity for a plethora 
of suicide genes for distinct uses in cell therapies. 
The advantage of NTR over other suicide genes is that its applicability would not be 
limited to its activity as a suicide gene, but could concurrently be exploited as a 
multimodal (FLI and PET/CT) imaging reporter gene. During the in vitro stages of 
CAR T-cell engineering, CytoCy5S activation by NTR could be leveraged for 
enrichment of fully functional cells by flow sorting or as a reporter of enzyme 
expression assessed by fluorescence microscopy, an advantage over other suicide 
genes that do not posses a specific NIR fluorescent substrate. In addition, the fate and 
expansion of NTR-engineered CAR T-cells after infusion could be tracked in vivo by 
PET/CT imaging using 18F-FMISO, as has already been demonstrated for HSV/TK-
engineered CAR T-cells using 18F-FHBG in glioma patients [243]. This approach is 
particularly useful when CAR T-cells are used to treat solid tumours, since it would 
allow visualisation of T-cell trafficking, confirming the cells penetrance into the 
tumours and possible on-target off-tumour accumulation, the two main limitations of 
CAR T-cells applied to solid tumours [245, 252]. This methodology would also allow 
side effects to be pre-empted before they have a major impact on the patient, helping 
to overcome some of the challenges affecting these therapies and improving clinical 
outcome. However, due to the bacterial origin of the NTR suicide/reporter gene, 
immunogenicity effects should be carefully evaluated in clinical studies. 
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6. Conclusions 
The work of this multidisciplinary thesis includes synthetic chemistry, basic 
molecular biology and molecular imaging. This work was based on the synthesis, 
purification and characterisation of small fluorescent molecules substrate of NTR and 
small molecules as biomarkers’ targeting ligands and their combination thereof. 
Alternative synthetic strategies have been successfully pursued in an attempt to 
increase the reaction yields by lowering the formation of by-products. Subsequent 
biological studies of these compounds both in vitro and in vivo and the use of 
molecular imaging modalities such as FLI and PET/CT imaging allowed us to:  
I) determine the best substrate for NTR expression interrogation in a 
preclinical oncology model using FLI 
II) demonstrate the high impact of the fluorophores on the biodistribution of 
fluorescent molecular targeting conjugates  
III) conclude that 18F-FMISO NTR PET/CT imaging is readily available for 
clinical application in NTR-based GDEPT settings 
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7. Future perspectives 
As discussed, the design of functional molecular dyes with optimal properties is a 
necessity for further development of the MI field and, at the same time, a challenge 
that requires careful chemical design to fine-tune the often in conflict 
physichochemical properties. To this end, the rational design of improved NIR dyes 
substrates of NTR aided by quantum chemistry calculations can improve our 
understanding of the structure-property relationships by using density functional 
theory (DFT). These calculations can also help us predict the optical properties of the 
different NIR dyes, reducing the need for lenghthy synthetic approaches to multiple 
compounds, leading to the synthesis and biological evaluation of a reduced number of 
candidates with the required characteristics.  
 
We aim to complete the study on the identification of superior fluorophores for 
targeted approaches in FIGS. For this purpose, we plan to assess the role of protein 
binding in the biodistribution of the different conjugates used in paper II and to 
analyse their fate in cells over time by fluorescence microscopy. Moreover, our group 
is working on the incorporation of linkers that allow the release of the fluorophore 
into the cytoplasm to exploit NTR-activatable dyes for targeted approaches. As 
already demonstrated by our group [121], CD24 is a promising target for FIGS in 
ovarian cancer. A multiplexing approach combining fluorescent targeting ligands 
against CD24 and FRα could help to reduce the impact of the high inter- and intra-
tumoral expression heterogeneity of FRα, improving the outcome of intraoperative 
procedures in ovarian cancer. To evaluate the full potential of this approach, 
representative animal models will be used to allow for complete cytoreductive 
surgery and survival studies. 
 
For suicide gene therapies, PET/CT imaging provides relevant information that can 
help stratify patients into those who will benefit from prodrug treatment and those 
who require an additional transduction prior to treatment. Hence, to increase the 
potential of 18F-FMISO PET/CT for imaging of NTR expression after in vivo 
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transduction we would like to investigate the correlation between the transduction 
efficiency and the SUVmax values. Since a commercial anti-NTR antibody is not 
available, we envision the generation of an NTR-specific nanobody to be able to 
confirm and quantify the in vivo transduction efficiency and correlate the 
heterogeneous levels of expression to distinct 18F-FMISO SUVmax values.  
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8. Appendix I:  
1. Introduction 
To further increase signal specificity, targeted strategies employing activatable 
fluorescent dyes may be implemented. The advantage of these dyes over “always-on” 
fluorophores is that they exhibit reduced off-target fluorescence signals and provide 
increased TBR [1, 2]. The fluorescence of such dyes is quenched until activation by 
tumour-specific enzymes [3] or by chemical reactions following cellular 
accumulation [4, 5]. CytoCy5S is a NIR activatable fluorophore whose fluorescence 
is quenched by the presence of the 3,5-dinitrobenzyl moiety. The enzyme 
nitroreductase NfsB (NTR) from E. coli is able to reduce the nitro groups (-NO2) to 
hydroxylamines (-NHOH) restoring its fluorescence. This bioreductive mechanism 
has previously been exploited to follow-up the dissemination of NTR-expressing 
cancer cells using CytoCy5S-FLI, providing higher sensitivity than bioluminescence 
or GFP-FLI, and to evaluate the therapeutic efficacy of a prodrug in a preclinical 
metastatic model [6].  
The NTR-activatable fluorescent dye CytoCy5S (substrate 1 in paper I) was 
conjugated to EDAF to obtain a fluorescent conjugate (2) that is expected to bind to 
the membrane-bound FRα. Endolysosomal internalisation of the conjugate and 
release of the fluorophore, with subsequent fluorescence enhancement after the 
activating reduction by NTR, will allow the localisation of engineered NTR-
expressing cancer cells. Furthermore, compared to the free dye, a reduction of the 
fluorescence signal in healthy tissues is expected. To test all this, the in vitro 
behaviour of this conjugate was compared with that of a conjugate (1) formed by an 
“always-on” fluorophore with the same squaraine scaffold (Cy5 active). 
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2. Results and discussion 
The specificity of 1 and 2 (Figure 1) towards FRα was investigated in vitro by 
fluorescence microscopy using three different cells lines, Skov-3, OV-90 and A549, 
with intermediate (Skov-3 and OV-90) and low (A549) levels of expression of the 
molecular target. First, calcein AM (green fluorescence) stained Skov-3NTR+ and 
A549 cells were incubated with 1 or 2 for 2.5 h and up to 36 h and imaged (Figure 1). 
A weak NIR fluorescence signal was observed 2.5 hours after incubation with 1, 
which increased with longer incubation times, particularly at 24 and 36 hours in 
Skov-3NTR+ (Figure 1a). A weaker NIR fluorescence signal is also observed in the 
negative control cell line A549 at 36 hours. No fluorescence signal in cells incubated 
with 2 was obtained at any of the given incubation times (Figure 1b). We next used 
the GFP+ OC cell line OV-90, which allowed us to follow the fate of 1 over time, 
starting 8 hours after conjugate removal. These results confirmed the data obtained 
previously (Figure 1a), demonstrating that the contrast agent is not able to reach the 
cytoplasm, but is retained in vesicles for up to 24 hours after removal of the conjugate 
from the medium.  
 
Figure 1: Live cell fluorescence confocal microscopy imaging. Images of the 
representative times for the green channel and for the far-red channel are presented 
with their corresponding chemical structures for a) 1, “always-on” dye and b) 2, 
activatable dye. 
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The selected activatable Cy5-derivative 2 and its control 1 served as proof of 
principle prior to working with more clinically relevant fluorophores e.g. Cy7. 
Retention in vesicles was observed after internalisation of 1 in the two different 
experiments, thus preventing the passage of the dye to the cytoplasm. This 
observation has a major impact for the use of 2 as the release of the dye into the 
cytoplasm is imperative for the activating reduction by NTR to occur and therefore 
no fluorescence signal can be observed at any given time with this conjugate. This 
finding deterred us from further experiments with these conjugates and prompted us 
to study new linkers to ensure cytoplasmic release of the CytoCy5S fluorophore to 
ultimately reduce the off-target signal in optical FLI (ongoing work in our group). 
 
3. Materials and methods 
3.1 Synthetic overview of conjugates 1 and 2 
γ-Ethylenediamine folate was conjugated to the NHS esters of Cy5 active (1, in 
house synthesised) and CytoCy5S (2, in house synthesised). As shown in Scheme 
1, activation of the carboxylic acid of the dyes 3 and 4 was performed by reacting 
them with NHS and DIC in dry DMSO at rt overnight. 5 and 6 were purified by 
RP-HPLC and further reacted with EDAF and DIPEA in dry DMSO at rt for 6 h 
to give conjugates 1 and 2 in modest yields. Conjugates 1 and 2 were purified by 




3.2 Cell lines and cell culture 
Human ovarian carcinoma, Skov-3 and OV-90GFP+ and lung carcinoma A549 cell 
lines were employed to study the suitability of conjugates 1 and 2 in a targeted 
approach. Cells were cultured in DMEM (Sigma-Aldrich, St. Louis, USA) with 
exception of OV-90 cultured in RPMI 1640, supplemented with 10% FBS and 1% 
L-glutamine (Sigma-Aldrich), and kept at 37 °C and 5% CO2. Skov-3 and OV-
90GFP+ cell lines were transduced in vitro to express E. coli NfsB nitroreductase 
(NTR) using lentiviral particles [7]. NTR expression was assessed using an 
established flow cytometric method [6]. 
 
3.3 Confocal fluorescence microscopy 
1 x 105 Skov-3NTR+ cells were seeded in 35 mm µ-dishes with high glass bottom 
(Ibidi, Martinsried, Germany) and incubated with 4 µM of 1 or 2 for 2.5, 12, 24 
and 36 hours at 75% confluency. 1 x 105 of A549NTR- cells incubated for 36 hours 
with 4 µM of the aforementioned conjugates were employed as negative control. 
30 minutes before fluorescence imaging, cells were washed with PBS and fresh 
medium containing calcein AM (1 µM) was added.  
Scheme 1. Synthesis of EDAF-Cy5 conjugates. 
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OV-90GFP+NTR+ cells (1 x 105) were incubated with 1 for 14 hours. After this time, 
the cells were thoroughly washed with PBS and fresh medium was added. 8 hours 
post-removal of the conjugate, fluorescence images were acquired at 10 min 
intervals for up to 16 hours (24 hours post-removal). Cells were maintained at  
37 °C and 5% CO2. 
Live cell imaging fluorescence was acquired using a confocal Andor Dragonfly 
microscope (Oxford Instruments America, Inc., Concord MA, USA) with a 40X 
magnification. 488 nm excitation filter and green emission filter (500 to 550 nm) 
for calcein AM internalisation and GFP expression and 637 nm excitation filter 
and far-red emission filter (663 to 738 nm) for Cy5-derivatives interrogation were 
employed. All data collected were analysed with Imaris 9.6 (Oxford Instruments, 
USA). 
 
3.4 Synthesis of (Z)-4-((1-(5-carboxypentyl)-3,3-dimethyl-3H-indol-1-ium-2-
yl)methylene)-3-oxo-2-(((E)-1,3,3-trimethylindolin-2-
ylidene)methyl)cyclobut-1-en-1-olate (3): [8] 
 
1,2,3,3-Tetramethyl-3H-indolium iodide (303 mg, 1.01 mmol), 1-(5-
carboxypentyl)-2,3,3-trimethyl-3H- indolium iodide (417 mg, 1.04 mmol) and 
3,4-dihydroxycyclobutane-1,2-dione (128 mg, 1.10 mmol) were mixed with 
pyridine (4.5 mL), acetic acid (4.5 mL) and acetic anhydride (1 mL) and the 
mixture was heated at 110 qC for 3 h. The reaction mixture was partitioned 
between dichloromethane (10 mL) and water (10 mL) and the organic layer was 
dried over MgSO4, filtered and the solvent was evaporated to yield an iridescent 
blue sticky residue. This material was purified using semi-preparative RP-HPLC 
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(50 - 90% acetonitrile in water, both solvents containing 0.1% formic acid) to give 
the title compound. 
Blue solid; 29 mg (21% yield). 1H-NMR (850 MHz, (CD3)2SO): δ = 12.10 (bs, 
1H), 7.52 (m, 2H), 7.34 (m, 4H), 7.16 (m, 2H), 5.79 (s, 1H), 5.76 (s, 1H), 4.07 (s, 
2H), 3.57 (s, 3H), 2.20 (t, J = 7.2 Hz, 2H), 1.71 (m, 2H), 1.68 (s, 12H), 1.56 (m, 
2H), 1.40 (m, 2H); 13C-NMR (MHz, (CD3)2SO): δ = 180.5 (2C), 178.8 (2C), 
174.3, 169.7, 168.9, 142.8 , 142.2, 141.4 (2C), 127.6 (2C), 123.3 (2C), 121.9 
(2C), 109.9 (2C), 85.9, 85.7, 48.4 (2C), 42.5, 33.2, 30.1, 26.1 (5C), 25.6, 23.9; 
ESI-MS: Calcd. m/z for C33H37N2O4+ [M + H]+: 525.3; found: 525.3 and 547.3.  
 
3.5 Synthesis of (Z)-2-(((E)-1-(5-carboxypentyl)-3,3-dimethylindolin-2-
ylidene)methyl)-4-((1-(3,5-dinitrobenzyl)-3,3-dimethyl-3H-indol-1-ium-2-
yl)methylene)-3-oxocyclobut-1-en-1-olate (4): [8] 
 
1-(5-Carboxypentyl)-2,3,3-trimethyl-3H-indolium iodide (765 mg, 1.9 mmol), 1-
(3,5-dinitrobenzyl)-2,3,3-trimethyl-3H-indolium iodide (999 mg, 2.1 mmol) and 
3,4-dihydroxy-3-cyclobuten-1,2-dione (238 mg, 2.1 mmol) were dissolved in 
pyridine (9.7 mL), acetic acid (9.7 mL) and acetic anhydride (2.2 mL) and the 
resulting mixture was heated at 110 qC for 3 h. The reaction mixture was 
partitioned between dichloromethane (10 mL) and water (10 mL). The combined 
organic phases were dried over MgSO4, filtered and evaporated under reduced 
pressure to give an iridescent blue sticky residue (1.261 g), which was purified 
using semi-preparative RP-HPLC (50 - 90% acetonitrile in water, both solvents 
containing 0.1% TFA). 
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Iridiscent blue solid; 109 mg (9% yield). 1H-NMR (850 MHz, (CD3)2SO) δ = 
11.99 (s, 1H), 8.73 (d, J = 2.6 Hz, 1H), 8.40 (d, J = 2.1 Hz, 2H), 7.58 (d, J = 7.3 
Hz, 1H), 7.55 (dd, J = 7.4, 1.1 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.38 (td, J = 7.7, 
1.2 Hz, 1H), 7.29 (td, J = 7.6, 1.2 Hz, 1H), 7.23 (q, J = 7.2 Hz, 2H), 7.16 (t, J = 
7.4 Hz, 1H), 5.88 (s, 1H), 5.75 (s, 1H), 5.66 (s, 2H), 4.14 (t, J = 7.6 Hz, 2H), 2.20 
(t, J = 7.3 Hz, 2H), 1.79 (s, 6H), 1.72 (m, 2H), 1.65 (s, 6H), 1.55 (p, J = 7.4 Hz, 
2H), 1.39 (p, J = 7.7 Hz, 2H); HR-ESI-MS: Calcd. m/z for C39H39N4O8+ [M+H]+: 
691.27624; found: 691.27721. 
 
Analytical data are in accordance with those reported previously [8] 
 
3.6 Synthesis of (Z)-4-((1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-
dimethyl-3H-indol-1-ium-2-yl)methylene)-3-oxo-2-(((E)-1,3,3-
trimethylindolin-2-ylidene)methyl)cyclobut-1-en-1-olate (5):  
 
3 (22.4 mg, 0.04 mmol), N-hydrosuccinimide (13. 6 mg, 0.11 mmol) and DIC 
(0.01 mL, 0.06 mmol) were dissolved in 1.5 mL of anhydrous DMSO and the 
reaction mixture was stirred at rt overnight protected from the light. The excess of 
solvent was removed by rotary evaporation to give a bright blue sticky solid 
residue, which was purified using semi-preparative RP-HPLC (50 - 90% 
acetonitrile in water, both solvents containing 0.1% TFA) to give the title 
compound.  
Iridiscent blue solid; 18.1 mg (73% yield). 
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4 (18.5 mg, 0.04 mmol), N-hydrosuccinimide (13. 6 mg, 0.11 mmol) and DIC 
(0.01 mL, 0.06 mmol) were dissolved in 1.5 mL of anhydrous DMSO and the 
reaction mixture was stirred at rt overnight protected from the light. The excess of 
solvent was removed by rotary evaporation to give a blue sticky solid residue, 
which was purified using semi-preparative RP-HPLC (50 - 90% acetonitrile in 
water, both solvents containing 0.1% TFA) to give the title compound.  
Iridiscent blue solid; 17.2 mg (55% yield). 
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3.8 Synthesis of (Z)-4-((1-(6-((2-(4-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-
yl)methyl)amino)benzamido)-4-carboxybutanamido)ethyl)amino)-6-
oxohexyl)-3,3-dimethyl-3H-indol-1-ium-2-yl)methylene)-3-oxo-2-(((E)-1,3,3-
trimethylindolin-2-ylidene)methyl)cyclobut-1-en-1-olate (1):  
 
Folate derivative 7 (13 mg, 0.027 mmol), 5 (18.1 mg, 0.03 mmol) and DIPEA 
(200 µL) were dissolved in DMSO (1.1 mL) and the mixture was stirred for 6 h at 
rt. The reaction mixture was then purified using semi-preparative RP-HPLC (30 - 
90% acetonitrile in water, both solvents containing 0.1% TFA) to give the title 
compound. 
Blue solid; 7.67 mg (30% yield). ESI-MS: Calcd m/z for C54H60N11O8+ [M + H]+: 
990.4621; found: 990.4622. 
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Folic acid derivative 7 (11 mg, 0.022 mmol), 6 (17.2 mg, 0.02 mmol) and DIPEA 
(200 µL) in DMSO (1 mL) were reacted for 6 h at rt. The reaction mixture was 
then purified using semi-preparative RP-HPLC (30 - 90% acetonitrile in water, 
both solvents containing 0.1% TFA) to give the title compound. 
Blue solid; 7.99 mg (32% yield). ESI-MS: Calcd m/z for C60H62N13O12+ [M + 
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Abstract: 15 
CytoCy5S™, a quenched, red-shifted fluorescent probe, has been used to exploit the 16 
imaging potential of the nitroreductase (NTR) reporter gene platform. Its use has been 17 
reported in a number of publications, however there are discrepancies in both the reported 18 
structure and its physicochemical properties. Herein, we aim to highlight these discrepancies 19 
and to define the best candidate of the four substrates under study for preclinical work in 20 
NTR reporting by optical applications. 21 
We report the synthesis, purification and characterisation of four NTR substrates, including 22 
alternately described structures currently referred by the name CytoCy5S. A comparative 23 
NTR enzymatic assay was performed to assess the spectroscopic characteristics of the 24 
different reductively activated probes. The NTR expressing triple-negative breast carcinoma 25 
cell line, MDA-MB-231 NTR+, was employed to compare, both in vitro and in vivo, the 26 
suitability of these fluorescent probes as reporters of NTR activity. Comparison of the 27 
reporting properties was achieved by flow cytometry, fluorescence microscopy and optical 28 
imaging, both in vivo and ex vivo. 29 
This study evaluated the different spectroscopic and biological characteristics of the four 30 
substrates and concluded that substrate 1 presents the best features for oncological in vivo 31 
preclinical optical imaging. 32 
Keywords: 33 
CytoCy5S, Cyanine, Squaraine, Nitroreductase, NfsB, Near-Infrared Fluorescence Imaging 34 
  35 
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1. Introduction 36 
Fluorescence imaging (FLI) is a non-invasive, easy to perform and cheap imaging modality 37 
permitting real-time visualisation, which has become fundamentally important in preclinical 38 
studies of oncological malignancies [1]. This technique relies on the detection of the light 39 
emitted directly by an exogenous fluorescent probe, endogenous reporter gene or indirectly 40 
by the combination of a reporter gene and its corresponding fluorescent substrate. By 41 
employing an appropriate selection of reporter genes, FLI can be used to assess anatomical 42 
location of tumour cells and ongoing biological processes [2, 3]. 43 
Of particular relevance in biological applications is the exploitation of the near-infrared 44 
(NIR) region of the electromagnetic spectrum (650 - 950 nm) [4, 5]. This privileged region is 45 
characterised by reduced tissue absorption caused by haemoglobin or melanin and deeper 46 
tissue penetration compared to the visible region [6, 7]. Non-invasive FLI using NIR dyes 47 
has proven to be a very useful tool in preclinical oncology models for detection of metastasis 48 
and treatment response monitoring in orthotopic models [8] and has been widely explored in 49 
both preclinical and clinical settings for fluorescence image-guided surgery [9-12]. A 50 
number of fluorescent probes that emit light in the NIR region such as phthalocyanines [13], 51 
porphyrins [14] or BODIPY dyes [15] (Figure 1A I - III) have been employed as contrast 52 
agents or theranostics. However, so far cyanines and their squaraine analogues (Figure 1A 53 
IV - V) have been the preferred NIR dyes for the study of oncological conditions [4, 16].  54 
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 55 
Figure 1: Common scaffolds employed for molecular interrogation in biological applications.  56 
A) Phthalocyanine (I), porphyrin (II), BODIPY (III), cyanine structure (IV), squaraine structure (V). B) 57 
Different substrates evaluated in this study. Structures 1 and 4 referred as CytoCy5S in the literature. 58 
(Structures are represented in their cis conformation although this is not the most stable one [17]). 59 
One limitation of these “always-on” probes is the accumulation of background fluorescence 60 
in off-target tissues that limits the detection of the pathology under study. To overcome this 61 
challenge, activatable probes that are specifically activated at the pathology of interest are 62 
employed, providing better contrast that allows non-invasive FLI of different biological 63 
processes associated with tumour growth [18-21]. 64 
Several examples can be found where reductive properties of nitroreductases have been 65 
exploited for non-invasive FLI of tumorigenesis and hypoxia in tumour cells [22, 23] but 66 
also of bacterial infections and response to antibiotics [24-26], among others [27]. 67 
Furthermore, the NTR reporter gene can be exploited as a suicide gene, in a gene directed 68 
enzyme prodrug therapy setting (GDEPT), with high potential as a theranostic agent, 69 
affording therapy and therapy efficacy visualisation simultaneously [8, 28]. NTR-activatable 70 
probes, including CytoCy5S[29] or 6-chloro-9-nitro-5-oxo-5H-benzo[a]phenoxazine 71 
(CNOB)[30], are non-fluorescent prior to enzymatic metabolism and become highly 72 
fluorescent after the catalytic reaction. These NTR-activatable probes contain aromatic nitro 73 
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corresponding hydroxylamines and/or amines by nitroreductases in the presence of FMN and 75 
NADH and NADPH restores fluorescence (Figure 2) [31, 32].  76 
 77 
Figure 2: NTR-mediated reduction of aromatic nitro groups 78 
NTR-mediated reduction of substrates 1 - 4 in the presence of FMN (bound to NTR) and NADH and NADPH 79 
to give the proposed product and restore fluorescence. 80 
CytoCy5S is the most extensively utilised NTR-activatable fluorescent probe. This 81 
compound has been widely exploited for different purposes [8, 24, 33-36] and despite its 82 
promising performance, there is a discrepancy in the literature with respect to its structure, as 83 
both 1 and 4 (Fig. 1B) have been referred to as CytoCy5S [37-39]. Both structures contain a 84 
3,5-dinitrobenzyl moiety, but while 1 is a squaraine derivative, 4 is a cyanine derivative. 85 
Consequently, there is also a lack of consensus in the literature regarding the spectroscopic 86 
properties and its behaviour in biological systems, which might hamper its use. The 87 
manufacturer describes CytoCy5S as a hydrophobic molecule, with limited availability in 88 
aqueous buffers, and with improved cell permeability [40], however Parker et al. [41] 89 
describe CytoCy5S as a photo-stable and water soluble compound. Furthermore, the reduced 90 
version of CytoCy5S is described by the manufacturer as a red-shifted substrate with 91 
excitation at 628 nm and emission at 638 nm [40], while Inglese et al. [42] reports the 92 
excitation and emission maxima for the reduced version to be 647 nm and 667 nm, 93 
respectively. No information on the structure was included [40, 42]. In our previous work, 94 
the final reduction product of 1 revealed excitation and emission maxima of 631 and 688 nm, 95 
respectively [8]. Finally, in a recent review [43], compound 4 is proposed as CytoCy5S and 96 
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the version we employed in the aforementioned work [8], 1, is described as a squaraine 97 
analogue of 4. 98 
Based on these discrepancies in the literature [8, 24, 33, 37, 40, 41, 43], we decided to 99 
compare four different NTR-activatable probes, two of them the alternative versions of 100 
CytoCy5S found in the literature. In addition, we included compound 2 (squaraine) as we 101 
believe that this compound might also have been used as CytoCy5S, however, also in order 102 
to investigate how the carboxylic acid tail that is present in both compounds 1 and 4 affects 103 
its behaviour in a biological system. Finally, we included compound 3 (squaraine) [37] since 104 
this NTR substrate was found to have superior spectroscopic properties to that of compound 105 
1 in an in vitro screening of different contrast agents (unpublished data). The four probes 106 
(Figure 1B) were synthesised and analysed in vitro and in vivo in order to shed light on their 107 
performance and properties with the intention of identifying the most suitable NIR dye for 108 
biological imaging of NTR. 109 
 110 
2. Materials and methods 111 
2.1. Synthesis and characterization of dyes 1 - 4 112 
Detailed protocols for the synthesis of 1 - 4 and investigations into increasing the yield 113 
for the synthesis of 1 are provided in the electronic supplementary material.  114 
2.2. NTR enzymatic assays 115 
A mixture containing 4.5% DMSO, 60 µM β-NADH in 10 mM Tris-HCl and 0.98 mM 116 
β-NADPH in 10 mM Tris-HCl was prepared and the reaction mixture completed as 117 
follows: For the blank, Tris-HCl 10 mM quantum satis (q.s.) and 0.2 µM NTR were 118 
added. For the references, 4 µM of either of 1 - 4 (in 90% DMSO and 10% Tris-HCl 100 119 
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mM) q.s. was added. And for the study sample, 4 µM of either of 1 - 4 (in 90% DMSO 120 
and 10% Tris-HCl 100 mM) q.s. and 0.2 µM NTR were added (all reagents added in the 121 
stated order). After a two-hour reaction, the excitation and emission spectra of the 122 
different dyes reductively activated by NTR were acquired. Excitation and absorbance 123 
scans were performed from 500 to 700 nm and emission scans from 600 to 800 nm in 2 124 
nm steps and a 20 nm bandwidth in both cases. 125 
The optimal settings for excitation and emission were then used to measure the 126 
fluorescence intensity during the course of the enzymatic reactions (up to 24 h). The 127 
optimal settings for the different substrates were defined as follows: substrates 1 and 2: 128 
λex/λem 630/645 nm; substrate 3: λex/λem 650/670 nm; substrate 4: λex/λem 660/690 nm; 5 129 
nm bandwidth in all cases. Fluorescence intensity was analysed using a Tecan Spark® 130 
multimode microplate reader (Tecan Group Ltd., Männedorf, Switzerland) and data 131 
was plotted as the average ± SD. 132 
2.3. Cell lines and cell culture 133 
The human mammary carcinoma cell line MDA-MB-231 was employed for in vitro and 134 
in vivo assays. MDA-MB-231Luc+ (NTR-) cells were kindly provided by Prof. James 135 
Lorens (University of Bergen) and MDA-MB-231Luc+GFP+NTR+ (NTR+) cells have been 136 
generated in our lab as previously reported by McCormack et al. [8]. All cell types were 137 
cultured in DMEM (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) supplemented 138 
with 10% FBS and 1% L-glutamine (Sigma-Aldrich) in a humidified atmosphere at 37 139 
°C and 5% CO2. 140 
2.4. Flow Cytometry  141 
Comparative quantification of the fluorescence intensities obtained with the different 142 
substrates was performed by incubating 1 x 105 of the NTR+ and NTR- cells (negative 143 
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control) with each of them. First, different substrate concentrations (1 µM, 3 µM, 12 µM, 144 
25 µM) were tested, by incubating the cells for one hour. Once the best concentration 145 
was identified, different incubation times were assessed in triplicate (0.25 h, 0.5 h, 1 h, 2 146 
h, 4 h and 8 h). In all cases, after the incubation time the cells were rinsed with PBS, 147 
trypsinised and washed twice before resuspension in PBS supplemented with 2% BSA. 148 
Acquisition was performed in a BD LSR Fortessa flow cytometer (BD Biosciences, 149 
Franklin Lakes, NJ, USA) with a 640 nm excitation laser and a 670 ± 14 nm emission 150 
filter. The voltage of the detector was optimised for the brightest signal and kept at the 151 
optimal setting for all the different experiments. 152 
2.5. Fluorescence microscopy 153 
1 x 105 NTR+ cells were seeded in 35 mm µ-dishes with high glass bottom (Ibidi, 154 
Martinsried, Germany) and were incubated with 3 µM of each individual substrate for 10 155 
min. Uptake, fluorescence release and the fate of the reduced substrates in the cell was 156 
followed at 10 min intervals for up to 4 h. Cells were maintained at 37 °C and 5% CO2. 157 
Live cell imaging fluorescence was acquired using a confocal Andor Dragonfly 158 
microscope (Oxford Instruments America, Inc., Concord MA, USA) with a 40X 159 
magnification, with the 488 nm excitation filter and green emission filter (500 to 550 160 
nm) for GFP expression and the 637 nm excitation filter and the far red emission filter 161 
(663 to 738 nm) for NTR interrogation. All data collected were analysed with Imaris 9.6 162 
(Oxford Instruments, USA). 163 
2.6. General animal care 164 
All applicable institutional and/or national guidelines for the care and use of animals 165 
were followed. All experiments were approved by The Norwegian Animal Research 166 
Authority (Application ID 14128) and conducted according to The European Convention 167 
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for the Protection of Vertebrates Used for Scientific Purposes. NOD-scid IL2Rgnull mice 168 
(referred to as NSG) were bred at Vivarium (University of Bergen) from breeding pairs 169 
purchased from Charles River. Mice were housed in groups of ≤  5 in individually 170 
ventilated cages (Techniplast S.p.A., Buguggiate, Italy). Observations for general 171 
condition and body weights were recorded twice a week. Mice were fed with low-172 
autofluorescence rodent imaging food (Rodent imaging diet D1001 from Research diets 173 
Inc., Brunswick, USA) from, at least, two weeks prior to experiments. Mice were 174 
depilated prior to image acquisition. When required, mice were anesthetised under 1.5% 175 
isoflurane (Abbot Laboratories Ltd., North Chicago, USA) and they were euthanised 176 
according to institutional guidelines. 177 
2.7. MDA-MB-231 subcutaneous xenografts 178 
NTR- and NTR+ MDA-MB-231 subcutaneous xenografts were implanted in the left flank 179 
of the scapular area by injection of 5 x 106 cells suspended in 100 µL DMEM with 25% 180 
Matrigel (Corning Inc., Waltham, USA). Tumour volumes were measured weekly with a 181 
digital calliper and calculated using the ellipsoid volume formula: Volume = π (length x 182 
width x height)/6. 183 
2.8. in vivo fluorescence imaging  184 
2.8.1. in vivo biodistribution 185 
For biodistribution and pharmacokinetic assessment of the four different substrates, 186 
when mean tumour volumes reached 120 ± 16 mm3, mice were intravenously injected 187 
with 100 µL of a 1 mM substrate solution. Optical imaging was performed at established 188 
time points (0 h, 0.75 h, 2 h, 4 h, 8 h, 12 h and 24 h) using an IVIS Spectrum imaging 189 
system (PerkinElmer Inc., Waltham, USA) with the following filter pairs (λex/λem) 190 
640/680 and 640/700 nm. To assess the background fluorescence, all mice were imaged 191 
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prior to injection. Analysis of the collected data was performed with the Living 192 
Imaging® software v4.5 (PerkinElmer Inc.). Regions of interest (ROI) in the lateral view 193 
were manually drawn around the tumours and fluorescence was expressed as radiance 194 
(p/s/cm2/sr). The radiance values reported were normalised by the mean of the NTR- 195 
radiance values.  196 
2.8.2. Longitudinal tumour imaging 197 
Tumours were longitudinally imaged three times over the course of the tumour 198 
progression. Imaging acquisitions were performed when the mean tumour volumes 199 
reached 222 ± 44 mm3, 300 ± 71 mm3 and 451 ± 115 mm3. 100 µL of a 1 mM substrate 200 
solution were injected intravenously and images were acquired after 0.75 hours for 1 and 201 
3 and after two hours for 2 using an IVIS Spectrum imaging system with λex = 640 nm 202 
and λem = 680 nm. To assess the background fluorescence, all mice were imaged prior to 203 
injection. Analysis of the collected data was performed as explained before. The radiance 204 
values reported were normalised by the mean of the NTR- radiance values. 205 
2.8.3. Ex vivo biodistribution 206 
Mice were euthanised 0.75 hours after i.v. administration of 1 and 3 and two hours after 207 
i.v 2 injection (100 µl, 1 mM) and tumours and organs were harvested. Organ 208 
biodistribution was assessed for each substrate in the NTR- and the NTR+ groups. 209 
Fluorescence intensities were measured and analysed as explained above. The reported 210 
values were normalised by the sum of the radiance values for all organs and they were 211 
presented as the percentage of biodistributed substrate in the organs of interest. 212 
2.9. Statistics 213 
Results are given as mean ± standard deviation (SD). All statistical tests were performed 214 
using GraphPad Prism v 6.0h (GraphPad Software Inc) and p < 0.05 was considered 215 
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significant. After randomisation, a one-way ANOVA was applied to ensure unbiased 216 
assignment of tumour volumes among the experimental groups. Comparison of means 217 
was performed using Student t-tests and one-way ANOVA. 218 
 219 
 Results and discussion 220 
3.1. Synthesis of 1 - 4 221 
Detailed discussion of the different synthetic approaches for 1 – 4, purification strategies 222 
and characterisation by 1H-NMR and high-resolution mass spectrometry (HRMS) are 223 
provided in the electronic supplementary material (Figures S1 to S22). 224 
3.2. Spectroscopic properties and performance of the four NTR substrates in an 225 
enzymatic assay 226 
After two hours incubation with NTR, absorbance, excitation and emission spectra 227 
(Figure S24C and Figure 3A) revealed overlapping excitation and emission maxima for 1 228 
and 2 and higher, red-shifted properties for 3 and 4, which presented the highest 229 
bathochromic shift and the largest Stokes shift (Table 1). For 3, this far-red shift is a 230 
result of the introduction of the methoxy groups, while for 4, this can be attributed to 231 
both the sulfonate group and the lower planarity of cyanines compared to the squaraine 232 
derivatives, which renders substrate 4 less conformationally restricted [17]. It was also 233 
observed that 1 and 2 exhibit an emission intensity in the same range as their 234 
corresponding excitation, although 2 exhibits a markedly lower absolute fluorescence 235 
intensity. 3 and 4, however, exhibit high excitation intensities but very low emission 236 
intensities (Table 1). The UV-vis-NIR absorbance spectra of the quenched substrates and 237 
the vis-NIR absorbance spectra of the reduced substrates can be found in the electronic 238 
supplementary material (Figure S24). 239 
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1 628 646 18 18500 18800 
2 628 646 18 3000 4300 
3 650 670 20 25000 4300 
4 666 692 26 205000 28000 
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241 
Figure 3: Spectral characterisation of substrates 1 - 4 242 
A) Chemical structures of substrates 1 – 4 and their respective excitation and emission spectra after two hours 243 
incubation of 4 µM of substrate and 0.2 µM NTR enzyme. The Y axis represents both the excitation and 244 
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emission fluorescence intensity maxima expressed in Relative Fluorescence Units (RFU) for each substrate. 245 
For each dye the maximum of the scale is adjusted to the highest excitation RFU as follows: 1 (Max: 19000 246 
RFU), 2 (Max: 4500 RFU), 3 (Max: 25000 RFU) and 4 (Max: 210000 RFU). B) Kinetic assessment of NTR 247 
reduction of the four different substrates, starting 3 minutes after NTR addition and over 24 hours, expressed in 248 
Relative Fluorescence Units (RFU) as arbitrary units (a.u.). Blank consists of DMSO, β-NADH and β-NADPH 249 
in Tris-HCl buffer and NTR (0.2 µM). Reference contains DMSO, β-NADH and β-NADPH in Tris-HCl buffer 250 
and substrate under study (4 µM). Sample is composed of DMSO, β-NADH and β-NADPH in Tris-HCl buffer, 251 
substrate under study (4 µM) and NTR (0.2 µM). C) Overlay of the four different reduction kinetic curves for 252 
the reference and the sample, for easier visual comparison of the fluorescence intensity of the different 253 
substrates before and after reduction. From 3 minutes after enzyme addition and up to 24 hours. 254 
From the excitation and emission spectra, the optimal fluorescence settings for each 255 
substrate were selected to perform a kinetic assay in which the fluorescence intensity was 256 
monitored for 24 hours. As shown in Figure 3B, 1, 3 and 4 displayed a similar kinetic 257 
profile reaching the maximum fluorescence emission intensity at around 0.75 hours, 258 
while maximum fluorescence for 2 was reached after seven hours. Of note, 1 exhibits the 259 
steepest reduction in fluorescence intensity of all the examined substrates (Figure 3C). 260 
Interestingly, despite the low absolute fluorescence intensity of 2, this is the substrate 261 
with the highest ratio of emission intensity at any given time between the reference and 262 
the sample, mainly due to the low fluorescence background it exhibits in the presence of 263 
NADH and NADPH (Figure 3C). The three other substrates showed higher non-specific 264 
activation by the NADH and NADPH present in the mixture. All the data suggest that the 265 
four fluorescent probes are suitable substrates of NTR and worthy of biological 266 
evaluation in cell cultures. 267 
3.3. in vitro performance of the four NTR substrates 268 
The suitability of the four substrates for intracellular interrogation of NTR expression 269 
was assessed by incubation of NTR- and NTR+ MDA-MB-231 cells with different 270 
substrate concentrations (1 – 25 µM), followed by flow cytometry analysis (Figure 4A). 271 
The mean fluorescence intensity (MFI) of the NTR+ cells increased with increasing 272 
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concentrations of the substrates, plateauing at 12 µM for 1 and 2. In contrast, a plateau 273 
was not observed for 3, demonstrating a high dependence of this substrate on the 274 
concentration. Indeed, MFI values of around 12 x 103 were obtained with 1 µM of 2 and 275 
3 µM of 1, while 12 µM of 3 were required to obtain MFI in the same range. The MFI of 276 
NTR- cells was notably lower but also increased with increasing concentrations of the 277 
substrates, except for 2 where a maximum was reached at 12 µM. 4 performed poorly at 278 
any given concentrations in both cell types. For 2, NTR+/NTR- ratios were very similar at 279 
all concentrations whereas for 1 and 3 the highest ratios were achieved at 12 µM, due to 280 
a higher MFI of the NTR+ cells for 1 and a reduced MFI of the NTR- cells for 3, at this 281 
concentration. Substrate 3 shows the highest NTR+/NTR- ratios followed by 1 and 2 with 282 
comparable ratios.  283 
 284 
Figure 4: Flow cytometry analysis 285 
A) Dose-dependent fluorescence intensity was assessed by incubation of NTR- and NTR+ cells for one hour 286 
with increasing concentrations of the four substrates. Values are reported as Mean Fluorescence Intensity 287 
(MFI). NTR+/NTR- ratios represented for each substrate at the different studied concentrations. B) With 3 µM, 288 
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time-dependent fluorescence intensity was determined at different incubation times with NTR- and NTR+ cells 289 
(0.25 h, 0.5 h, 1 h, 2 h, 4 h and 8 h). NTR+/NTR- ratios represented for each substrate at the different studied 290 
time points. 291 
In order to examine the dependency of MFI on incubation times, the suboptimal 292 
concentration of 3 µM was chosen and different incubation times (0.25 h to 8 h) were 293 
assessed (Figure 4B). For the NTR- cells, the MFI showed a similar trend for the four 294 
different substrates with the highest values observed at the longest incubation times. 295 
Non-specific activation of the substrates was observed, however not significantly higher 296 
compared to the unstained cells (Figure S25). For the NTR+ cells, the fluorescence 297 
intensity of 1 and 3 plateaued at two hours, in accordance with the observations in the 298 
kinetic enzymatic assay where the fluorescence intensity started to decrease after three 299 
hours. The results for 2 are also in accordance with the delayed reduction reaction 300 
observed during the kinetic assay (Figure 3B), with MFI values reaching the maximum at 301 
eight hours, although in the same range for two, four and eight hours. Interestingly, the 302 
NTR+/NTR- ratios for all substrates did not increase with increasing incubation times, 303 
reaching their maximum after 0.5 h.  304 
Based on the spectroscopic data, similar fluorescence behaviour was expected for 3 and 305 
4, however, as can be seen in Figures 4A and 4B, the sulfonated 4 exhibited almost no 306 
fluorescence enhancement at any of the given conditions. In contrast, substrate 3 resulted 307 
in modest MFI values when incubated in NTR- cells and a high fluorescence 308 
enhancement in NTR+ cells, rendering this substrate around 200 times brighter after 309 
reduction (Figure 4B). 1 and 2 showed comparable results, both under concentration- and 310 
time-dependent conditions, with NTR+/NTR- ratios in the same range.  311 
The flow cytometry results suggest different substrate-cell interactions and confocal 312 
fluorescence microscopy was performed to investigate the intracellular behaviour of the 313 
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substrates. Qualitative analysis of the fluorescence live imaging of NTR+ cells incubated 314 
with the different substrates (3 µM) corroborated the previous observations, yielding 1 315 
and 2 as the brightest substrates and highlighting the low emission intensity from 3 and 4 316 
(Figure S23). As can be seen in Figure 5, substrate 4 required longer incubation times for 317 
the signal to be observed. From the images obtained, cellular accumulation of this 318 
substrate occurred in discrete vesicle-like structures, in contrast to the more 319 
homogeneous staining observed for the other substrates. 1, 2 and 3 displayed 320 
homogeneous perinuclear staining. While the localisation of these three substrates was 321 
the same, the kinetics of accumulation of 3 differed from the others. The first two 322 
substrates appear to sustain comparable fluorescence intensity during four hours of 323 
incubation, while the fluorescence intensity of 3 starts decaying after 90 minutes of 324 
incubation, in line with the steeper decrease in MFI observed in flow cytometry (see 325 
video S1 - S4 for full time lapse for each substrate). To get a clearer idea of the 326 
biological behaviour of these substrates, in particular regarding tumour biodistribution, 327 
they were further investigated in murine xenograft models. 328 
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 329 
Figure 5: Live cell fluorescence confocal microscopy imaging 330 
Uptake, fluorescence enhancement and localisation of the NTR-reduced metabolites were assessed over time 331 
and up to four hours. Cells were incubated with 3 µM of each substrate for ten minutes and sequential images 332 
were acquired every ten minutes for 240 minutes. Images of the most representative time points are presented 333 
as the merged images of the green channel (GFP; excitation: 488 nm and emission: 500 - 550 nm) and far-red 334 
channel (NTR-substrate; excitation: 637 nm and emission: 663 – 738 nm) obtained at 40X magnification. GFP 335 
is included to allow localisation of the cells in the field of view. Images are displayed in the optimal far-red 336 
channel intensity for each of the substrates. A video with the complete time-lapse for each substrate is included 337 
in the electronic supplementary material (Video S1 – S4). 338 
 339 
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3.4. in vivo biodistribution 340 
To understand the pharmacokinetic properties of these substrates, in vivo biodistribution 341 
studies over a course of 24 hours were performed and compared in a subcutaneous 342 
xenograft model. Mice bearing NTR- or NTR+ subcutaneous tumours in the scapular 343 
region (indicated by the pink sphere in Figure 6A) were intravenously injected with 100 344 
µL of a 1 mM substrate solution and imaging was performed at the optimal excitation 345 
and emission wavelengths for each substrate (n = 3 per substrate and cell type). As 346 
shown in Figure 6A, fluorescence from the NTR+ tumours was observed 0.75 hours post-347 
intravenous administration with the exception of 2, whose signal became obvious two 348 
hours post-injection.  349 
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 350 
Figure 6: in vivo pharmacokinetic assessment  351 
A) NIR FLI of NTR- and NTR+ xenografts (n = 3 per group per substrate) at the two most representative time 352 
points acquired, one and two hours, after i.v. injection of 100 µL of a 1 mM substrate solution. Accumulation in 353 
the NTR+ tumours is observed after one-hour injection of 1 and 3 and after two hours for 2. Substrate 4 354 
accumulates indistinctly in NTR- and NTR+ tumours at both time points. B) Fluorescence intensity of NTR- and 355 
NTR+ tumours over time and up to 24 hours for each substrate. Data expressed as radiance in px108/s/cm2/sr. 356 
For substrate 4, fluorescence intensity is consistently higher in NTR- than in NTR+ xenografts. C) NTR+/NTR- 357 
ratios calculated to determine the time point with the best contrast for each substrate. One hour for 1 and 3 and 358 




Radiance decreased with time for substrates 1, 3 and 4 after 0.75 h, 2 h and 0.75 h 362 
respectively, and increased with time for substrate 2 reaching the maximum at 8 h 363 
(Figure 6B). As seen in Figure 6C, the best contrast (dashed black box in Figure 6C) for 364 
1 and 3 was observed 0.75 h post-injection, with NTR+/NTR- ratios of 1.5 and 1.8 365 
respectively, and after two hours for 2 with an NTR+/NTR- ratio of 1.3. These time 366 
points were employed for longitudinal imaging. The fluorescence intensity of 4 was 367 
consistently higher in NTR- compared to NTR+ tumours at all time points studied (Figure 368 
6B), thus it was excluded from further in vivo experiments. Interestingly, strong 369 
fluorescence intensity decay was observed for 1 after 0.75 h, in accordance with the 370 
observations in vitro. Also, the decrease in fluorescence emission of 3 after two hours is 371 
in line with the fluorescence decay observed by confocal microscopy (Figure 5). 372 
3.5. Longitudinal tumour imaging 373 
Further longitudinal FLI studies were performed at different mean tumour volumes, with 374 
the selected incubation times for each substrate. Mice bearing NTR- and NTR+ tumours  375 
(n = 6 per substrate and cell type) were injected with the three different substrates under 376 




Figure 7: Longitudinal in vivo optical imaging of MDA-MB-231 NTR- and NTR+ subcutaneous xenografts and 380 
ex vivo biodistribution 381 
A) Representative NIR fluorescence images of NTR- and NTR+ xenografts (n = 6 per group and substrate) at 382 
different mean tumour volumes. B) NTR+/NTR- ratios calculated for the different mean tumour volumes. For 1 383 
and 2, average radiance was significantly higher in the NTR+ group at any mean tumour volume (with p-values: 384 
**, p < 0.01 and *, p < 0.05 respectively at 220 mm3; ***, p < 0.001 for both at 300 mm3 and ****, p < 0.0001 385 
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for both at 450). The NTR- and NTR+ groups imaged with 3 showed no significant differences in average 386 
radiance until mean tumour volumes reached 450 mm3 (**, p < 0.01). C) ex vivo biodistribution assessment 387 
after i.v. injection of 100 µL of a 1 mM substrate solution. Values expressed as radiance in px109/s/cm2/sr. 1: 388 
NTR- tumour; 2: NTR+ tumour 3: Interscapular brown adipose tissue (BAT); 4: Liver; 5: Kidneys; 6: Stomach; 389 
7: Intestine; 8: Muscle. D) ex vivo biodistribution of the different substrates represented as % of sum average 390 
radiance in all organs. It shows hepatobiliary clearance of 1 and 3 and high biodistribution of the former in the 391 
gastrointestinal tract. 2 biodistributes, to all organs studied, in a more homogenous manner than the other two 392 
substrates. Higher biodistribution in NTR+ tumours than in NTR- was observed in all instances. 393 
For 1 and 2 average radiance was significantly higher in the NTR+ group at any mean 394 
tumour volumes. NTR+/NTR- ratios through the longitudinal image range for 1 from 1.7 395 
± 0.5 to 2.1 ± 0.2 (p-values from 0.01 to 0.0001) and for 2 from 1.3 ± 0.2 to 2.2 ± 0.4 (p-396 
values from 0.05 to 0.0001). In the case of 3, no significant differences in average 397 
radiance were observed until mean tumour volumes reached 450 mm3 when NTR+/NTR- 398 
ratio was 1.9 ± 0.6 (p < 0.01) (Figure 7B). As observed in Figure 4A, substrate 3 requires 399 
higher concentrations (12 µM) to achieve fluorescence intensities in the range of those 400 
obtained with 3 µM of 1 or 1 µM of 2. It was also observed that, due to the low 401 
brightness of substrate 3, fluorescence intensities after 0.75 h were closer to background 402 
fluorescence than those from the other two substrates. NTR+/background ratios for 403 
substrates 1, 2 and 3 were 3.8 ± 2.1, 14.0 ± 5.9 and 2.9 ± 1.3, respectively. From these 404 
results it can be concluded that tumour contrast increased with the increase of the mean 405 
tumour volumes for all substrates. The quantitative comparison of fluorescence intensity 406 
as a function of time in NTR+ vs. NTR- xenografts over the progression of the tumours 407 
allowed us to conclude that 1 is the best substrate for in vivo NTR interrogation even at 408 
small tumour volumes, with the highest significance between groups.  409 
3.6. ex vivo biodistribution 410 
To acquire a deeper understanding of the substrates’ biodistribution, 0.75 hours post-411 
injection of 100 µL of a 1 mM solution of 1 and 3 and two hours post-injection of 2, 412 
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NTR- and NTR+ tumour-bearing mice were euthanised, their organs excised and imaged 413 
(Figure 7C). The percentage of biodistributed substrate was calculated and plotted in 414 
Figure 7D. Consistent with the in vivo observations (Figure 6A) high hepatobiliary 415 
uptake is observed for 1 and particularly for 3, compatible with their highly lipophilic 416 
character. 1 also exhibits high fluorescence signal in the gastrointestinal tract with uptake 417 
in the stomach and with high uptake in the large intestine, due to activation by bacterial 418 
nitroreductases present in the GI tract [8, 33]. 2 exhibits a homogeneous accumulation 419 
pattern in all organs, without clear hepatobiliary or renal excretion pathway evidence, 420 
and with a slightly higher accumulation in NTR+ tumours compared to other organs. 421 
Residual signal is also observed for substrate 2 in control organs such as muscle and in 422 
mitochondria-enriched tissues, with known nitroreductase activity [44], such as the 423 
interscapular brown adipose tissue. 424 
 425 
4. Conclusions 426 
We have previously demonstrated that CytoCy5S is useful for non-invasive preclinical NIR 427 
NTR reporter gene imaging in cancers in vivo [8]. In the present study, we set out to clarify 428 
an ongoing discrepancy regarding the structure and physicochemical properties of CytoCy5S 429 
in order to establish which of the structures denoted CytoCy5S is best suited for preclinical 430 
studies in oncology models.  431 
The introduction of the methoxy group in 3 and the sulfonate and cyanine scaffold in 4 432 
resulted in a modest bathochromic shift compared to 1 and 2. All compounds were 433 
confirmed as NTR substrates with delayed kinetics observed for 2 and low emission 434 
intensities for 3 and 4. In vitro, 3 was found to display the highest NTR+/NTR- ratio, 435 
followed by 1. 4 performed poorly in vitro and in vivo. These results are in line with 436 
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previous studies which reported that due to the contribution of the sulfonate group to 437 
increased fluorescent probe polarity these compounds exhibit limited lipid bilayer penetrance 438 
[45, 46]. Despite its promising performance in vitro, 3 did not prove useful for discerning 439 
between NTR- and NTR+ until tumours reached 450 mm3 due to the limited brightness of this 440 
substrate in vivo. This substrate might benefit from an increase in concentration for in vivo 441 
applications, and although this may yield better imaging results, the cost may make in vivo 442 
use of this probe impracticable. 1 and 2 provided similar suitability for NTR interrogation, 443 
being 1 slightly more sensitive at smaller tumour volumes and presenting faster kinetics. 444 
In conclusion, the spectral and biological properties of substrates 1 – 4 have been discerned 445 
and compared. NIR dye 1 was found to be best suited for imaging of NTR, both in vitro and 446 
in vivo, with superior kinetics and lower background fluorescence from surrounding tissues 447 
allowing a better delineation of tumours in our model than 2. The latter result could 448 
potentially be explained by 2 having a methyl group and thus is expected to more easily 449 
permeate across cell membranes. Another key advantage of 1 over 2 is the presence of the 450 
carboxylic functionality, which can be exploited for further derivatisation or conjugation to 451 
biomolecules of interest for biomarker interrogation, making substrate 1 the ideal candidate 452 
for further studies. Although the substrates have been investigated in an oncology model we 453 
believe that these results can be extrapolated to other uses as already shown elsewhere [24]. 454 
 455 
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 16 634 
(Z)-2-(((E)-1-(5-carboxypentyl)-3,3-dimethylindolin-2-ylidene)methyl)-4-((1-(3,5-635 
dinitrobenzyl)-3,3-dimethyl-3H-indol-1-ium-2-yl)methylene)-3-oxocyclobut-1-en-1-olate 636 
(1): 17 637 
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1,3,3-trimethylindolin-2-ylidene)methyl)cyclobut-1-en-1-olate (2): 18 639 
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ene-1,2-dione (18): 23 653 
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Figure S1: 1H-NMR spectrum of 5 in DMSO 25 656 
Figure S2: 1H-NMR spectrum of 6 in DMSO 26 657 




Figure S4: 1H-NMR spectrum of 8 in MeOD 28 659 
Figure S5: 1H-NMR spectrum of 9 in DMSO 29 660 
Figure S6: 1H-NMR spectrum of 10 in DMSO 30 661 
Figure S7: 1H-NMR spectrum of 11 in DMSO 31 662 
Figure S8: 1H-NMR spectrum of 12 in DMSO 32 663 
Figure S9: 1H-NMR spectrum of 13 in DMSO 33 664 
Figure S10: 1H-NMR spectrum of 14 in DMSO 34 665 
Figure S11: 1H-NMR spectrum of Substrate 1 in DMSO 35 666 
Figure S12: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 1; B: 667 
HRMS spectrum of Substrate 1 36 668 
Figure S13: 1H-NMR spectrum of Substrate 2 in DMSO 37 669 
Figure S14: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 2; B: 670 
HRMS spectrum of Substrate 2 38 671 
Figure S15: 1H-NMR spectrum of Substrate 3 in DMSO 39 672 
Figure S16: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 3; B: 673 
HRMS spectrum of Substrate 3 40 674 
Figure S17: 1H-NMR spectrum of Substrate 4 in DMSO 41 675 
Figure S18: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 4; B: 676 
HRMS spectrum of Substrate 4 42 677 
Figure S19: 1H-NMR spectrum of 15 in DMSO 43 678 
Figure S20: 1H-NMR spectrum of 16 in DMSO 44 679 
Figure S21: 1H-NMR spectrum of 17 in DMSO 45 680 
Figure S22: 1H-NMR spectrum of 18 in DMSO 46 681 
Figure S23: Confocal fluorescence microscopy with substrates 1 – 4 with the same scale 682 
for “NTR substrate” channel 47 683 
Figure S24: Absorbance spectrum 48 684 
Figure S25: Flow cytometry analysis 49 685 
Video S1: Full time lapse for substrate 1 49 686 
Video S2: Full time lapse for substrate 2 49 687 
Video S3: Full time lapse for substrate 3 49 688 
Video S4: Full time lapse for substrate 4 49 689 





Synthesis of dyes: 692 
The Fischer bases that were required for the synthesis of the asymmetric substrates  693 
1 - 4 were obtained through N-alkylation of 2,3,3-trimethyl-3H-indole, its 5-methoxy 694 
analogue or 1,1,2-trimethyl-1H-benzo[e]indole (Scheme S1). The crude yields ranged 695 
from 24% to 94% and the intermediates, with the exception of the sulfonated 7, were 696 
employed in further steps without purification, as we found that except for 7, 697 
purification of the intermediates did not give any increase in the yields for the next 698 
steps. The introduction of the sulfonate functionality that was required for substrate 4 699 
proved as a challenge, as several isomers of 7 were formed during sulphonation of the 700 
benzoindole. The sulfonated Fischer base 13 and its precursor 7 were purified by C18 701 
flash chromatography to give the target compounds in modest yields of 14% and 702 







Scheme S1. Synthesis of Fischer bases 8 - 13 that have been employed in the synthesis of NIR dyes 1 – 706 
4. 707 
As shown in Scheme S2, one-pot condensation of the various Fischer bases with 708 
either squaric acid or malonaldehyde bis(phenylimine) successfully gave substrates 1, 709 
3 and 4. In all cases, the reactions also gave the undesired symmetric side products, 710 
which resulted in overall low yields (1% to 16%) for the target dyes. The particularly 711 
low yield for substrate 4 is due to the co-elution with the symmetric dinitrobenzyl side 712 


















































































unsuccessful. In the end, this material was purified by attaching it to a 2-chlorotrityl 714 
chloride resin, which was washed thoroughly prior to release and purification of 4 715 
(see experimental section below). The product was isolated with acceptable purity but 716 
signals from a minor isomer can still be observed in the 1H-NMR spectrum of 717 
substrate 4. 718 
 719 
















1. NaOH 1M, MeCN, rt, 1 h
























































For substrate 2, the one-pot approach proved to be unsuccessful as only the symmetric 722 
side product containing N-methylated side chains could be isolated from the reaction 723 
mixture. Substrate 2 was ultimately obtained through first synthesis of the mono-724 
substituted methyl squaraine intermediate (Scheme S2), which after conversion to 14 725 
under acidic conditions followed by condensation with 8 gave substrate 2 in a 726 
modestly higher yield than what was obtained for the other three substrates. 727 
 728 
Based on the results for the synthesis of substrate 2 and in order to reduce the 729 
formation of the symmetric side products, a stepwise introduction of methylene bases 730 
was attempted also for substrate 1 (see Scheme S3) using either methyl or ethyl 731 
squarate as starting material. 732 
 733 
Scheme S3. Stepwise introduction of methylene bases [1-3]. 734 
To our dismay, these reactions produced complex mixtures, which translated into 735 
tedious purification procedures for each intermediate. Interestingly, the 3,5-736 
dinitrobenzyl containing 8 gave particularly low conversion, both at room temperature 737 
and at reflux. On the other hand, both 16 and 17 proved amenable to further 738 










80 ºC, 3 h
16: R = Et (21%)




































conditions with 15 were largely unsuccessful. In the end, the stepwise approach only 740 
resulted in an increase time requirement while the overall yield was not improved. 741 
 742 
In a final attempt to improve the synthetic route to 1, a solid supported approach was 743 
investigated (Scheme S4) [4]. Toward this end, 9 was immobilized on a 2-chlorotrityl 744 
chloride resin followed by reaction with squaric acid at rt and at 80 °C. Unfortunately, 745 
test-cleavage of a small amount of the resulting resin bound material did not provide 746 
the desired product. On the other hand, reaction of 18 with immobilised 9 (Scheme 747 
S4) in the presence of a carbodiimide (DIC) proved successful for the synthesis of 1 748 
[4]. Overall, the solid supported approach reduced the number of side products 749 
formed, which alleviated the purification. Nevertheless, the overall yield of substrate 750 
1 was not increased and together with the cost and the extra time required this 751 
approach did not prove to be advantageous. 752 
 753 
Scheme S4: Synthesis of substrate 1 using a solid supported approach 754 
1. DIPEA, DCM, rt, 1 h
2.18, DIPEA, DIC, DCM, 80 ºC, 3 h 










1. DIPEA, DCM, rt, 4 h
2. DCM/MeOH/DIPEA 








Materials and instruments 755 
The reactants and reagents employed in the synthetic work were obtained from 756 
Sigma-Aldrich and were used as received. Reactions were generally carried out under 757 
argon atmosphere using overnight oven-dried equipment (130 °C) that was cooled 758 
down under reduced pressure and purged with argon prior to use. Solid phase 759 
syntheses were performed using a 2-chlorotrityl chloride polystyrene (1% DVB) resin 760 
(100 – 200 mesh, 1.14 mmol/g loading) provided by Novabiochem using 10 mL 761 
reactor vials (Biotage). Dry DCM was obtained from an anhydrous solvent delivery 762 
system (SPS-800 system from M. Braun GmbH, Garching, Germany) and kept in a 763 
Schlenk flask. Acetone, ethanol and methanol were dried over 3Å molecular sieves 764 
(10% w/v) overnight and stored under argon.  765 
Flash chromatography was performed using silica (Silica gel 60, 0.040 – 0.063 mm, 766 
Merck) using manually packed glass columns or on a Puriflash XS 420 system 767 
(Interchim, Montlucon Cedex, France) using GraceTM RevelerisTM SRC C18 768 
cartridges (40 µm, 40g, Grace Discovery Sciences, Maryland, USA). Preparative 769 
high-performance liquid chromatography (HPLC) was performed on a Gilson 321 770 
multisolvent pump with a Dionex Ultimate 3000 variable wavelength detector using 771 
an Ascentis C18 (250 x 21.2 mm, 100 Å, 5 µm) column with mixtures of acetonitrile 772 
and water (both containing 0.1% TFA) as eluent.  773 
Analytical HPLC was performed on a 1290 Infinity II Flexible pump with a 1260 774 
Infinity II DAD WR detector using a ZORBAX RRHD Eclipse plus 300-SB C18 (50 775 
x 2.1 mm, 300 Å, 1.8 µm) column with mixtures of acetonitrile and water (both 776 
containing 0.1% TFA) as eluent. High-resolution mass spectra were recorded with an 777 
AccuTOFTM mass spectrometer operated with an orthogonal electrospray ionization 778 
(ESI) source, an orthogonal accelerated time of flight (TOF), single stage reflectron 779 
mass analyzer and a dual micro channel plate (MCP) detector. NMR spectra were 780 
recorded using either a Bruker BioSpin AV500 and/or a Bruker BioSpin Ascend 781 
spectrometer operating at 850 MHz with an inverse-detected triple resonance (TCI) 782 





3,5-Dinitrobenzyl iodide (5): 785 
 786 
3,5-Dinitrobenzyl chloride (5.00 g, 23 mmol) and KI (8.87 g, 53 mmol) were 787 
dissolved in dry acetone (50 mL) under an argon stream. The resulting orange 788 
mixture was stirred for 20 h at rt. Thereafter, the orange solution was filtered and 789 
washed with cold acetone (3 x 20 mL). The solvent was removed under reduced 790 
pressure to afford the title compound, which was used in the next step without 791 
further purification. 792 
Yellow-orange solid; 7.84 g (quantitative crude yield). 1H-NMR (500 MHz, 793 
(CD3)2SO) δ = 8.73 (d, J = 2.1, 2H), 8.68 (t, J = 2.1, 1H), 4.88 (s, 2H). 794 
Analytical data are in accordance with those reported previously [5] 795 
 796 
5-Methoxy-2,3,3-trimethyl-3H-indole (6): 797 
 798 
3-Methyl-2-butanone (3.7 mL, 34.6 mmol) and 4-methoxyphenylhydrazine (3.00 799 
g, 17.2 mmol) were dissolved in acetic acid (30 mL) and the resulting pale pink 800 
mixture was heated at 100 °C (oil bath) for 2.5 h. The mixture was allowed to cool 801 
to rt and the solvent was evaporated under reduced pressure. The resulting dark 802 
brown residue was separated between ethyl acetate (30 mL) and a saturated 803 
solution of NaHCO3 (60 mL). The organic phase was dried over MgSO4, filtered 804 
and the solvent was removed using a rotary evaporator to give the title compound. 805 










Brown oil; 2.22 g, (68% yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 7.30 (d, J = 807 
8.3, 1H), 7.03 (d, J = 2.6, 1H), 6.80 (dd, J = 8.3, 2.6, 1H), 3.76 (s, 3H), 2.15 (s, 808 
3H), 1.22 (s, 6H).  809 
Analytical data are in accordance with those reported previously [6] 810 
 811 
1,1,2-Trimethyl-1H-benzo[e]indol-3-ium-7-sulfonate (7): [7] 812 
 813 
1,1,2-Trimethyl-1H-benz(e)indole (530 mg, 2.5 mmol) was cooled in an ice/water 814 
bath and partially dissolved in sulphuric acid (1 mL). To his mixture, fuming 815 
sulfuric acid (2.5 mL) was added dropwise and the mixture was stirred for 30 min 816 
after which the cooling bath was removed and stirring continued at rt overnight. 817 
The resulting mixture was poured into ice/water (50 mL) and the mixture was 818 
stirred for 30 min. Concentrated KOH was then added until basic pH (pH = 12). 819 
The mixture was placed in an ice/water bath to induce precipitation and the pearly 820 
yellow solid obtained was extracted with hot methanol. The solid material was 821 
isolated by filtration and dried under reduced pressure. The dried residue was then 822 
triturated with ethyl acetate, filtered and collected after drying by vacuum suction 823 
and it was further dried under vacuum. The crude product was purified using RP 824 
flash chromatography (1 - 50% acetonitrile in water, both solvents containing 10 825 
mM of NH4OAc) to give the title compound. 826 
Yellow solid; 228 mg (32% yield). 1H-NMR (500 MHz, (CD3)2SO): δ 8.21 (d, J = 827 
1.8, 1H), 8.07 (d, J = 8.7, 1H), 7.95 (d, J = 8.5, 1H), 7.78 (dd, J = 8.7, 1.8, 1H), 828 
7.69 (d, J = 8.5, 1H), 2.31 (s, 3H), 1.47 (s, 6H). The spectrum shows presence of a 829 
minor isomer. 830 









1-(3,5-Dinitrobenzyl)-2,3,3-trimethyl-3H-indol-1-ium iodide (8): [6] 833 
 834 
Iodide 7 (15.92 g, 51.7 mmol) was dissolved in 1,2-dichlorobenzene (65 mL) 835 
under argon and 2,3,3-trimethylindolenine (8.4 mL, 52.3 mmol) was added and 836 
the resulting brown mixture was stirred for 6 h at 90 °C (oil bath). The mixture 837 
was allowed to cool to rt, upon which a precipitate was formed. The red solid was 838 
isolated by filtration and washed with dichlorobenzene (2 x 25 mL) and diethyl 839 
ether (3 x 30 mL). The resulting yellow solid material was dried under vacuum to 840 
give the title compound, which was used in the next step without any further 841 
purification. 842 
Yellow solid; 22.24 g (92% crude yield). 1H-NMR (500 MHz, CD3OD): δ = 9.04 843 
– 9.00 (m, 1H), 8.60 – 8.55 (m, 2H), 7.90 – 7.81 (m, 2H), 7.69 (t, J = 7.7, 1H), 844 
7.62 (t, J = 7.7, 1H), 6.15 (s, 2H) 1.73 (s, 6H). One CH3 signal assumed to be 845 
hidden by solvent signal. LR-ESI-MS: Calcd. m/z for C18H18N3O4+ [M]+: 340.1; 846 
found: 340.2. 847 
Analytical data are not reported previously 848 
 849 
1-(5-Carboxypentyl)-2,3,3-trimethyl-3H-indol-1-ium iodide (9): 850 
 851 
2,3,3-Trimethyl-3H-indolenine (3.2 mL, 20.0 mmol), 6-bromohexanoic acid 852 
(4.826 g, 24.7 mmol) and KI (4.168 g, 25.1 mmol) were dissolved in acetonitrile 853 













argon atmosphere. After cooling to rt, the resulting red solution was filtered to 855 
remove the beige solid (KBr) and the filtrate was concentrated using rotary 856 
evaporation. The brown oily residue was mixed with warm (65 °C) ethyl acetate 857 
(500 mL) and was slowly cooled (kept in the fridge overnight). The excess of 858 
solvent was removed by rotary evaporation to give the title compound, which was 859 
used in the next step without any further purification. 860 
Grey solid; 5.275 g (66% crude yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 12.00 861 
(bs, 1H), 8.00 – 7.95 (m, 1H), 7.87 – 7.82 (m, 1H), 7.65 – 7.60 (m, 2H), 4.45 (t, J 862 
= 7.8, 2H), 2.84 (s, 3H), 2.23 (t, J = 7.3, 2H), 1.89 – 1.80 (m, 2H), 1.60 - 1.51 (m, 863 
2H), 1.54 (s, 6H), 1.47 – 1.38 (m, 2H). LR-ESI-MS: Calcd. m/z for C17H24NO2+ 864 
[M]+: 274.2; found: 274.2. 865 
Analytical data are in accordance with those reported previously [9] 866 
 867 
1,2,3,3-Tetramethyl-3H-indol-1-ium iodide (10): 868 
 869 
In three separate 10 mL microwave vials, 2,3,3-trimethylindolenine (0.96 mL x 3, 870 
17.9 mmol in total) and iodomethane (0.56 mL x 3, 27.0 mmol in total) were 871 
dissolved in acetonitrile (2.0 mL x 3).  The vials were sealed, and the reaction 872 
mixtures were heated at 130 °C in an oil bath for 30 min. The mixtures were 873 
allowed to cool to rt and then further cooled in an ice/water bath. The solvent was 874 
decanted, and the pink needle-shaped crystals from each vial were pooled and 875 
isolated by filtration, washed with cold ethanol and dried under vacuum. The 876 
crude product was used in the next step without further purification. 877 
Pink crystalline solid; 5.099 g (94% crude yield). 1H-NMR (500 MHz, (CD3)2SO): 878 
δ = 7.92 – 7.89 (m, 1H), 7.84 – 7.81 (m, 1H), 7.65 – 7.59 (m, 2H), 3.97 (s, 3H), 879 
2.76 (s, 3H), 1.52 (s, 6H); LR-ESI-MS: Calcd. m/z for C12H16N [M]+: 174.1; 880 
found: 174.2. 881 






1-(3,5-Dinitrobenzyl)-5-methoxy-2,3,3-trimethyl-3H-indol-1-ium iodide (11): 883 
 884 
To a solution of 6 (1.11 g, 5.9 mmol) in 1,2-dichlorobenzene (6 mL), 5 (2.72 g, 885 
8.8 mmol) was added. The reaction mixture was heated to reflux for 30 min and it 886 
was then allowed to cool to rt before it was cooled further in an ice/water bath. 887 
Once crystallization started, the mixture was heated to reflux for another 2 h and 888 
cooled to rt before the precipitate that formed was isolated by filtration and 889 
washed with 1,2-dichlorobenzene and diethyl ether and dried under vacuum to 890 
give the title compound. 891 
Pale orange powder; 1.36 g (48% crude yield). 1H-NMR (500 MHz, (CD3)2SO): δ 892 
= 8.82 (t, J = 2.0, 1H), 8.62 (d, J = 2.0, 2H), 7.77 (d, J = 8.9, 2.5, 1H), 7.53 (d, J = 893 
2.5, 1H), 7.11 (dd, J = 8.9, 2.5, 1H), 6.04 (s, 2H), 3.85 (s, 3H), 2.91 (s, 3H), 1.60 894 
(s, 6H). The spectrum contains additional peaks. LR-ESI-MS: Calcd. m/z for 895 
C19H20N3O5+ [M]+: 370.1; found: 370.2. 896 
Analytical data are in accordance with those reported previously [6]  897 
 898 
1-(5-Carboxypentyl)-5-methoxy-2,3,3-trimethyl-3H-indol-1-ium bromide 899 
(12): 900 
 901 
To a solution of 6 (1.11 g, 5.9 mmol) in 1,2-dichlorobenzene (6 mL) 6-902 
bromohexanoic acid (1.73 g, 8.8 mmol) was added. The reaction mixture was 903 















diethyl ether (10 mL) upon which a black precipitate formed. The solvents were 905 
removed by decantation and the residue was triturated with dichloromethane. The 906 
residue was suspended in diethyl ether and the solid material was isolated by 907 
filtration and dried under high vacuum. 908 
Purple powder; 530 mg (24% crude yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 909 
12.00 (bs, 1H), 7.87 (d, J = 8.9, 1H), 7.48 (d, J = 2.5, 1H), 7.14 (dd, J = 8.9, 2.5, 910 
1H), 4.41 (t, J = 7.7, 2H), 3.86 (s, 3H), 2.76 (s, 3H), 2.22 (t, J = 7.3, 2H), 1.86 - 911 
1.78 (m, 2H), 1.58 – 1.53 (m, 2H), 1.51 (s, 6H), 1.44 - 1.36 (m, 2H). LR-ESI-MS: 912 
Calcd. m/z for C18H26NO3+ [M]+: 304.2; found: 304.2. 913 
Analytical data are in accordance with those reported previously [6] 914 
 915 
3-(5-Carboxypentyl)-1,1,2-trimethyl-1H-benzo[e]indol-3-ium-7-sulfonate 916 
(13): [7] 917 
 918 
A mixture of potassium 7 (228 mg, 0.8 mmol) and 6-bromohexanoic acid (195 919 
mg, 1.0 mmol) in 1,2-dichlorobenzene (3 mL) was heated to reflux for 48 h. The 920 
solvent was decanted off and the solid residue was triturated with ethyl acetate. 921 
The product was then dissolved in distilled water and methanol and the solvents 922 
were evaporated under reduced pressure. The crude product was purified using RP 923 
flash chromatography (1 - 50% acetonitrile in water, both solvents containing 10 924 
mM of NH4CO2CH3) to give the title compound. 925 
Brown/orangish solid; 46 mg (14% yield). 1H NMR (500 MHz, (CD3)2SO): δ = 926 
7.99 (d, J = 1.9, 1H), 7.88 (d, J = 8.8, 1H), 7.77 (d, J = 8.7, 1H), 7.57 (dd, J = 8.8, 927 
1.9, 1H), 7.15 (d, J = 8.7, 1H), 3.61 (t, J = 7.3, 2H), 2.19 (t, J = 7.3, 2H), 1.90 (s, 928 











2H), 1.24 (s, 2H). The spectrum contains additional peaks. LR-ESI-MS: Calcd. 930 
m/z for C21H26NO5S+ [M + H]+: 404.2; found: 404.2. 931 
Analytical data are in accordance with those reported previously [8] 932 
 933 
(E)-3-hydroxy-4-((1,3,3-trimethylindolin-2-ylidene)methyl)cyclobut-3-ene-934 
1,2-dione (14): 935 
 936 
10 (1.72 g, 5.7 mmol) was dissolved in acetonitrile (40 mL) and reacted with a 937 
1M solution of NaOH (70 mL) for 1 h at rt. The final product was extracted by 938 
means of CH2Cl2 (3 x 30 mL), dried over MgSO4 and the excess of solvent was 939 
removed by rotary evaporation to give the activated Fischer base (989 mg, 5.7 940 
mmol). The dried activated Fischer base and 3,4-dimethoxy-3-cyclobutene-1,2-941 
dione (817 mg, 5.7 mmol) were dissolved in dry methanol (2.5 mL) and the 942 
resulting mixture was stirred at rt for 18 h and then cooled in the fridge for 2 h. 943 
The red solid was isolated by filtration and washed with cold methanol and cold 944 
diethyl ether and dried under high vacuum to give (E)-3-methoxy-4-((1,3,3-945 
trimethylindolin-2-ylidene)methyl)cyclobut-3-ene-1,2-dione as a yellow solid. 946 
The crude product (872 mg) was dissolved in acetic acid (9.5 mL) and a 1M 947 
solution of HCl (1.55 mL) was added. The yellow-orangish mixture was heated at 948 
80 °C for 5 h and the resulting mixture was evaporated under reduced pressure to 949 
give a dark green iridescent residue. This residue was triturated with diethyl ether, 950 
and the solid material was isolated by filtration and washed with diethyl ether and 951 
dried under high vacuum to give the title compound, which was used in the next 952 
step without further purification. 953 
Dark green solid; 783 mg (86% crude yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 954 
7.43 – 7.36 (m, 1H), 7.29 – 7.22 (m, 1H), 7.14 – 7.08 (m, 1H), 7.04 – 6.97 (m, 955 
1H), 5.45 (s, 1H), 3.34 (s, 3H), 1.55 (s, 6H). The spectrum shows presence of 956 













oxocyclobut-1-en-1-olate (1): 962 
 963 
Compound 8 (999 mg, 2.1 mmol), 9 (765 mg, 1.9 mmol) and 3,4-dihydroxy-3-964 
cyclobuten-1,2-dione (238 mg, 2.1 mmol) were dissolved in pyridine (9.7 mL), 965 
acetic acid (9.7 mL) and acetic anhydride (2.2 mL) and the resulting mixture was 966 
heated at 110 °C for 3 h. The reaction mixture was partitioned between 967 
dichloromethane (10 mL) and water (10 mL). The combined organic phases were 968 
dried over MgSO4, filtered and evaporated under reduced pressure to give an 969 
iridescent blue sticky residue (1.261 g), which was purified using semi-970 
preparative RP-HPLC (50 - 90% acetonitrile in water, both solvents containing 971 
0.1% TFA) to give the title compound. 972 
Iridiscent blue solid; 109 mg (9% yield). 1H-NMR (850 MHz, (CD3)2SO): δ = 973 
12.00 (bs, 1H), 8.74 (d, J = 2.4, 1H), 8.40 (d, J = 2.4, 2H), 7.58 (d, J = 7.4, 1H), 974 
7.55 (dd, J = 7.4, 1.2, 1H), 7.42 (d, J = 8.0, 1H), 7.38 (td, J = 7.7, 1.2, 1H), 7.29 975 
(td, J = 7.7, 1.2, 1H), 7.24 – 7.22 (m, 2H), 7.16 (t, J = 7.4, 1H), 5.88 (s, 1H), 5.75 976 
(s, 1H), 5.66 (s, 2H), 4.14 (t, J = 7.6, 2H), 2.20 (t, J = 7.3, 2H), 1.79 (bs, 6H), 1.72 977 
(m, 2H), 1.65 (s, 6H), 1.55 (m, 2H), 1.39 (m, 2H); HR-ESI-MS: Calcd. m/z for 978 
C39H39N4O8+ [M+H]+: 691.2762; found: 691.2772. 979 














oxo-2-(((E)-1,3,3-trimethylindolin-2-ylidene)methyl)cyclobut-1-en-1-olate (2): 983 
 984 
Squaric acid derivative 14 (398 mg, 1.5 mmol) and 8 (695 mg, 1.5 mmol) were 985 
dissolved in pyridine (7 mL), acetic acid (7 mL) and acetic anhydride (1.5 mL) 986 
and the resulting mixture was heated at 110 °C for 6 h. The reaction mixture was 987 
partitioned between dichloromethane (10 mL) and water (10 mL). The combined 988 
organic phases were dried over MgSO4, filtered and evaporated under reduced 989 
pressure to give an iridescent blue sticky residue (1.099 g). The crude residue was 990 
purified by flash chromatography (CH2Cl2/MeOH, 95:5) to give a green/bluish 991 
material (307 mg). This material was further purified using semi-preparative RP-992 
HPLC (50 - 90% acetonitrile in water, both solvents containing 0.1% TFA) to 993 
give the title compound. 994 
Dark blue solid; 171 mg (20% yield). 1H-NMR (850 MHz, (CD3)2SO): δ = 8.73 (s, 995 
1H), 8.40 (d, J = 2.1, 2H), 7.57 (d, J = 7.4, 1H), 7.55 (dd, J = 7.4, 1.2, 1H), 7.43 996 
(d, J = 7.7, 1H), 7.38 (td, J = 7.7, 1.2, 1H), 7.28 (td, J = 7.7, 1.2, 1H), 7.25 – 7.21 997 
(m, 2H), 7.15 (m, 1H), 5.85 (s, 1H), 5.75 (s, 1H), 5.65 (s, 2H), 3.64 (s, 3H), 1.80 998 
(s, 6H), 1.65 (s, 6H); HR-ESI-MS: Calcd. m/z for C34H31N4O6+ [M+H]+: 999 
591.2238; found: 591.2247. 1000 














1-ium-2-yl)methylene)-3-oxocyclobut-1-en-1-olate (3): 1005 
 1006 
5-Methoxy indolenine 11 (264 mg, 0.5 mmol), 5-methoxy indolenine 12 (200 mg, 1007 
0.5 mmol) and 3,4-dihydroxy-3-cyclobutene-1,2-dione (66 mg, 0.6 mmol) were 1008 
dissolved in pyridine (2.25 mL), acetic acid (2.25 mL) and acetic anhydride (0.5 1009 
mL) and the resulting mixture was stirred at 110 °C for 5 h. The resulting mixture 1010 
was evaporated under reduced pressure to give a green/bluish iridescent residue 1011 
(673 mg). This residue was purified by flash chromatography (CH2Cl2/MeOH, 1012 
90:10) to give a green/bluish material (96 mg). This material was further purified 1013 
using semi-preparative HPLC (50-90% acetonitrile in water, both solvents 1014 
containing 0.1% formic acid) to give the title compound. 1015 
Iridiscent blue solid; 62 mg (16% yield) 1H-NMR (850 MHz, (CD3)2SO): δ = 1016 
12.00 (s, 1H), 8.73 (bs, 1H), 8.38 (bs, 2H), 7.33 (d, J = 8.6, 1H), 7.23 (d, J = 2.5, 1017 
1H), 7.21 (d, J = 2.5, 1H), 7.16 – 7.11 (m, 1H), 6.93 (dd, J = 8.6, 2.5, 1H), 6.84 1018 
(dd, J = 8.6, 2.5, 1H), 5.78 (s, 1H), 5.65 (s, 1H), 5.61 (s, 2H), 4.14 – 4.07 (m, 2H), 1019 
3.79 (s, 3H), 3.78 (s, 3H), 2.19 (t, J = 7.2, 2H), 1.79 (bs, 6H), 1.71 – 1.69 (m, , 1020 
2H), 1.64 (s, 6H), 1.55 – 1.53 (m, 2H), 1.37 – 1.36 (m, 2H); HR-ESI-MS: Calcd. 1021 
m/z for C41H43N4O10+ [M+H]+: 751.2974; found: 751.2982. 1022 
















benzo[e]indol-3-yl)hexanoate (4): 1027 
 1028 
Benzo(e)indolenine 13 (146 mg, 0.33 mmol), dinitrobenzyl indolenine 8 (169 mg, 1029 
0.36 mmol) and malonaldehyde bis(phenylimine) monohydrochloride (91 mg, 1030 
0.35 mmol) were dissolved in pyridine (4.5 mL), acetic acid (4.5 mL) and acetic 1031 
anhydride (1 mL) and the resulting mixture was heated at 110 °C for 5 h under an 1032 
argon stream. The resulting mixture was cooled to rt and evaporated under 1033 
reduced pressure to give a green/bluish iridescent oil (656 mg). A portion of the 1034 
crude product (242 mg) was purified by means of solid support resin using 2-1035 
chlorotrityl chloride (281 mg). Briefly, a mixture of 4 and DIPEA (4 equiv) in dry 1036 
DCM was loaded in the resin by agitation at rt for 3 h. The resin was then washed 1037 
with DCM (6 x 2 mL) until solvent was colourless. Cleavage from the resin was 1038 
facilitated by treatment with TFA, triisopropylsilane (TIS) and water (95:2.5:2.5, 1039 
2 mL) for 2 h. The mixture of sulfonate isomers obtained from the cleavage of the 1040 
resin was further purified by semi-preparative RP-HPLC (50 - 70% acetonitrile in 1041 
water, both solvents containing ammonium acetate 10 mM) to give the title 1042 
compound. 1043 
Dark greenish solid; 3.61 mg (1% yield). 1H-NMR (850 MHz, (CD3)2SO): δ = 1044 
8.75 (s, 1H), 8.53 – 8.46 (m, 1H), 8.44 (s, 2H), 8.32 (t, J = 13.0, 1H), 8.30 (s, 1H), 1045 
8.25 (d, J = 8.8, 1H), 8.20 (d, J = 8.8, 1H), 7.89 (dd, J = 8.8, 1.7, 1H), 7.83 (d, J = 1046 
9.0, 1H), 7.64 (d, J = 7.1, 1H), 7.33 (t, J = 7.6, 1H), 7.29 (d, J = 7.9, 1H), 7.19 (t, J 1047 
= 7.6, 1H), 6.54 (m, 2H), 6.19 (m, 1H), 5.62 (s, 2H), 4.30 (m, 2H), 2.08 (bs, 2H), 1048 












(m, 2H) The spectrum contains additional peaks. HR-ESI-MS: Calcd. m/z for 1050 
C42H43N4O9S+ [M+H]+: 779.2745; found: 779.2754. 1051 
Analytical data not reported previously 1052 
 1053 
 (E)-6-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)methylene)-3,3-1054 
dimethylindolin-1-yl)hexanoic acid (15): 1055 
 1056 
To a solution of 9 (306 mg, 0.76 mmol) in dry ethanol (3 mL), 3,4-diethoxy-3-1057 
cyclobutene-1,2-dione (110 µL, 0.74 mmol) was added and the resulting mixture 1058 
was treated with triethylamine (300 µL, 2.15 mmol) and heated to reflux for 3 h. 1059 
After cooling to rt, the solvent was removed under reduced pressure to give a dark 1060 
brown viscous residue that was further evaporated under vacuum. The residue was 1061 
purified using flash chromatography (ethyl acetate to 10% methanol in ethyl 1062 
acetate) to give the title compound as a dark yellow solid. 1063 
Dark yellow solid; 251 mg (86 % yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 1064 
11.99 (s, 1H), 7.43 (dd, J = 7.4, 1.2, 1H), 7.29 (td, J = 7.7, 1.2, 1H), 7.17 (d, J = 1065 
7.7, 1H), 7.07 (td, J = 7.4, 1.2, 1H), 5.35 (s, 1H), 4.81 (q, J = 7.1, 2H), 3.90 (t, J = 1066 
7.3, 2H), 2.19 (t, J = 7.3, 2H), 1.65 (p, J = 7.3, 2H), 1.59 – 1.49 (s and m, 6H and 1067 
2H), 1.44 (t, J = 7.1, 3H), 1.39 – 1.32 (m, 2H). LR-ESI-MS: Calcd. m/z for 1068 
C23H26NO5- [M+H]-: 396.2; found: 396.1. 1069 













ethoxycyclobut-3-ene-1,2-dione (16):  1073 
 1074 
To a solution of 8 (133 mg, 0.39 mmol) in dry ethanol (4 mL), 3,4-diethoxy-3-1075 
cyclobutene-1,2-dione (60 µL, 0.39 mmol) was added and the resulting mixture 1076 
was treated with triethylamine (150 µL, 1.08 mmol) and it was heated to reflux for 1077 
3 h. The crude product was concentrated under reduced pressure to give a dark 1078 
purple residue that was further evaporated under vacuum.  1079 
Purple solid; 305 mg (21% yield). 1H-NMRz (500 MHz, (CD3)2SO): δ = 8.59 (d, J 1080 
= 2.4, 1H), 8.14 – 8.11 (m, 1H), 7.45 (dt, J = 7.6, 1.0, 1H), 7.34 (td, J = 7.6, 1.0, 1081 
1H), 7.08 (td, J = 7.6, 1.0, 1H), 7.01 (d, J = 7.6, 1H), 6.23 (bs, 1H), 5.37 (bs, 2H), 1082 
4.47 (q, J = 7.1, 2H), 3.20 (q, J = 7.1, 2H), 1.42 (s, 6H), 1.28 (t, J = 7.1, 3H). The 1083 
rest of the signals correspond to 79% of unreacted starting material.  1084 
Analytical data not reported previously. 1085 
 1086 
(E)-3-((1-(3,5-dinitrobenzyl)-3,3-dimethylindolin-2-ylidene)methyl)-4-1087 
methoxycyclobut-3-ene-1,2-dione (17):  1088 
 1089 
To a solution of 8 (328 mg, 0.97 mmol) in dry methanol (7 mL), 3,4-dimethoxy-3-1090 
cyclobutene-1,2-dione (153 mg, 1.1 mmol) was added and the resulting mixture 1091 

















evaporated under reduced pressure to give the crude product (855 mg), which was 1093 
purified using flash chromatography (hexanes/ethyl acetate, 6:4) to give the title 1094 
compound. Unreacted 8 (71 mg) was also isolated. 1095 
Orange powder; 106 mg (25% yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 8.73 (t, 1096 
J = 2.1, 1H), 8.38 (d, J = 2.1, 2H), 7.54 - 7.50 (m, 1H), 7.30 - 7.24 (m, 1H), 7.19 – 1097 
7.16 (m, 1H), 7.14 - 7.08 (m, 1H), 5.55 (s, 2H), 5.42 (s, 1H), 4.36 (s, 3H), 1.65 (s, 1098 
6H). LR-ESI-MS: Calcd. m/z for C23H20N3O7+ [M+H]+: 436.1; found: 436.1. The 1099 
mass spectrum contains additional peaks and the product peak is of very low 1100 
intensity. 1101 
Analytical data not reported previously. 1102 
 1103 
(E)-3-((1-(3,5-dinitrobenzyl)-3,3-dimethylindolin-2-ylidene)methyl)-4-1104 
hydroxycyclobut-3-ene-1,2-dione (18): 1105 
 1106 
17 (280 mg, 0.62 mmol) was dissolved in acetic acid (6 mL) and a 1M solution of 1107 
HCl (0.45 mL) was added. The dark orange mixture was heated at 80 °C for 5 h 1108 
and the resulting mixture was evaporated under reduced pressure to give a brown 1109 
viscous residue. This residue was triturated with diethyl ether, and the solid 1110 
material was isolated by filtration and washed with diethyl ether and dried under 1111 
high vacuum to give the title compound, which was used in the next step without 1112 
further purification. 1113 
Olive green solid; 156 mg (58% yield). 1H-NMR (500 MHz, (CD3)2SO): δ = 8.73 1114 
(t, J = 2.1, 1H), 8.40 (d, J = 2.1, 2H), 7.47 (dd, J = 7.6, 1.2, 1H), 7.22 (td, J = 7.6, 1115 
1.2, 1H), 7.10 – 7.01 (m, 2H), 5.50 (s, 1H), 5.45 (s, 2H), 1.66 (s, 7H). The 1116 
material contains residual acetic acid and diethyl ether. LR-ESI-MS: Calcd. m/z 1117 











Analytical data not reported previously. 1119 
 1120 
Synthesis of 1 using immobilized 9: 1121 
2-Chlorotrityl chloride resin (71 mg, 0.15 mmol) was swelled in dry CH2Cl2 for 1 h at 1122 
rt in a 10 mL reactor vial (Biotage) and the solvent was drained off by vacuum 1123 
suction. A mixture of 9 (45 mg, 0.1 mmol) and DIPEA (25 µL, 0.2 mmol) in dry 1124 
CH2Cl2 (2 mL) was added to the swelled resin and the reaction mixture was agitated 1125 
for 4 h at rt. The resin was then rinsed four times with DCM (2 mL) and the resin was 1126 
agitated with a capping solution consisting of DCM/MeOH/DIPEA (8:1.5:0.5, 2 mL) 1127 
rt for 10 min (step repeated twice). After a DCM (2 mL) wash, DIPEA (0.2 mL, 10 1128 
mmol) in DCM (2 mL) was added and reacted for 1 h at rt. After washing with DCM 1129 
(3 x 2 mL), a mixture of 18 (45.1 mg, 0.1 mmol), DIPEA (25 µL, 0.2 mmol) and DIC 1130 
(15 µL, 0.1 mmol) in DCM (2 mL) was added to the resin. The reaction mixture was 1131 
transferred to a sealed vial and heated at 80 °C for 3 h. The resin was washed 1132 
thoroughly with DCM (6 x 2 mL). The final compound was then cleaved from the 1133 
resin with a mixture consisting of DCM/TFA (9.5:0.5, 2 mL) with agitation for 10 1134 
min at rt (step repeated twice). The TFA fraction was concentrated under reduced 1135 
pressure and cold diethyl ether was added to the residual TFA. The title compound 1136 
was isolated from diethyl ether by extraction with acetonitrile/water + 0.1%TFA 1137 
(50:50) and was purified by semi-prep RP-HPLC (50 - 90% acetonitrile in water, both 1138 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S12: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 1; B: HRMS spectrum of Substrate 1 
Acq. Data Name: ElviraG_160620_CytoC5S,CY5M,CYSulfo,CY5OMe_ESI+_LC 
Spec. Record Interval: 0.5[s] Internal Sample Id:  
Ring Lens Volt: 8[V] Orifice1 Volt Sweep: 16V Ionization Mode: ESI+ 
Time of Maximum: 10.342[min] Acquired m/z Range: 200.0..1500.0 MS Calibration Name: PEG_ESI+_2000 
Reduction History: Determine m/z[Peak Detect[Centroid,50,Area];Correct Base[5.0%]];Average(MS[1] 10.334..10.353)-1.0*Average(MS[1] 9.249..9.286);Correct Base[5.0%] 
Operator Name: Accutof Experiment Date/Time: 6/16/2020 10:34:28 

















639.36076427.40458 1202.06928903.77744 1077.63125279.17143 992.92836813.72828 1331.24573590.08808510.26552
Sample Name CytoCy5S 1mM stock solution in
DMSO
Project Name Elvira_2019
Injection Acq Method Name short col 0.4 ml 50 to 90 in 7 min 10 µl injection.amx
Injection Acquired Date 2020-06-09 10:27:33+02:00
Sample Name RT Area Peak Area % Peak Height Peak Height %
























































5.461 - 5.46 (PeakAll)  (2020-06-09 10-26-42+02-00-02.dx)
Single Injection Report
Elvira report template.rdl [Rev. 37] Printed:  2020-06-09 12:16:08+02:00 Page 2 of 5
Sample Name CytoCy5S 1mM stock solution in
DMSO
Project Name Elvira_2019
Injection Acq Method Name short col 0.4 ml 50 to 90 in 7 min 10 µl injection.amx
Injection Acquired Date 2020-06-09 10:27:33+02:00
Sample Name RT Area Peak Area % Peak Height Peak Height %
























































5.461 - 5.46 (PeakAll)  (2020-06-09 10-26-42+02-00-02.dx)
Single Injection Report
Elvira report template.rdl [Rev. 37] Printed:  2020-06-09 12:16:08+02:00 Page 2 of 5



















































































































































































































Figure S14: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 2; B: HRMS spectrum of Substrate 2 
 
Acq. Data Name: ElviraG_160620_CytoC5S,CY5M,CYSulfo,CY5OMe_ESI+_LC 
Spec. Record Interval: 0.5[s] Internal Sample Id:  
Ring Lens Volt: 8[V] Orifice1 Volt Sweep: 16V Ionization Mode: ESI+ 
Time of Maximum: 26.329[min] Acquired m/z Range: 200.0..1500.0 MS Calibration Name: PEG_ESI+_2000 
Reduction History: Determine m/z[Peak Detect[Centroid,50,Area];Correct Base[5.0%]];Average(MS[1] 26.225..26.331)-1.0*Average(MS[1] 24.087..24.892);Correct Base[5.0%] 
Operator Name: Accutof Experiment Date/Time: 6/16/2020 10:34:28 

















424.22784 1019.62005345.26299 1278.42583779.31519 869.45695
Sample Name Cy5M 1mM stock solution in
DMSO
Project Name Elvira_2019
Injection Acq Method Name short col 0.4 ml 50 to 90 in 7 min 10 µl injection.amx
Injection Acquired Date 2020-06-09 10:41:54+02:00
Sample N me RT Area Peak Area % Peak Height Peak Height %
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Single Injection Report
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A
Sample Name Cy5M 1mM stock solution in
DMSO
Project Name Elvira_2019
Injection Acq Method Name short col 0.4 ml 50 to 90 in 7 min 10 µl injection.amx
Injection Acquired Date 2020-06-09 10:41:54+02:00
Sample Name RT Area Peak Area % Peak Height Peak Height %
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Figure S16: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 3; B: HRMS spectrum of Substrate 3 
 
Acq. Data Name: ElviraG_160620_CytoC5S,CY5M,CYSulfo,CY5OMe_ESI+_LC 
Spec. Record Interval: 0.5[s] Internal Sample Id:  
Ring Lens Volt: 8[V] Orifice1 Volt Sweep: 16V Ionization Mode: ESI+ 
Time of Maximum: 58.303[min] Acquired m/z Range: 200.0..1500.0 MS Calibration Name: PEG_ESI+_2000 
Reduction History: Determine m/z[Peak Detect[Centroid,50,Area];Correct Base[5.0%]];Average(MS[1] 57.985..58.304)-1.0*Average(MS[1] 53.938..55.026);Correct Base[5.0%] 
Operator Name: Accutof Experiment Date/Time: 6/16/2020 10:34:28 





























































Sample Name Cy5OMe 1mM stock solution in
DMSO
Project Name Elvira_2019
Injection Acq Method Name short col 0.4 ml 50 to 90 in 7 min 10 µl injection.amx
Injection Acquired Date 2020-06-09 11:10:38+02:00
Sample Name RT Area Peak Area % Peak Height Peak Height %
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Figure S18: A: Analytical RP-HPLC chromatogram and UV trace of Substrate 4; B: HRMS spectrum of Substrate 4 











































Acq. Data Name: ElviraG_160620_CytoC5S,CY5M,CYSulfo,CY5OMe_ESI+_LC 
Spec. Record Interval: 0.5[s] Internal Sample Id:  
Ring Lens Volt: 8[V] Orifice1 Volt Sweep: 16V Ionization Mode: ESI+ 
Time of Maximum: 41.199[min] Acquired m/z Range: 200.0..1500.0 MS Calibration Name: PEG_ESI+_2000 
Reduction History: Determine m/z[Peak Detect[Centroid,50,Area];Correct Base[5.0%]];Average(MS[1] 41.081..41.199)-1.0*Average(MS[1] 36. 69..39.020);Correct Base[5.0%] 
Operator Name: Accutof Experiment Date/Time: 6/16/2020 10:34:28 




















Sample Name Cy5Sulfo 1mM stock solution in
DMSO
Project Name Elvira_2019
Injection Acq Method Name short col 0.4 ml 50 to 90 in 7 min 10 µl injection.amx
Injection Acquired Date 2020-06-09 10:56:17+02:00
Sample Name RT Area Peak Area % Peak Height Peak Height %
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Figure S23: Confocal fluorescence microscopy with substrates 1 – 4 with the same scale for “NTR substrate” channel 
 










Figure S24: A) Chemical structures of substrates 1 – 4, their respective B) absorbance spectra (200 – 900 nm) from the HPLC 
UV trace showing the absorbance of the acetonitrile used as the buffer and the absorbance of each substrate at the given 







Figure S25: Flow cytometry analysis of unstained NTR- and NTR- and NTR+ stained with 3 µM of substrates 1 - 4 for four 
hours. Values are reported as Mean Fluorescence Intensity (MFI) with the corresponding statistically significant differences 




Video S1: Full time lapse for substrate 1 
 
Video S2: Full time lapse for substrate 2 
 
Video S3: Full time lapse for substrate 3 
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Abstract 
Nitroreductases (NTR) are a family of bacterial enzymes used in gene directed enzyme prodrug therapy 
(GDEPT) that selectively activate prodrugs containing aromatic nitro groups to exert cytotoxic effects 
following gene transduction in tumours. The clinical development of NTR-based GDEPT has, in part, 
been hampered by the lack of translational imaging modalities to assess gene transduction and drug 
cytotoxicity, non-invasively. This study presents translational preclinical PET imaging to validate and 
report NTR activity using the clinically approved radiotracer, 18F-FMISO, as substrate for the NTR 
enzyme. 
Methods: The efficacy with which 18F-FMISO could be used to report NfsB NTR activity in vivo was 
investigated using the MDA-MB-231 mammary carcinoma xenograft model. For validation, subcutaneous 
xenografts of cells constitutively expressing NTR were imaged using 18F-FMISO PET/CT and fluorescence 
imaging with CytoCy5S, a validated fluorescent NTR substrate. Further, examination of the non-invasive 
functionality of 18F-FMISO PET/CT in reporting NfsB NTR activity in vivo was assessed in metastatic 
orthotopic NfsB NTR expressing xenografts and metastasis confirmed by bioluminescence imaging. 
18F-FMISO biodistribution was acquired ex vivo by an automatic gamma counter measuring radiotracer 
retention to confirm in vivo results. To assess the functional imaging of NTR-based GDEPT with 
18F-FMISO, PET/CT was performed to assess both gene transduction and cytotoxicity effects of prodrug 
therapy (CB1954) in subcutaneous models. 
Results: 18F-FMISO retention was detected in NTR+ subcutaneous xenografts, displaying significantly 
higher PET contrast than NTR- xenografts (p < 0.0001). Substantial 18F-FMISO retention was evident in 
metastases of orthotopic xenografts (p < 0.05). Accordingly, higher 18F-FMISO biodistribution was 
prevalent ex vivo in NTR+ xenografts. 18F-FMISO NfsB NTR PET/CT imaging proved useful for monitoring 
in vivo NTR transduction and the cytotoxic effect of prodrug therapy. 
Conclusions: 18F-FMISO NfsB NTR PET/CT imaging offered significant contrast between NTR+ and 









PET/CT imaging proved efficient in monitoring the two steps of GDEPT, in vivo NfsB NTR transduction 
and response to CB1954 prodrug therapy. These results support the repurposing of 18F-FMISO as a 
readily implementable PET imaging probe to be employed as companion diagnostic test for NTR-based 
GDEPT systems. 
Key words: 18F-FMISO, Gene-directed enzymatic prodrug therapy, GDEPT, nitroreductase, NTR, cancer, 
xenograft, preclinical, mouse, PET/CT, imaging 
Introduction 
Gene directed enzyme prodrug therapy 
(GDEPT) is a promising anti-cancer strategy that aims 
to reduce off-target toxicity and limit severe 
side-effects by the combination of a prodrug and its 
activating enzyme [1]. In a first step, tumours are 
transduced to express a gene encoding for the 
prodrug-activating enzyme. In a second step, a 
non-toxic prodrug is delivered systemically and 
subsequently converted in situ to a cytotoxic 
derivative by the expressed enzyme [2]. In this way, 
GDEPT achieves high concentration of cytotoxic 
compounds locally, minimising systemic side effects 
associated with conventional cancer chemotherapy 
[3]. 
The most extensively studied prodrug/enzyme 
pairs for GDEPT are ganciclovir (GCV)/herpes 
simplex virus-thymidine kinase (HSV-TK) [4] and 5- 
(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954, Figure 
1B)/E. Coli nitroreductase NfsB (onwards referred as 
NTR) [5]. HSV-TK phosphorylates GCV, allowing its 
incorporation into DNA, resulting in toxicity due to 
interference with the DNA synthesis [6]. NTR reduces 
the nitro groups (R-NO2) present in CB1954, into 
hydroxylamines (R-NHOH), resulting in the 
formation of an alkylating agent with cytotoxic 
activity [7, 8]. Moreover, the diffusion of the activated 
compound into neighbouring non-targeted cells 
amplifies this cytotoxic effect (bystander effect) [9, 10]. 
Several trials have evaluated the clinical application of 
HSV-TK and NTR-based GDEPT strategies with 
contrasting results [5, 11, 12]. The largest clinical trial, 
including 124 patients receiving HSV-TK-based 
GDEPT, reported no difference in comparison to 
standard therapy. Modest HSV-TK expression was 
suggested as a potential limiting factor [11]. Indeed, a 
phase II HSV-TK-based GDEPT trial using a more 
efficient gene transduction strategy reported a 
significant increase in survival [12]. These studies 
illustrate the need for monitoring the gene 
transduction efficiency. One of the NTR-based 
GDEPT clinical trials assessed the transduction 
efficiency using immunohistochemistry in tumour 
biopsies [5]. However, immunohistochemistry is time 
consuming and may be affected by inadequate 
sampling of representative tumoral areas. For large 
clinical trials, non-invasive techniques such as 
imaging, which allows for easier clinical 
implementation, are required. In this respect, positron 
emission tomography (PET), which is routinely 
employed in clinical settings, enables detection of the 
activity for some of the enzymes used in the GDEPT 
strategies and may be suitable for interrogation of 
transduction efficiency in clinical trials [13, 14]. 
The activity of HSV-TK can be evaluated using 
radiolabeled probes, such as 18F-FIAU (1-(2- 
deoxy-2-[18F]-fluoro-1-D-arabinofuranoside)-5-iodour
acil), 18F-FHBG (9-[4-[18F]fluoro-3-(hydroxymethyl) 
butyl]guanine) and GCV analogues [15, 16]. HSV-TK 
PET/CT imaging has indeed been successfully 
applied for monitoring transduction efficiency, tissue 
specificity and therapeutic effect preclinically [15, 17]. 
Subsequently, HSV-TK PET/CT imaging was 
incorporated into phase I clinical trials to monitor 
transduction efficiency in healthy individuals and in 
cancer patients [18, 19]. In an ongoing phase I clinical 
trial investigating the use of HSV-TK-based GDEPT in 
combination with immunotherapy (NCT04313868), 
HSV-TK PET/CT imaging with 18F-FHBG has been 
implemented to explore the effect of viral 
administration routes in transduction efficacy. 
NTR activity has been effectively imaged in a 
preclinical context using the near-infrared fluorescent 
probe CytoCy5S [20] and a caged bioluminescent 
substrate “NTR caged luciferin” (NCL) [21]. 
However, the non-invasive clinical application of 
optical imaging approaches is challenging due to 
limited tissue penetrance of light and associated 
autofluorescence. This could potentially be overcome 
by employing PET as the imaging modality, provided 
that an appropriate NTR specific tracer is available. 
For this purpose, we have focused on radiolabelled 
2-nitroimidazoles (2-NI) that have been extensively 
utilised as hypoxia imaging agents (e.g. FMISO or 
FETNIM) [22, 23]. Hypoxia induces expression of 
oxygen-sensitive nitroreductases, able to convert 2-NI 
(e.g. FMISO, Figure 1A) into the corresponding 
hydroxylamines, which covalently bind to 
macromolecules in the tumour, allowing PET contrast 
[24]. The mechanistic similarity between oxygen- 
sensitive and E.coli nitroreductases, oxygen- 
insensitive, (Figure 1B) and their ability to convert 
aromatic nitro groups of various substrates (Figure 





1A) into aromatic hydroxylamines, render 2-NI as 
plausible probes for clinical imaging of NTR activity 
[25]. 
Recently, Mowday and co-workers [26] have 
demonstrated effective NTR PET imaging employing 
NfsA from E. Coli in combination with the 2-NI PET 
tracer 18F-HX4. Similarly, in this work we have 
investigated whether 18F-FMISO, a PET tracer 
approved by FDA as an investigational new drug for 
human use, could be repurposed as a PET probe for 
non-invasive imaging of NTR for application in the 
context of GDEPT. 18F-FMISO was validated as an 
NTR specific PET imaging tracer using mammary 
carcinoma xenograft models. Further, the 
applicability of 18F-FMISO imaging was demonstrated 
in the two steps of GDEPT i.e. gene transduction and 
cytotoxicity effects of prodrug therapy. These results 
support 18F-FMISO as a readily implementable NTR 
specific PET imaging probe to be employed as a 
companion diagnostic test for NTR-based GDEPT. 
Materials and methods 
In vitro experiments 
Cell culture 
Cells were maintained in a humidified 
atmosphere at 37 °C in 5% CO2 in complete medium, 
consisting of DMEM (Sigma-Aldrich, MO, USA) or 
RPMI-1640 supplemented with 10% FBS, 1% 
penicillin/streptomycin (Sigma-Aldrich), and 1% 
L-glutamine (Sigma-Aldrich). 293T cells were 
purchased from DSMZ (Braunschweig, Germany). 
MDA-MB-231Luc+ and NCI-H460 Luc+ cells, stably 
expressing luciferase, (onwards referred to as NTR-) 
 
 
Figure 1. Nitroreductases and nitroaromatic substrates for multiple applications. (A) Nitroreductase subtrates employed in imaging or GDEPT. (B) Comparison of 
the catalytic mechanisms of oxygen-sensitive and oxygen-insensitive nitroreductases in normoxic and hypoxic conditions. 





were kindly provided by Prof. James Lorens 
(University of Bergen). Generation of MDA-MB- 
231Luc+GFP+NTR+ and NCI-H460Luc+GFP+NTR+ cells, stably 
expressing luciferase, GFP and NfsB (onwards 
referred to as NTR+) has been previously described by 
McCormack et al. [20]. Characterisation of the cell 
lines by flow cytometry can be found in Figures S1 
and S3. To avoid possible expression drift due to cell 
culturing, NTR+ cells were sorted prior to the 
experiments employing the flow cytometric methods 
described previously. 
NTR lentivirus production 
A custom-made lentiviral expression vector, 
pCDH-EF1α-NTR, containing the coding sequence of 
E. coli NfsB gene under the control of the 
EF1α promoter was produced by System Bioscience 
(CA, USA). Packaging into VSV-G pseudotyped viral 
particles was performed by co-transfection of 
pCDH-EF1α-NTR, pMD2.G and psPAX2 (Figure S1) 
into 293T cells. Viral titers were reported as 
transforming units (TU) per mL. TU were measured 
by transduction of 293T cells with serial dilutions of 
conditioned medium from virus packaging cells and 
analysis of NTR expression using a flow cytometric 
method described previously by McCormack et al. 
[20]. For validation purposes, it was confirmed that 
NTR expression levels in MDA-MB-231 cells 
transduced with pCDH-EF1α-NTR and in the NTR+ 
cell line were within the same range (Figure S1). 
Flow cytometry 
For the analysis of NTR expression 0.1 x 106 cells 
were incubated at 37 °C with DMEM supplemented 
with 1 µM of CytoCy5S for 1 hour. All samples were 
washed twice with PBS + 2% BSA before acquisition 
with the BD Accuri C6 flow cytometer (BD 
Biosciences, NJ, USA) with a laser excitation at 640 
nm and emission filter at 675 ± 12.5 nm. 
In vivo experiments 
General animal care 
All experiments were approved by The 
Norwegian Animal Research Authority (FOTS 
approval ID 9059) and conducted according to The 
European Convention for the Protection of 
Vertebrates Used for Scientific Purposes. NOD-scid 
IL2Rgnull mice (referred to as NSG) were bred at 
Vivarium (University of Bergen). Mice were housed in 
groups of ≤ 5 in individually ventilated cages 
(Techniplast, Italy). General condition and body 
weight were recorded twice per week. 
MDA-MB-231 and NCI-H460 subcutaneous 
xenografts 
Tumours were engrafted subcutaneously mono- 
or bi-laterally in the scapular area. 5 × 106 cells were 
prepared in 50 μL DMEM with 25% BD Matrigel™ (BD 
Science, CA, USA) and injected at each site to form a 
single tumour. Tumour volumes were measured 
weekly with a digital calliper and calculated using the 
ellipsoid volume formula: Volume = π (length × 
width × height)/6. 
MDA-MB-231 orthotopic xenografts 
1 × 106 cells were prepared in 50 μL of DMEM 
with 25% BD Matrigel™ (BD Science) and engrafted in 
the right inguinal mammary fat pad, as previously 
described [20, 27]. Prior to cell implantation, mice 
were injected with 0.1 mg/kg buprenorphine 
(Temgesic, Indivior, UK) for analgesia. 
CB1954 treatment 
CB1954 (Sigma-Aldrich) was resuspended in 
DMSO at 26.6 mg/mL. CB1954 treatment was 
initiated when mean tumour volumes reached 172 ± 
65 mm3 in NTR+ and NTR- xenografts or four weeks 
after in vivo transduction in NTR transduced 
xenografts. Animals received two intraperitoneal 
(i.p.) treatments in a six-day interval with a dose of 40 
mg/kg diluted in saline. 
In vivo NTR transduction with lentiviral particles 
NTR lentiviral particles were concentrated using 
Lenti-Pac Lentivirus Concentration solution 
(Genecopoeia, MD, USA). Subcutaneous xenografts 
were transduced in vivo by intratumoral injection of 8 
× 107 TU resuspended in 75 μL of the complete 
medium supplemented with 5 μg/mL Polybrene 
(Sigma-Aldrich) when mean tumour volume was 70 ± 
25 mm3. A single injection of viral particles per 
tumour was performed administering the viral 
suspension throughout the diameter of the tumour. 
18F-FMISO biodistribution 
Tumours and organs were harvested from four 
mice, two hours post i.v. administration of 18F-FMISO 
(150 µL, 8-12 MBq, 228-342 MBq/kg) and radiation 
was measured on a Wizard2® Automatic Gamma 
Counter (Perkin Elmer, MA, USA). The results are 
expressed as a percentage of the injected dose per 
gram of tissue (% ID/g). 
Histopathology examinations 
Following euthanasia, the tumour and the 
organs were fixed in neutral buffered formalin 
solution 10% (Sigma-Aldrich) at room temperature for 
24 hours and later kept in PBS and stored in darkness 
at 4 °C. 5 μm thick sections were stained with 





haematoxylin and eosin (HE) and were examined by a 
pathologist for verification of malignancy. 
Immunohistochemical (IHC) staining was done 
on tumour tissue sectioned at 5 µm thickness. 
Deparaffinisation and antigen retrieval was 
performed with EnVision FLEX Target Retrieval 
Solution, Low pH (DAKO, Copenhagen, Denmark) on 
a Dako PT Link instrument (Dako). After antigen 
retrieval, tissues were incubated for 8 min with 
peroxidase blocker (Peroxidase Blocking Reagent, cat 
#S2001, Agilent Technologies) and thereafter for 10 
min with protein blocker (Protein Block Serum-free, 
cat # X090930-2, DAKO) at room temperature. The 
blocking solution was then removed and the slide was 
wiped dry around the tissue section before 
application of the primary antibody. The sections 
were then incubated overnight at 4 ºC degrees with 
the HIF1α primary antibody (ab51608, Abcam, 
Cambridge, UK) dilution 1:300. The staining was 
performed on a DAKO Autostainer using the 
EnVision+ System-HRP Labelled Polymer 
Anti-Rabbit K4002 as secondary antibody for 30 min 
(Agilent Technologies, Norway). 3,3`-Diaminobenzine 
(DAB+) Substrate-Chromogen was used as 
chromogen for 10 min. Sections were counterstained 
with haematoxylin (cat # S3301, Agilent Technologies) 
for 10 min, dehydrated, and mounted with a coverslip 
(Agilent Technologies) using Pertexx mounting 
medium (Histolab Products AB, Askim, Sweden). 
Human placenta with known reactivity to the selected 
marker was used as positive control. 
Whole tissues were scanned employing an 
Olympus VS120 S6 Slide scanner (Olympus 
Corporation, Tokio, Japan). Quantification of the 
normalised HIF1α positive area was performed 
employing FIJI [28], following the protocol described 
by Crowe et al. [29]. 
PCR for monitoring in vivo NTR transduction 
Following euthanasia, part of the tumour was 
snap-frozen on dry ice and stored at -80 ºC. DNA was 
purified using QIAamp DNA Mini Kit (QIAGEN, 
Germany). A 348 bp fragment of the coding sequence 
of E. coli NfsB gene was PCR amplified in a 
thermocycler under standard conditions using Taq 
DNA Polymerase (Invitrogen, CA, USA) and the 
following primers: NTR-F 5’ GCGTCATTCCACTAA 
GGCAT 3’ and NTR-R 5’ GCGAAGAACTTGCGACC 
TTT 3’. DNA amplification was visualised by gel 
electrophoresis followed by imaging on a Gel Doc EZ 
system (Bio-Rad, CA, USA). Nancy-520 (Sigma- 
Aldrich) was used as an intercalating agent and 1 kb 
DNA Ladder (Sigma-Aldrich) to estimate DNA size. 
Imaging techniques 
During bioluminescence and fluorescence 
imaging mice were anaesthetised with 1.5% isoflurane 
(Abbot Labor Ltd, IL, USA), 3-4% sevoflurane (Abbot 
Labor Ltd) during PET/CT imaging. 
Bioluminescence imaging 
D-Luciferin (Biosynth, Switzerland) was 
administered i.p. at a dose of 150 mg/kg 10 minutes 
before imaging. Images were acquired using an 
In-Vivo FX Pro molecular imaging system 
(Carestream Health Inc., NY, USA). Analysis was 
performed with the Carestream molecular imaging 
software v5.0.6.20. 
CytoCy5S-Fluorescence imaging 
CytoCy5S was synthesised following a 
published method [20]. 100 µL of a 1 mM CytoCy5S 
solution were injected intravenously. Imaging was 
performed after a 1-hour washout using an IVIS 
Spectrum imaging system (PerkinElmer, MA, USA.). 
Analysis was performed with the Living Imaging® 
software v4.5 (PerkinElmer). 
18F-FMISO PET/CT imaging 
18F-FMISO synthesis 
18F-fluoride was produced by the 18O(p,n)18F- 
reaction in a niobium target on a GE PETtrace6 
cyclotron (GE Healthcare,) with EOB-activities in the 
range of 80 - 100 GBq. The activity was delivered to 
the synthesis hot-cell by a Safe Transfer System 
(Skistad Elektroautomasjon AS, Norway). 18F-FMISO 
was produced on a FASTlab2 (GE Healthcare, IL, 
USA) with the synthesis sequence provided by the 
supplier. The radiosynthesis has been described in 
detail previously [30, 31]. Reagents and synthesis 
cassette were purchased from GE Healthcare Norway 
AS (Norway). Purification of 18F-FMISO was 
performed through a series of SPE-cartridges, and 
thus did not require any semi-preparative HPLC. The 
final 18F-FMISO formulation contained approx. 7% 
ethanol. Total synthesis time was approximately 50 
minutes and yields in the order of 20-30% (not decay 
corrected). 
PET/CT imaging 
PET/CT scans were acquired using the 
integrated nanoScan PC PET/CT (Mediso Ltd, 
Hungary) featuring spatial resolution of 800 μm and 
300 μm of the PET and CT detector systems, 
respectively. The field of view (FOV) was 9.6 × 10 cm 
in axial direction and transaxial direction allowing 
whole-body imaging of the mice. The PET detectors 
consist of LYSO crystals, and acquisition was 
performed in a 1:5 coincidence and normal count 





mode. Mice were scanned using a dual mouse bed 
with integrated heating (37 °C). Each PET scan was 
conducted over 30 minutes, 1.5 hours post i.v. 
administration of 18F-FMISO (8-12 MBq, 228-342 
MBq/kg). Prior to PET acquisition, a whole-body CT 
scan (helical projections with tube energy of 50kVp, 
exposure time 300 ms, 720 projections, max FOV, 
binning 1:4) was performed providing anatomical 
information, as well as attenuation correction PET 
image reconstruction. 
PET/CT reconstruction and processing 
PET images were reconstructed using the 
Nucline software by employing the Tera-Tomo 3D 
(OSEM) algorithm (four iterations and six subsets, 1-5 
coincidence mode) and the following corrections: 
depth-of-interaction (DOI), randoms, crystal dead 
time, normalisation. Prior to PET, a whole-body CT 
(low energy) was acquired for anatomic reference and 
attenuation correction. CT images were reconstructed 
using a RamLak filter. The PET and CT images were 
co-registered automatically. Images were 
reconstructed with a voxel size of 0.25×0.25×0.25 mm3 
for CT, and 0.4×0.4×0.4 mm3 for PET. Data analyses 
were performed using InterView Fusion version 
3.03.078.0000 (Mediso Ldt.). Standard uptake value 
(SUV) was calculated using the equation: SUV = 
CPET(T)/(ID/BW), where CPET(T) was the measured 
activity in tissue, ID the injected dose measured in 
kBq, and BW the mouse’s body weight in kg. For each 
scan a spherical volume of interest (VOI) with radius 2 
mm was drawn manually over the muscle in the neck 
and SUVmean was calculated to serve as reference. This 
value enabled segmentation of putative tumour tissue 
having SUV ratios of twice higher than reference for 
18F-FMISO. VOIs of primary tumours and of likely 
metastases were drawn semi-automatically in the PET 
images for estimation and calculation of SUVmax and 
SUVpeak values. SUVmax is the maximum SUV value of 
all voxels included in the VOI. For SUVpeak analysis a 
specific volume was set (5 mm3 for SUVp5 and 10 mm3 
for SUVp10) and all the possible spheres with that 
volume fitting inside the VOI were identified. The 
average SUV of all voxels within the spheres was 
calculated for all possible spheres and the highest 
average SUV values from this analysis were reported 
as SUVp5 and SUVp10. The SUVpeak analyses were 
performed using PMOD software (Version 3.8). 
Statistics 
Results are given as mean ± standard deviation 
(SD). All statistical tests were performed using 
GraphPad Prism v 6.0h (GraphPad Software Inc, CA, 
USA) and p < 0.05 was considered significant. After 
randomisation, a one-way ANOVA was applied to 
ensure unbiased assignment of tumour volumes 
among the experimental groups. Comparison of 
means was performed using Student’s t-tests. Test for 
equality of variances was performed using an F test. 
When variances were not equal Welch’s correction 
was applied to Student’s t-tests. Correlations were 
analysed by computing Pearson’s correlation 
coefficients. 
Results 
18F-FMISO permits imaging of NTR expression 
in subcutaneous xenograft models 
Although fluorescent [20] and chemiluminescent 
[21] substrates have been successfully applied to 
report NTR expression in preclinical models of 
cancers, their clinical potential is limited. We 
hypothesised that 18F-FMISO, a clinically approved 
PET tracer known to be sequestered and reduced in 
hypoxic cancer environments, may provide a 
PET-based imaging modality for the visualisation of 
NTR activity in vivo. To examine the potential of 
18F-FMISO as a PET tracer of NTR expression in vivo, 
18F-FMISO NTR PET/CT imaging and CytoCy5S-FLI 
were compared in a subcutaneous xenograft model. 
Briefly, mice were xenografted bi-laterally in the 
scapular region with either NTR+ or NTR- cells (n = 3 
mice per group) in addition to one mouse implanted 
with both NTR+ and NTR- on adjacent scapulae. Mice 
were imaged at three timepoints post-engraftment 
(weeks four, five and seven) and imaging results 
compared (Figure 2A). CytoCy5S-FLI confirmed 
significantly higher contrast between NTR+ and NTR- 
xenografts from week five (p < 0.05, Figure 2A), when 
mean tumour volumes reached 243.6 ± 94.6 mm3. 
18F-FMISO NTR PET/CT resulted in significantly 
higher contrast between NTR+ and NTR- xenografts 
earlier, at week four, when mean tumour volumes 
were 154.0 ± 75.8 mm3. At week four, NTR+ and NTR- 
xenograft SUVmax values were 3.64 ± 0.36 g/mL and 
1.24 ± 0.42 g/mL respectively (p < 0.0001). Contrast 
remained significantly higher at weeks five and seven 
(Figure 2A and 2B). To confirm these results, 
18F-FMISO tracer biodistribution was analysed ex vivo. 
The highest tracer retention was detected in the 
bladder, consistent with high renal clearance, and in 
the large intestine (Figure 2C), which is expected as a 
consequence of the expression of nitroreductases by 
the local microbiota. 18F-FMISO retention was higher 
in NTR+ compared to NTR- xenografts and remaining 
organs. Thus, our results suggest that 18F-FMISO can 
act as an NTR PET tracer. 
To confirm that the higher retention of 
18F-FMISO observed in NTR+ is specific for NTR 
expression, we wanted to compare the hypoxic status 





of the NTR- and NTR+ xenografts. The hypoxic status 
of the subcutaneous MDA-MB-231 NTR- and NTR+ 
xenografts was assessed employing IHC to detect 
HIF1α accumulation (Figure S2A). Quantification of 
the normalised area positive for HIF1α shows no 
statistical significance between MDA-MB-231 NTR- 
and NTR+ xenografts (Figure S2B). This result 
suggests that 18F-FMISO retention in NTR+ xenografts 
is not related to increased levels of hypoxia, 
confirming 18F-FMISO as an NTR PET tracer. 
Next, we wanted to analyse the performance of 
18F-FMISO as an NTR PET tracer in the presence of 
other nitroreductases, both oxygen-insensitive and 
oxygen-sensitive. For this purpose we selected the 
non-small cell lung carcinoma NCI-H460 cell line, 
with high endogenous levels of the nitroreductase 
DT-diaphorase [32] and increased levels of hypoxia in 
comparison to MDA-MB-231 (hypoxic fractions of 
13.6% and 4.7% respectively [33, 34]). First we 
confirmed in vitro that NTR+/NTR- ratio was notably 
lower for NCI-H460 than for MDA-MB-231 cell line, 
being respectively 5.4 and 50 (Figure S3A). Then, mice 
were xenografted bi-laterally in the scapular region 
with either NTR+ or NTR- NCI-H460 cells (n = 4 
tumours per group). Mice were imaged two weeks 
after engraftment and imaging results compared 
(Figure S3B). 18F-FMISO NTR PET/CT resulted in 
significantly higher contrast between NCI-H460 NTR+ 
and NTR- xenografts with SUVmax values of 2.07 ± 0.36 
g/mL and 1.51 ± 0.30 g/mL respectively (p < 0.05; 
Figure S3C). Interestingly, no significant differences 
were observed between SUVmax values from 
MDA-MB-231 NTR- xenografts (1.24 ± 0.42 g/mL) and 
from NCI-H460 NTR- xenografts. These results 
suggest that 18F-FMISO can act as an NTR PET tracer, 
even in models with notable presence of oxygen- 
insensitive and oxygen-sensitive nitroreductases. 
18F-FMISO imaging of NTR+ metastatic lesions 
in orthotopic xenograft 
models 
Having demonstrated the 
ability of 18F-FMISO to act as an 
NTR PET tracer in subcutaneous 
tumours, we next examined the 
suitability of the tracer for the 
detection of small metastatic 
lesions. We have previously 
visualised the axillary lymph 
node metastatic capacity of 
MDA-MB-231 cells when 
implanted orthotopically in 
immunodeficient mice via BLI 
[27]. Thus, 1 × 106 NTR+ cells 
were xenografted orthotopically 
in the mammary fat pad (n = 3) 
and imaged weekly with BLI 
and, from the initiation of 
metastasis, also with 18F-FMISO 
NTR PET/CT for five weeks 
(Figure 3A). Axillary lymph 
node metastases were clearly 
visible from week 8, with 
progressive increase in BLI up to 
week 12 (Figure 3A). 
Comparative 18F-FMISO NTR 
PET/CT imaging of the same 
mice demonstrated contrast at 
the axillary lymph node 
metastatic site with SUVmax 
values of 2.37 ± 0.88 g/mL from 
week 9 (Figure 3B). Metastatic 
contrast increased in weeks 10, 
11 and 12 with SUVmax values of 
 
 
Figure 2. 18F-FMISO permits imaging of NTR expression in subcutaneous xenograft models. (A) 
Representative 18F-FMISO PET/CT MIP images and CytoCy5S-FLI 2D surface weighted images over four weeks. NTR- 
tumour (right flank) and NTR+ tumour (left flank). (B) SUVmax values, were significantly higher in NTR+ xenografts for all 
the time points (****, p < 0.0001, n=7). (C) Ex vivo biodistribution (n = 3) of 18F-FMISO obtained at week seven. 
Biodistribution observed mainly in large intestines and bladder. Biodistribution was higher in NTR+ tumours than in 
NTR- tumours and remaining organs. The p-values are represented as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and 
**** p < 0.0001. 





2.88 ± 1.41, 3.36 ± 1.37 and 4.25 ± 2.04 g/mL, which 
were significant from background (SUVmax of 
reference tissue range: 0.4-0.56 g/mL; p < 0.05). 
Further analysis of 18F-FMISO NTR PET/CT images 
of NTR+ xenografts revealed additional contrast in the 
thoracic and lumbar regions of metastatic mice 
suggestive of hepatic and pulmonary metastasis 
(Figure 3C, upper). Subsequently, mice were 
euthanised, and suspected metastatic 
organs excised. Histological 
examination of HE stained sections of 
the lungs, liver and axillary lymph 
node demonstrated the presence of 
metastases in organs where 
accumulation of 18F-FMISO had been 
observed by 18F-FMISO NTR PET/CT 
imaging (Figure 3C, lower). 
18F-FMISO allows assessment of 
NTR expression after in vivo 
transduction 
While the aforementioned 
18F-FMISO imaging results 
demonstrate the useful application of 
18F-FMISO NTR PET/CT imaging for 
detection of constitutive NTR 
expression, the imaging demands of 
GDEPT are far greater. Initially, 
imaging of GDEPT should permit 
visual confirmation of in vivo viral 
transduction, which will occur in a 
discrete fraction of the tumoral cells 
[11, 12]. To examine the potential of 
18F-FMISO NTR PET/CT imaging to 
assess in vivo transduction of tumour 
cells by NTR, an NTR lentiviral 
construct was designed (Figure S1). 
Viral particles were collected, 
concentrated and 8 x 107 TU injected 
intratumorally into NTR- subcutaneous 
xenografts (Figure 4A). 
NTR transduced xenografts (n = 
10), in addition to NTR+ and NTR- 
controls (n = 4 per group) were 
18F-FMISO NTR PET/CT imaged, two 
and four weeks post-transduction 
(Figure 4A). Clear contrast of NTR+ 
controls could be demonstrated over 
NTR- controls both at week 2 and 4 
(SUVmax of 3.97 ± 0.40 and 3.82 ± 0.57 
g/mL respectively; p <0.001 Figure 4B 
& C). At week 2, minimal contrast was 
visualised in NTR transduced 
xenografts, albeit non-significant 
compared to NTR- controls (SUVmax of 
1.94 ± 0.38 and 1.74 ± 0.32 g/mL 
respectively; Figure 4C). Imaging at 
week 4 demonstrated significant 
contrast compared with NTR- controls 
 
 
Figure 3. 18F-FMISO imaging of NTR+ metastatic lesions in orthotopic xenograft models. (A) 
Representative images from week eight to 12. Presence of primary tumour (inguinal area) and axillary 
metastases (red square) by BLI. 18F-FMISO NTR PET/CT imaging in the axillary area. (B) Evolution of lymph 
node metastasis SUVmax compared to the reference tissue. Significant difference is observed at weeks ≥ 10 (*, 
p < 0.05), n = 3. (C) Whole body MIP images of 18F-FMISO NTR PET/CT show contrast in the primary tumour, 
liver, lung and axillary lymph node. HE staining shows widespread metastatic neoplasia in all the analysed 
organs. The histological features associated with neoplasia (marked with black arrows) include atypical mitosis, 
pyknosis, hyperchromatism, desmoplasia, irregular shape and size. Excessive extranodal tumour extension 
invading the adjacent muscle tissue can be seen in the axillary lymph (marked with black arrow). The lungs 
show signs of scattered micrometastases and venous infiltration (marked with black arrow). The p-values are 
represented as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 





(SUVmax of 4.12 ± 3.18 and 2.03 ± 0.20 g/mL 
respectively; p < 0.05). Similar results were obtained 
when SUVpeak was analysed (Figure S4). Interestingly, 
contrast in lentiviral transduced tumours was 
observed at discrete foci (Figure 4B). 
At week 4, NTR transduced xenografts were 
randomised to receive CB1954 (two 40 mg/kg i.p. 
injections in a six-day interval) or vehicle (Figure 4A). 
Post-treatment 18F-FMISO NTR PET/CT imaging, at 
week 6, showed a further increase in contrast in 
xenografts treated with vehicle, although non- 
significant (pre-treatment SUVmax of 3.5 ± 2.5 and 
post-treatment SUVmax of 4.4 ± 3.0 g/mL Figure 4D & 
E). On the other hand, a significant decrease in 
contrast was observed in xenografts treated with 
CB1954 (pre-treatment SUVmax of 5.57 ± 3.73 and 
post-treatment SUVmax of 2.02 ± 0.32 g/mL; p < 0.05; 
Figure 4D & E). 
 
 
Figure 4. 18F-FMISO allows assessment of NTR expression after in vivo transduction. (A) Experimental set-up for in vivo NTR lentiviral transduction, CB1954 
treatment and 18F-FMISO PET/CT imaging. (B) Representative 18F-FMISO PET/CT MIP images suggesting the expression of NTR in the in vivo transduced tumours both at week 
two and four after transduction. (C) Four weeks after transduction, the SUVmax in the in vivo transduced tumours was significantly higher (*, p < 0.05 and ***, p < 0.001), n = 10). 
(D) Representative 18F-FMISO PET/CT MIP images suggesting a decrease in 18F-FMISO PET contrast in NTR transduced xenografts treated with CB1954 (E) SUVmax of the in vivo 
transduced tumours treated with vehicle showed a non-significant increase. SUVmax of the in vivo transduced tumours treated with CB1954 decreased significantly (*, p < 0.05 n 
= 6) (F) Confirmation of NTR transduction by PCR amplification of NTR coding sequences only in NTR+ xenografts and NTR transduced xenografts treated with vehicle. The 
p-values are represented as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 





To confirm these imaging results, tumours were 
isolated post necropsy, DNA isolated and NTR 
transduction was corroborated by PCR amplification 
of an NTR coding sequence in the NTR transduced 
xenografts treated with vehicle and NTR+ controls 
(Figure 4F). These results confirm the utility of 
18F-FMISO NTR PET/CT imaging for detecting NTR 
expression after in vivo viral transduction. 
To exclude any possible confounding effect on 
18F-FMISO NTR PET/CT imaging arising from 
hypoxia induced by intratumoral injection, at the end 
of the experiment the accumulation of HIF1α was 
measured in NTR- transduced xenografts and 
compared with NTR- tumours not receiving an 
intratumoral injection. The spatial pattern of HIF1α 
accumulation was similar in both tumour groups 
(Figure S5A) and the mean normalised HIF1α positive 
area was indeed significantly lower in intratumorally 
injected tumours (Figure S5B). All the above- 
mentioned data confirms 18F-FMISO NTR PET/CT 
imaging as a technique able to detect in vivo NTR viral 
transduction. 
18F-FMISO NTR PET/CT imaging reports 
CB1954 treatment efficacy in NTR expressing 
xenografts 
Having demonstrated the potential of 18F-FMISO 
NTR PET/CT imaging to successfully visualise in vivo 
NTR transduction, the capacity of 18F-FMISO NTR 
PET/CT imaging to report on CB1954 prodrug 
treatment efficacy was examined. NTR- and NTR+ 
subcutaneous xenografts (n = 7 per group) were 
treated with CB1954 (two 40 mg/kg i.p. injections in a 
six-day interval) (Figure 5). 18F-FMISO NTR PET/CT 
imaging was performed pre-treatment (day -4), 
during treatment (day 3) and following completion of 
treatment (day 17), in addition to calliper 
measurements of tumour volumes (Figure 5A). As 
expected, pre-treatment 18F-FMISO NTR PET/CT 
imaging of NTR+ xenografts resulted in significant 
contrast in comparison to NTR- xenografts (SUVmax of 
4.07 ± 0.23 and 1.22 ± 0.35 g/mL respectively; p < 0.001 
(Figure 5B and C). At day 3, a significant decrease in 
NTR+ tumour volumes was observed versus 
corresponding NTR- xenografts (normalised tumour 
volumes 2.53 ± 0.27 and 1.43 ± 0.41 mm3; p < 0.0001). 
Similarly, significant decrease in NTR+ tumour 
SUVmax values was also noted in 18F-FMISO PET 
contrast performed at day 3 in comparison to 
pre-treatment SUVmax values (SUVmax 4.07 ± 0.23 and 
3.19 ± 0.41 g/mL; p < 0.001). Progressive reductions in 
NTR+ xenograft tumour volume continued following 
the completion of CB1954 treatment at days 7, 10 and 
14 (p < 0.001), with normalised volumes of 0.1 ± 0.02 at 
termination of the experiment (Figure 5A). Final PET 
imaging of xenografts on day 17 (Figure 5B) 
confirmed calliper measurement results, with 
observed SUVmax values reduced to 0.72 ± 0.12 g/mL 
(p < 0.0001) (Figure 5C). These preclinical results 
validate translational development of 18F-FMISO 
PET/CT for prodrug treatment efficacy monitoring in 
the context of NTR-based GDEPT. 
Discussion 
GDEPT has been suggested as an attractive novel 
therapeutic strategy aiming to address both drug 
resistance and off-target cytotoxicity [35], with 
promising preclinical results [36-39] and a number of 
HSV-TK-based GDEPT phase II/III clinical trials 
opened in the last five years (NCT02831933; 
NCT02768363; NCT03004183; NCT03541928; 
NCT03603405; NCT03596086; NCT02446093). Recent 
phase I studies (NCT03281382; NCT04313868) are 
evaluating the use of HSV-TK-based PET imaging as a 
companion diagnostic tool, facilitating the analysis of 
HSV-TK transduction efficacy and prodrug therapy 
response. 
In the current study, we have investigated the 
repurposing of 18F-FMISO, an FDA approved PET 
tracer as investigational new drug for human use, as a 
companion diagnostic tool for NTR-based GDEPT. 
Employing a mammary carcinoma xenograft model 
constitutively expressing NTR, we demonstrated that 
18F-FMISO PET/CT imaging is sensitive for detection 
of NTR, even in small metastases. 18F-FMISO NTR 
PET/CT imaging was found to be effective for 
detection of in vivo NTR transduction and for 
monitoring response to CB1954 treatment, 
demonstrating the feasibility of 18F-FMISO NTR 
PET/CT imaging in the context of GDEPT. 
Whilst this work has utilised breast and lung 
cancer models, 18F-FMISO NTR PET/CT imaging is 
expected to be applicable to any solid tumour type. As 
suggested by our results, the interaction between 
18F-FMISO NTR and 18F-FMISO hypoxia PET/CT 
imaging does not appear to compromise this NTR 
imaging strategy. Indeed, preclinical 18F-FMISO 
hypoxia PET/CT imaging in many different tumour 
types reported SUVmax values in the range of 0.19-0.70 
mg/mL [40-45], notably lower than the SUVmax values 
values for 18F-FMISO NTR PET/CT imaging reported 
in this study (1.5-9.95 mg/mL). 
The general applicability of 18F-FMISO NTR 
PET/CT imaging might be limited by the distribution 
of the tracer to the bladder and large intestine [46], 
which might interfere with the imaging of tumours in 
the abdominal cavity. One strategy to reduce PET 
signal in the abdominal cavity is to increase the bowel 
motility using laxatives prior to imaging, this has been 
explored in preclinical models [47]. Another possible 





solution would be to employ NfsA, which is an NTR 
orthologue with higher affinity towards 18F-FMISO 
[26]. NfsA may permit the use of lower 18F-FMISO 
doses, resulting in a decrease in the retention in the 
abdominal cavity. 
We acknowledge the limitations and 
sub-optimal PK properties of 18F-FMISO. However, 
the extensive clinical use of this tracer for PET 
 
 
Figure 5. 18F-FMISO NTR PET/CT imaging reports CB1954 treatment efficacy in NTR expressing xenografts. (A) CB1954 treatment response and 
experimental set-up for treatment monitoring employing 18F-FMISO PET/CT imaging (B) Representative 18F-FMISO PET/CT MIP images from NTR- tumour (left flank) and NTR+ 
tumour (right flank) before treatment and three and 17 days after CB1954 dosing. (C) Before treatment, the SUVmax values were significantly higher in NTR+ than in NTR- 
tumours (****, p < 0.0001, n = 7). Three and 17 days after, the SUVmax became significantly lower in NTR+ xenografts in comparison to before treatment (****, p < 0.0001, n = 
7). After 17 days, SUVmax of NTR+ xenografts became significantly lower than the corresponding SUVmax of NTR- xenografts (***, p < 0.0001, n = 7). The p-values are represented 
as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 





imaging of hypoxia makes the process of approval for 
a repurposed application easier. In parallel, novel 
tracers with optimised pharmacokinetic properties, in 
order to achieve high tumour accumulation and rapid 
healthy tissue clearance, are under development. A 
second generation 2-NI, 18F-DiFA, has displayed 
slightly improved hypoxia sensitivity in clinical 
studies, accompanied by minimal distribution into the 
gastrointestinal tract [46, 48] and is an interesting 
candidate for further studies in the context of NTR 
imaging. 
In comparison to HSV-TK-based GDEPT, NTR- 
based GDEPT possesses higher therapeutic potential, 
as NTR-based GDEPT targets cells independently of 
the cell cycle phase or proliferation status [49] and it 
results in a notable bystander effect caused by the 
diffusion of activated derivatives through the cell 
membrane [9, 10]. Despite the superior therapeutic 
potential of NTR-based GDEPT, clinical development 
is still in the early phases, as several of the steps for 
the NTR-based GDEPT strategy still need 
optimisation. 
Efforts for optimisation of NTR-based GDEPT 
have in recent years focused on the key aspects of the 
technology, namely the delivery system, the 
NTR-enzyme and the prodrug. In an NTR GDEPT 
clinical trial, immune responses to the viral particles 
were detected [5]. Although it is not known if immune 
mediated responses will compromise the therapeutic 
efficacy, new gene delivery systems amenable for 
clinical translation, such as extracellular vesicles [50] 
and ultrasound and microbubble mediated 
sonoporation have been investigated [51]. While NfsB 
from E. coli has been the most commonly employed 
gene for NTR-based GDEPT, different NTR orthologs 
and homologs, with a much higher catalytic activity, 
such as NfsA from E. coli and Nme from N. meningitidis 
have been evaluated [26, 52, 53]. Finally, development 
of improved prodrug candidates is ongoing [54], since 
CB1954 has been associated with dose-limiting 
hepatotoxicity in humans [55]. Indeed, the last two 
aspects, NTR-enzyme and prodrug, have been 
optimised simultaneously through the engineering of 
a modified NTR enzyme that confers higher catalytic 
activity for an improved prodrug. Remarkable efforts 
by Gungor and co-workers employing an NTR from 
S. saprophyticus, Ssap-NtrB, and a library of different 
nitro-containing scaffolds has led to promising in vitro 
prodrug candidates, such as benzamide derivatives 
N-(2,4-dinitrophenyl)-4-nitrobenzamide, A5 or A20, 
and piperazine derivatives NHN12 or NHN14 [54, 
56-58]. Other examples of such a strategy include 
HChrR6 with CNOB [59, 60] and NfsA variant no. 22 
with PR-104A [61]. Interestingly, NfsA variant no. 22 
retained reductive activity towards the hypoxia PET 
tracers, 18F-EF5 and 18F-HX4, allowing the possibility 
of NTR PET/CT imaging as companion diagnostic 
tool, as shown in the recently published work of 
Mowday et al. [26, 61]. 
Increasing preclinical knowledge will contribute 
significantly to the successful clinical translation of 
NTR-based GDEPT. The combination of a clinically 
amenable gene delivery system, optimised NTR 
enzymes and improved prodrugs is expected to boost 
the clinical application of NTR-based GDEPT. 
18F-FMISO NTR PET/CT imaging should be 
integrated into the clinical testing of future 
NTR-based GDEPT strategies, providing a robust and 
sensitive technology to monitor forthcoming clinical 
trials. 18F-FMISO NTR PET/CT is an FDA 
methodology readily available for clinical application. 
Our preclinical studies further establish this strategy 
as a strong candidate for companion diagnostic 
testing of NTR-based GEDPT. 
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NTR lentiviral packaging plasmids. In vitro analysis of the levels of expression of NTR in the MDA-
MB-231 NTR+ cell line and in the MDA-MB-231 after transduction and sorting with the lentiviral 






 (A) Example of HIF1α IHC in NTR- and NTR+ MDA-MB-231 xenografts. (B) No significant 
difference was observed in the normalised area positive for HIF1α between NTR- and NTR+ MDA-




(A) NTR+/NTR- ratio was notably lower for NCI-H460 than for MDA-MB-231 cell line. (B) 
Representative 18F-FMISO PET/CT MIP images of NCI-H460 xenografts. NTR- tumour (right flank) 
and NTR+ tumour (left flank). (C) SUVmax values were significantly higher in NTR+ xenografts. (*, p 
< 0.05, n = 4). 







SUVmax , SUVp5 and SUVp10 analyses show similar results in the in vivo transduced tumours. 






 (A) The spatial pattern of HIF1α accumulation was similar in both intratumorally injected and non-
injected tumours MDA-MB-231 NTR- xenografts. (B) The normalised HIF1α positive area was 
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